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ABSTRACT
The vast majority of nanomaterials are chemically synthesized, a costly process,
that is environmentally risky, and the produced nanoparticles are potentially toxic
to patients. Nature-based nanomaterials, however, are proving to be much more
biocompatible with lower environmental toxicity. Even though a variety of natural
nanomaterials have been designed, fabrication technologies for the desired
natural nanoparticles with reproducible quality, high productivity and low cost
remain a challenge. My objective has been to establish strategies for the isolation,
purification and characterization of nanoparticles using a production system
based on green tea and fungus (Arthrobotrys oligospora) and also to develop
new approaches for sustainable ―green manufacture‖ of gold nanoparticles for
biomedical applications. First, an infusion-dialysis procedure to isolate of the tea
nanoparticles (TNPs) from a green tea infusion was developed and validated.
The TNPs are spherical with a diameter of 100-300 nm, and have a zeta
potential of -26.52 mV at pH 7.0. The TNPs enhance secretion of the cytokines
and the chemokines from mouse macrophages, suggesting a potential
immunostimulatory effect. As a natural nanocarrier, the TNPs are able to form
complexes with doxorubicin (DOX). The DOX-loaded TNPs increase cellular
DOX uptake, leading to higher cytotoxicity in cancer cells. Second, a new
isolation procedure was established to purify the fungal nanoparticles (FNPs)
from A. oligospora, giving two purified FNP fractions. Both purified FNPs had a
reduced diameter of 100-200 nm, with glycosaminoglycan as the main
vi

constituent. The purified FNPs cause mild cytotoxicity by inducing apoptosis and
regulating

the

cell

immunostimulatory

cycle

in

effect.

multiple

tumor
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have

have
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immunochemotherapeutic effect upon complexing with DOX against tumor cells.
Third, a sustainable system for green manufacturing of gold nanoparticles was
developed by using actively growing English ivy. The efficient uptake of the
synthesized gold nanoparticles in mammalian cells provides the potential for
biomedical applications. Finally, a simple one-step approach using dopamine, a
monoamine neurotransmitter appearing naturally in the human brain, to
synthesize highly branched gold nanoflowers (AuNFs) was developed. These
AuNFs are highly biocompatible and provide high surface enhanced Roman
scattering (SERS) performance.
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CHAPTER I
INTRODUCTION
Personalized medication and treatment are the optimal goals for disease
treatment. This is particularly true for cancer therapy, due to the heterogeneity of
cancer and its diverse causes. Individualized treatment could be achieved by
developing an effective theranostic, defined as material that combines the
modalities of the therapeutic medication and diagnostic imaging capability. [1]
One huge advantage of theranostic is the avoidance of an adverse reaction
between the diagnostics and the selectivity of the drug utilized in the treatment.
Nanomaterials, which combine the imaging agents and the therapeutic drugs into
molecules have the potential to be developed as the next generation of
theranostics.

The next generation drug delivery system: Nanoparticles
Conventional therapeutic agents are distributed nonspecifically in the body where
they affect both cancerous and normal cells. Thus the limiting dosage may not be
optimal for treatment due to the excessive toxicities. Nanoparticles, loaded with
therapeutic drugs and modified for the tissue, cell and organelle targeting motifs,
are able to target cancer cells using the unique pathophysiology of tumors,
including cancerous cellular markers, organelle localization signals, and the
enhanced permeability and retention effect of the tumor microenvironment.
Additionally, nanoparticle carriers are able to improve the delivery of poorly
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water-soluble drugs and enhance the circulation time of the drug in vivo to further
reduce the dosage needed for treatment.

Targeting: necessity or luxury?
Current clinically approved nano-products are relative simple and lack of
targeting motif. In fact, nearly 30 years after the first targeted l targeted
liposomes is constructed. [2] Unfortunately, thus far this technology had a limited
impact on human health. The reasons are complex and comprehensive.
Targeted delivery of a therapeutic drug is a complicated procedure, involving the
stability of the delivery particles, the mode of action of the drug and the efficiency
of the site-specific delivery. In some cases, it is believed that targeting can cause
anchoring of the delivery systems, reducing the efficiency of diffusion and tissue
penetration. [3] However, dramatic molecular biology advances over the last 30
years have expanded our understanding of the mechanisms involved, providing
the means to develop new approaches to the design of drug delivery systems.
The identification of specific molecular markers in different types of cancer cells
provides new therapeutic targets, making it increasingly feasible to engineer a
muti-functional and specific drug delivery system for therapeutic applications.
This system is already being actively employed. Recently the phase I trial has
been completed for CALAA-01[4], a transferrin-targeted particle delivering siRNA
to reduce the expression of the M2 subunit of the ribonucleotide reductase (R2)
for solid tumor therapy.

2

Polymer-based Nanoparticles as drug delivery systems
Several types of nanoparticles can be utilized in the design of a delivery system,
including polymer-based drug carriers, polymeric nanoparticles, polymeric
micelles, dendrimers, liposomes, viral nanoparticles, carbon nanotubes. Polymerbased nanoparticles are derived from polymers such as albumin, chitosan, and
heparin. They can be naturally used as material to deliver oligonucleotides, DNA,
proteins and therapeutic drugs, including paclitaxel and doxorubicin. Doxorubicin,
an anticancer drug, inhibits DNA topoisomerase II, an enzyme that is in both
mitochondria and nucleus. DOX has been used in several studies as a
therapeutic drug delivered into cancer cells. DOX has been successfully
encapsulated into human serum albumin nanoparticles to treat anoikis-resistant
breast cancer cells. The DOX-conjugated nanoparticles have proven to be
significantly more cytotoxic to the breast cancer cells than free DOX. The
conjugated nanoparticles have been delivered into the cells much more efficiently
than the free DOX by avoiding the drug efflux pump system. [5] DOX has also
been delivered by folate-conjugated P(NIPAAm- co -DMAAm- co -UA)- g cholesterol nanoparticles, which target the folate receptor of the cancerous cells
enabling a more rapid entry into the nucleus. Based on this model, this study
defines a mechanism for faster nuclear entry using folate as a cell specific
targeting factor and undecenoic acid as a PH sensitive component which
mediates a more efficient drug release and nucleus entry. [6]
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The production of gold nanoparticles for biomedical applications
Gold nanoparticles are of great interest in fields as diverse as electronics,
coatings,

photonics,

surface-enhanced

Raman

scattering

(SERS)

and

biotechnology. This is due to their unique properties, including size- and shapebased optical and electronic characteristics, their high surface area to volume
ratio and their ability to be easily modified with ligands containing functional
groups such as thiols and amines. [7] Additionally, gold nanoparticles are able to
traverse through the vasculature, be localized in targeted areas, and can be
attached to single strands of DNA nondestructively. [8] The use of gold
nanoparticles to date suggests that they may be potentially useful in many
biomedical applications. Considering their broad potential, the production of gold
nanoparticles on a large-scale and in a controlled manner depending on the size,
shape and crystallization has drawn significant attention in recent years.

It is well known that the production of nanoparticles can be achieved by various
methods. Although several chemical and physical strategies have been utilized to
successfully produce pure and well-defined gold nanoparticles, these methods
are toxic, expensive and/or potentially dangerous to the environment. A
biologically synthesis of gold nanoparticles could be easily prove to be superior
to the chemical and physical processes, due to the low cost, high efficacy,
suitability for large-scale synthesis and low environmental impact. [9, 10] A
variety of plants, fungus, and bacteria have been successfully used for rapid
biological synthesis for gold nanoparticles. Plant extracts, such as lemongrass
4

(Cymbopogon flexuosus) [11], Aloe vera [12], geranium (Pelargonium graveolens)
[13], tamarind (Tamarindus indica) [14], and English ivy [15] have been shown to
have the ability to reduce Au(III) ions to Au(0). Microorganisms like bacteria,
yeast and a number of species of fungus have also been employed, such as
Fusarium oxysporum [16], Colletotrichum sp.[13], Rhodopseudomonas capsulate
[17], and Trichothecium sp. [18]. The use of different plants and systems
resulting in gold nanoparticlces with various shapes and sizes has led to the
discovery of the role of reductases and reducing agents involved in the synthesis.
Nitrate reductase from a fungus (Fusarium oxysporum) has been demonstrated
to utilize NADPH as a reducing agent. [9] A variety of proteins, polyphenols and
carbohydrates are involved in the synthesis of gold nanoparticles with different
sizes and shapes. [9] These constituents present in plants and microorganisms
may be useful in the synthesis of individualized nanoparticles. The involvement
of these constituents in the mechanism of the synthesis needs further
experimental examination. [9]

Thesis Objectives
A great deal of research has led to the development of chemically synthesized
nanomaterials; however, a variety of natural nanomaterials, including viruses [19],
lipoproteins[20],

diatoms nano-biosilica [21], ivy nanoparticles [22, 23], and

fungal nanoparticles (A. Oligospora) [24], have recently drawn widespread
attention. They have the advantages of being biocompatible, have low

5

environmental toxicity associated with production, and have promising medical
applications. [22, 25, 26]

Tea, one of the most popular beverages in the world, has numerous therapeutic
effects. It has been implicated as a players in lowering blood pressure [27],
decreasing blood coagulation [28], treating HIV [29], repairing oxidative
damage[30, 31], and cancer prevention and treatment. [32-35] Several studies
have shown that the most active anticancer compounds in tea are polyphenols,
such as (-)-epigallocatechin gallate (EGCG), (-)-epigallocatechin (EGC), and (+)gallocatechin (GC). [36-38] These polyphenols exhibit anticancer effects by
affecting various genes involved in the regulation of the cell cycle, apoptosis,
invasion, metastasis, and angiogenesis. [39, 40] In addition to the polyphenols,
natural polysaccharides from tea have also drawn researchers’ attention due to
their antitumor, immunostimulatory and antioxidant properties. [28, 41, 42]
Interestingly, some naturally occurring nanoparticles with diameters of 200-300
nm in black tea were reported by Groning et al in 1995; [43] however, not enough
nanoparticles were isolated from black tea for further component analysis and
specific biomedical characterization. This thesis elucidates a novel efficient
method for purifying the tea nanoparticles to utilize their potential therapeutic
properties for cancer therapy.

Organic nanoparticles have shown promise in cancer treatment, due to their
biocompatibility, biodegradation and multifunctional capacities. [44] Most reports
6

on natural organic nanoparticles are focusing on development in higher
organisms, especially marine species and plants. Considering the rich biological
diversity of the earth, natural organic nanoparticles may be produced in different
forms and with different functions from unique origin. Investigation of
nanoparticles in natural systems will not only help us to understand the roles of
the nanoparticles in biological systems, but also provide us opportunities to
develop these nanoparticles for specific biomedical applications. The discovery
of new natural nanoparticles from A. Oligospora and the exploration of ―scalable
green manufacturing‖ nanoparticles for cancer therapy is a step in this process.

Gold nanoparticles have been utilized for many purposes. They have been
proved to be especially effective for Surface Enhanced Raman Spectroscopy
(SERS) [45], cancer diagnostics [46] and thermal therapy [47]. Several chemical
and physical processes have been design in attempts to synthesize different
sizes and shapes of gold nanoparticles. In order to reduce the use of toxic
chemicals used in typical AuNP synthesis, active investigation for alternative
synthesis methods are being employed using biological materials (proteins,
polysaccharides, polyphenol, etc.) for green-synthesis of gold nanoparticles.
While the use of plant extracts to synthesize AuNPs has been proposed, it has
some serious drawbacks. Harvesting AuNPs from plant tissue introduces
additional complexions due to the limited amount of AuNPs relative to the large
plant biomass [48, 49], resulting in increased costs, and production delays. This
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work offers a rapid and sustainable English ivy-based production system
developed to synthesize gold nanoparticles for biomedical applications.

Gold nanoflowers are specialized gold nanoparticles with multiple highly
branched tips, which

give

the overall appearance of

a flower.

The

nanomorphology of the highly tipped and branched often leads to the formation
of sharp peaks and valleys, which are potential ―hot spots‖ for localized near-field
enhancements. [45, 50, 51] The highly branched nanostructures can dramatically
increase the ratio of total surface to volume. These factors lead to the
enhancement of

the

Raman

scattering on

the highly branched

gold

nanostructures. [52, 53] Compared to smooth surfaces, highly branched surfaces
(such as dendrites, multi-pods, and nanoflowers) have a greater potential for
SERS based bioimaging and biosensing. While their potential usefulness has
stimulated further research, the controllable synthesis of these unique
nanostructures at a low cost remains a challenge. This thesis proposes a novel,
one-step synthesis method to produce gold nanoflowers, using dopamine to
insure a high SERS performance.
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CHAPTER II
TEA NANOPARTICLES FOR IMMUNOSTIMULATION AND
CHEMO-DRUG DELIVERY IN CANCER TREATMENT
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Introduction
Much research has contributed to the development of chemically synthesized
nanomaterials; however, a variety of natural nanomaterials, such as viruses [19],
lipoproteins [20], diatoms nano-biosilica [21], ivy nanoparticles [22, 23], and
fungal nanoparticles (A. Oligospora) [24], have recently drawn researchers’
attention due to their promising biocompatibility, less environmental toxicity
associated with their production, and their features desired in medicine. [22, 25,
26]
Tea is one of the most popular beverages in the world and has been linked to
numerous therapeutic effects, including lowering blood pressure [27], decreasing
blood coagulation [28], treating HIV [29], repairing oxidative damage[30, 31], and
cancer prevention and treatment[32-35]. Several studies have shown that the
most active anticancer compounds in tea are polyphenols, such as (-)epigallocatechin

gallate

(EGCG),

(-)-epigallocatechin

(EGC),

and

(+)-

gallocatechin (GC) [36-38]. These polyphenols exhibit anticancer effects by
affecting various genes involved in the regulation of the cell cycle, apoptosis,
invasion, metastasis, and angiogenesis. [39, 40] In addition to the polyphenols,
natural polysaccharides from tea have also drawn researchers’ attention due to
their antitumor, immunostimulatory and antioxidant properties. [28, 41, 42]
Interestingly, some natural nanoparticles with diameters of 200-300 nm in black
tea were reported by Groning et al in 1995 [43]; however, they didn’t isolate
enough nanopartiles from black tea for further component analysis and specific
biomedical applications. Considering the success of other natural-based
10

nanoparticles

for

cancer

chemotherapy

and

immunotherapy

[24],

we

hypothesized that tea is an ideal source of highly biocompatible nanomaterials
for different biomedical applications, especially for cancer therapy. Due to the
traditional role of tea as a cancer preventing beverage and good biocompatibility,
we believe that the development of nanoparticles from tea as a biomaterial may
open a new avenue for cancer therapy.
The goal of this study was to develop a fabrication method for isolation of natural
nanoparticles from tea, and to explore their potential applications as a
immunostimulatory agent and a nanocarrier for chemo-drug delivery in cancer
therapy in vitro. For this purpose, an infusion-dialysis based procedure was
developed to isolate spherical nanoparticles with diameters of 100-300 nm from
green tea infusions (Figure 1). These TNPs were characterized by (atomic force
microscopy) AFM, (scanning electron microscopy) SEM and (dynamic light
scattering) DLS/ (electrophoretic light scattering) ELS. We have also conducted
studies to quantitatively measure the concentration of protein, polysaccharide
and other small molecules in the TNPs. The potential for the TNPs to be used as
an immunostimulatory agent, and a natural drug nanocarrier for chemo-drug
delivery to sensitive and resistant tumor cells was further evaluated through this
study.
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Figure 1 Schematic of the infusion-dialysis based procedure for isolating the TNPs from
green tea leaves for drug delivery.
(A) Green tea infusion was prepared by hot DI water. (B) The syringe filter was used to remove
big debris. (C) The dialysis tubing (MWCO=300KD) was used to remove small molecules in
green tea infusion. (D) Isolation of the TNPs was determined by SEC-HPLC. (E) Sephadex G75
column was used to separate the DOX-loaded TNPs and free DOX. (F) Isolated DOX-loaded
TNPs were used for drug delivery.
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Materials and Methods
Materials

Laoshan® green tea was purchased from China. (-) Epigallocatechin gallate
(EGCG),

caffeine,

theobromine,

1,9-dimethyl-methylene

blue

(DMMB),

chondroitin sulfate (CS), doxorubicin hydrochloride (DOX), HEPES, Sephadex
G75 and phosphate buffered saline (PBS) were purchased from Sigma-Aldrich
(St. Louis, MO). LysoTracker Green DND-26 and Hoechst 33342 were obtained
from Invitrogen Life Technologies (Grand Island, NY). Fetal bovine serum,
DMEM medium and RPMI 1640 medium were purchased from Mediatech
(Manassas, VA). Penicillin (10000 units/ml)-streptomycin (10000 µg/ml) solution
was obtained from MP biomedicals (Solon, OH). RAW 264.7 murine
macrophages (TIB-71) and human non-small-cell lung cancer A549 cells (CCL185) were obtained from the American Type Culture Collection (Manassas, VA).
The human breast tumor cell line MCF-7 and its resistant cell line MCF-7/ADR
were obtained from the Frederick National Laboratory for Cancer Research
(Frederick, MD).
Preparation of Tea Nanoparticles (TNPs)

Green tea infusions were made by steeping 15 g of dried green tea leaves in 200
ml of boiling deionized water (DI water) for 20 minutes. The resulting hot tea
infusion was then centrifuged at 5000 rpm for 10 min, and the supernatant was
filtered through a 1 µm filter (Whatman Inc., Florham Park, NJ). The filtered
13

solution was then sonicated in a water-bath sonicater (model 750D, VWR) at
room temperature for 30 min. The free small molecules, such as alkaloids, and
polyphenols, were removed by dialysis using 300KD MWCO tubing against DI
water for 3 days at room temperature. Size-exclusion high-performance liquid
chromatography (SEC-HPLC) was used to further isolate the nanoparticles after
dialysis. 250 µl of the dialyzed solution was loaded onto a SEC-HPLC column
(Phenomenex® BIOSEP-SEC-S4000), and eluted with distilled water at
1.0 ml/min of flow rate. The UV absorption at 280 nm was measured, and all
fractions were collected.

Determination of Chemical Components of TNPs

The total amounts of polysaccharides were measured using the anthrone-sulfuric
acid assay [54]. Briefly, the anthrone reagent was prepared freshly before
analysis by dissolving 0.02 g of anthrone (0.2%) in 10 ml of concentrated sulfuric
acid (98%). A standard glucose solution was prepared in PBS and serially diluted
to 0, 15.625, 31.25, 62.5, 125, and 250 µg/ml. 0.2 ml of the glucose standards or
tea nanoparticle solution (1mg/ml) was added to 0.5 ml of the freshly prepared
0.2% anthrone-sulfuric acid. The mixture was stirred immediately and incubated
in boiling water for 15 min. All samples were then put on ice for 5 min to stop the
reaction. After keeping 10 min at room temperature, samples were placed in a
96-well plate, and read at 620 nm in a microplate reader (Bio-Tek µQuant). The
amount of proteins in the TNPs was determined using a bicinchoninic acid (BCA)
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protein assay kit (Pierce) following the manufacturer’s instructions. Small
molecules present in the TNPs, i.e. EGCG, caffeine and theobromine, were
determined by the RP-HPLC method as reported previously.[55] Briefly, HPLC
analysis was conducted on a Agilent 1200 series HPLC system equipped with
DAD detector. The DAD acquisition wavelength was set from 200 to 400 nm, with
output channel A at wavelength 280 nm and output channel B at 360 nm. 1 mg of
the freeze-dried TNP sample was dissolved in 70% methanol solution, then
incubated at room temperature for three hours and filtered through 0.22 µm filters
(Carrigtwohill, Co. Cork, Ireland). 10µl of the filtered samples were then analyzed
on an Eclipse XDB-C18 (4.6 mm ×150 mm, 5 µm) column. Gradient elution was
performed by varying the proportion of solvent A (water-acetic acid, 97:3 v/v) to
solvent B (methanol), with the flow rate of 1 ml/min. The mobile phase
composition started at 100% solvent A for 1 min, followed by a linear increase of
solvent B to 63% in 27 min, and then go back to the initial conditions in 2 min for
the next run.
Characterization of TNPs

10µl of the TNP solution was air-dried on a silicon substrate or glass cover slip
for SEM and AFM analysis to characterize the particle size and morphology of
the TNPs. The SEM analysis was performed using a high resolution FE-SEM
system (LEO 1525, Germany). AFM analysis (MFP-3D, Asylum Research, Santa
Barbara, CA) was operated based on the software Igor Pro from Wavemetrics in
AC mode, and an ACTA Probe from AppNano (Santa Clara, CA) at room
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temperature. The samples were further analyzed by dynamic light scattering
(DLS) and electrophoretic light scattering (ELS), using a Zetasizer Nano (Malvern
Instruments Ltd, Worcestershine, UK), to determine the size distribution and zeta
potential of the TNPs in solution.

In Vitro Immunostimulatory Activity

The mouse macrophage cell line, RAW 264.7, was incubated for 24 h in DMEM
culture medium supplemented with 10% FBS and 1% penicillin-streptomycin at
37°C in 5% CO2. The cells were then plated in 12-well plates at a density of
5×106 cells/ml and cultured for 24 h. The TNP samples at the concentration of
50µg/ml were added in each well. After incubation for 24 h, the supernatants
were collected for ELISArray analysis. Mouse common cytokines and
chemokines multi-analyte ELISArray kits (SABiosciences Corporation, Frederick,
MD) were used to determine various cytokines (IL-1A, IL-1B, IL-2, IL-4, IL-6, IL10, IL-12, IL-17A, IFNγ, TNFα, G-CSF, and GM-CSF) and chemokines (RANTES,
MCP-1, MIP-1a, MIP-1b, SDF-1, IP-10, MIG, Eotaxin, TARC, MDC, KC, and
6Ckine) in the supernatants following the manufacturer’s instructions.
Preparation and Characterization of Doxorubicin (DOX)-loaded TNPs

The DOX-loaded TNPs were prepared by mixing DOX (0.3 mM) with the TNPs
(1mg/ml) in HEPES buffer (20mM, pH=7.0) at room temperature for 3 hours. The
DOX loaded into the TNPs were isolated from the free DOX in the solution by a
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Sephadex G75 column method as previously reported.[56] The concentration of
DOX loaded into the TNPs was determined by the DOX characteristic peak at
480 nm. The absorbance was measured by a microplate reader (Bio-Tek
µQuant). In order to evaluate the effect of pH on drug loading to the TNPs, the
DOX-loaded TNPs were prepared under different pH conditions (20mM HEPES
buffer, pH=7.0, 5.5 and 3.5). After incubation at room temperature for 3 hours,
samples were applied to the Sephadex G75 column, and eluted with 20 mM
HEPES buffer under the corresponding pH values. Elution profiles of the DOXloaded TNPs (λ=480 nm) were plotted versus elution volumes. In order to
characterize the hydrophobic interactions between DOX and the TNPs, the
ultraviolet and visible (UV-Vis) spectra of the blank TNP solution, the DOXloaded TNP solution, and free DOX solution (with the same DOX concentration)
were

measured

using

a

Thermo

Scientific

Evolution

600

UV-Visible

spectrophotometer. Fluorescence spectra of the DOX-loaded TNPs and free
DOX were then measured by using a spectrofluorimetry (LS-50B, Perkin Elmer)
at the wavelength of 480nm (excitation). Fourier-transform infrared spectroscopy
(FTIR) was finally performed to determine the possible binding effect of DOX and
the TNPs. The DOX-loaded TNPs, and the blank TNPs were freeze-dried prior to
FTIR analysis. Dry powders were mixed with potassium bromide, and
transmission spectra were acquired with a Bruker Vertex 70 FT-IR spectrometer
(Bruker Optics Inc, Billerica MA), equipped with a deuterated triglycine sulfate
detector and controlled by the OPUS 6.5 software package.
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In Vitro Release of DOX from TNPs
In vitro release of DOX from the TNPs under acidic and neutral conditions
(pH=5.0, 6.0 and 7.5) was evaluated. The release study was conducted in
phosphate buffered saline (PBS, pH=7.5 and 6.0) and 0.1 M acetate buffer
(pH=5.0) at room temperature with moderate shaking. Briefly, 1 ml of the DOXloaded TNPs or free DOX solution (with the same concentration of DOX= 0.1mM)
was added to a dialysis membrane tube (MWCO= 12KD) and immersed in a
glass container containing 30 ml of release buffers. 0.5 ml of the released
solution was collected at different time intervals and replenished immediately with
the same volume of the corresponding fresh medium. DOX release profiles were
determined by a Synergy HT multi-detection microplate reader (Bio-Tek
Instruments Inc., Winooski, VT) at 480 nm excitation and 590 nm emission.
Cellular Uptake and Confocal Microscopic Study of DOX-loaded TNPs
The quantification of intracellular DOX uptake in cancer cells was evaluated by
flow cytometry. In general, A549, MCF-7 and MCF-7/ADR cells were cultured in
6-well plates at densities of 1×106 cells/ml, and incubated at 37°C in 5% CO2.
The DOX-loaded TNPs or free DOX solution at 10µM of DOX concentration
were added into the wells and incubated at 37°C for 1h, 2h, and 3h, respectively.
The media were aspirated and cells were rinsed with PBS for three times. Flow
cytometry analysis was carried out on an Epics XL Analyzer (Beckman Coulter
Inc., Brea, CA) by collecting 20000 events for each sample and measuring the
cell associated fluorescence. Confocal laser scanning microscopy (CLSM) was
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used to investigate intracellular DOX distribution in the above three cell lines
treated with the DOX-loaded TNPs, and free DOX was used as a control. Briefly,
the cells were seeded on cover slips with a density of 10 6 cells/ml in a 6-well
plate and cultured at 37°C in 5% CO2 for 24 h. The cells were then treated with
the DOX-loaded TNPs at 10 µM of DOX concentration for 1 h and 3h. To observe
the intracellular distribution, endolysosome and nuclear markers, LysoTracker ®
green (100 nm) and Hoechst 33342 (4µM) were incubated with the cells for 30
min prior to the confocal visualization. The cover slip was washed with PBS three
times and then set on a microscope slide and examined by CLSM.
In Vitro Cytotoxicity
The cytotoxicity of the DOX-loaded TNPs against A549, MCF-7 and MCF-7/ADR
was evaluated by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium
bromide) assay.[57] Briefly, 5000 cells were plated in 96-well plates in 100 µl
DMEM (for A549 cells) or RPMI 1640 (for MCF-7 and MCF-7/ADR cells) and
supplemented with 10% fetal bovine serum (FBS) and 1.0 % penicillinstreptomycin per well and incubated at 37 °C in 5% CO2 for 24 h to allow the
cells to attach. The cells were then treated with different concentrations of the
DOX-loaded TNPs for 48 h. Free DOX and the blank TNPs were used as
controls. After the 48 h treatment, 10 μl of MTT solution (5 mg/ml in PBS; pH 7.4)
was then added to each well and the plates were incubated for another 4 h. The
cell culture media were removed and replaced with 100 µl DMSO. The
absorbance was measured by a microplate reader (Bio-Tek µQuant) at 570 nm,
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and the average IC50 (the dose having 50% cell inhibition) value was determined
by cell survival plots using the ―DoseResp‖ function in OriginPro 8.0.
Statistical Analysis
Values were presented as mean ± standard deviation (S.D.) of at least three
independent measurements. Statistical significance was tested by one-way
ANOVA followed by a Student's t test for multiple comparison tests. A p value of
<0.05 was considered statistically significant.
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Results and Discussion
Spherical nanoparticles isolated from tea infusion
An infusion-dialysis based procedure was developed to isolate nanoparticles
from tea infusion (Figure 1A-B). To remove the large debris, the tea infusion was
centrifuged at 5000 rpm for 10 min. The supernatant was then filtered through a
1µm filter, and dialyzed to remove any compounds with MW of less than 300KD.
To further validate the infusion-dialysis based procedure, size exclusion
chromatography-high performance liquid chromatography (SEC-HPLC) analysis
was utilized for separating the tea infusions before and after the dialysis. As
shown in Figure 1, there were multiple UV peaks at 280 nm that occurred at
different elution times before the dialysis (Figure 1B), while only one well-defined
peak was detected at 0-10 min after the dialysis (Figure 1D). The single peak in
the SEC-HPLC profile indicated that the dialyzed sample was more homogenous
and likely contained a narrow range of nanoparticles.[58] To determine if the
nanoparticles could be found in the fraction collected from this peak, the sample
was scanned using AFM and SEM. As hypothesized, AFM images (Figure 2A-B)
showed clearly that abundant spherical nanoparticles with diameters in the range
of 100-300 nm were observed. Similarly, SEM analysis revealed the presence of
abundant spherical nanoparticles in the range of 50-200 nm in diameter (Figure
2C). To determine the size distribution of the TNPs in solution, DLS was
conducted on the TNP containing fraction. Results in Figure 3 and Table 1, the
tea nanoparticles showed a relatively broad distribution of size with a mean
hydrodynamic diameter of 318.3 nm.
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Figure 2 AFM (A-B) and SEM (C) images of the TNPs obtained from the green tea infusion.
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Figure 3 The size distribution of the TNPs at pH= 7.0 (A), and the DOX-loaded TNPs at pH=
7.0 (B), pH= 5.5 (C), and pH= 3.5 (D) in suspension measured by DLS.
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Table 1 Characteristics of the TNPs and the DOX-loaded TNPs.
Diameter
[nm]

PDI

Zeta
potential
[mV]

Protein
[µg/mg]

Polysaccharide
[µg/mg]

318.3

0.324

-26.52±2.21

453.36±7.71

189.12±9.03

287.0

0.305

-6.34±1.49

--

--

DOX-loaded
TNPs
(pH=5.5)

301.6

0.292

-8.30±1.35

--

--

DOX-loaded
TNPs
(pH=3.5)

271.9

0.275

-9.15±0.33

--

--

Samples
TNPs
(pH=7.0)
DOX-loaded
TNPs
(pH=7.0)
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Further, the surface charge potential of the TNPs was analyzed using ELS. The
TNPs were found to be -26.52±2.21 mV at pH 7.0. The results from this analysis
clearly demonstrated that the method developed for isolating nanoparticles from
green tea infusion was effective, leading to a stable population of the TNPs. At
present, it is not well understood how the nanoparticles are formed in tea, and
what roles they play in the growth and development processes of green tea.
However, several studies have reported the observation and tentative
components of the nanoparticles in black tea.[43, 59] In 1995, a study reported
nanoparticles in aqueous black tea extracts formed on cooling.[43] The black tea
nanoparticles showed particle size of about 200-300 nm, similar to the
nanoparticles isolated from green tea in this study. A study in 1963 [59] proposed
that the main components in black tea nanoparticles were caffeine, theaflavins
and the thearubingins; however, there was no direct evidence to validate these
tentative components in their paper.[43] Due to the use of the infusion-dialysis
based procedure for the TNP isolation in our study, small molecules not
complexed with the TNPs were removed, thus several bioactive phytochemicals
in green tea were not expected to be contained in the TNP fraction. In order to
validate this assumption, we have analyzed the concentrations of three common
phytochemicals from green tea, including (-)-epigallocatechin gallate (EGCG),
caffeine and theobromine, using the reversed phase HPLC (RP-HPLC) method.
To effectively solubilize these small molecules from the TNPs, a single extraction
with methanol was used[60]. As shown in Figure 4A-C, the UV 280nm
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Figure 4 HPLC chromatograms of EGCG (A), caffeine (B), theobromine (C) as standards,
and isolated TNPs (D) at 280 nm.
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peaks of 10 µg/ml EGCG, caffeine and theobromine standards appeared at
respective retention time of 11.59, 12.66 and 7.68 min. However, no peak from
EGCG, caffeine and theobromine was observed in the TNP fraction, indicating
that they were not present in the TNPs (Figure 4D). To further investigate the
possible chemical components of the TNPs, we detected the concentrations of
two common macromolecules (i.e., protein and polysaccharide) in the TNPs,
measured by the BCA protein assay and anthrone-sulfuric acid method,
respectively. As shown in Table 1, there were about 453.36 µg proteins and
189.12 µg polysaccharides in 1 mg TNPs. According to previous studies, the
polysaccharides

from

green

tea

were

believed

to

be

a

typical

heteropolysaccharide and consisted of mannose, ribose, rhamnose, glucuronic
acid, galacturonic acid, glucose, xylose, galactose and arabinose [61], and some
acidic polysaccharides were reported to be bound to protein [62]. Considering the
excellent biocompatibility of green tea, although there is no complete dissection
for all components in these new natural nanoparticles, the two confirmed
components, polysaccharide and protein, can still provide an opportunity for us to
explore the potential biomedical application of the TNPs (Figure 1E-F).

Immunostimulatory effect of TNPs on RAW 264.7 mouse macrophages
As is well-known,polysaccharides isolated from a wide range of plants, including
higher plants, mushrooms, lichens and algae often have macrophage modulatory
effects

[63],

and

thus

are

promising
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candidates

for

therapeutics

in

immunomodulatory, anti-tumor and wound healing applications [63, 64].
Polysaccharides from green tea have also been reported to possess
immunological and anti-cancer properties both in vivo and in vitro [65, 66].
Inspired by these studies, we have evaluated the potential immunological effect
of the TNPs in vitro. It is well-known that macrophages as the first line of host
defense can function as antigen-presenting cells, and interact with other immune
cells to modulate the immune response [63]. For cancer treatment, macrophages
mediate tumor cytotoxicity via the production of various cytokines and other
immune factors [67]. Testing the secretion of cytokines and chemokines from
macrophages induced by potential immunostimulatory substances is a common
approach to evaluate their immunostimulatory activity [68]. Using a murinederived macrophages RAW 264.7, we first tested 12-cytokine profiles, including
IL-1A, IL-1B, IL-2, IL-4, IL-6, IL-10, IL-12, IL-17A, IFN-γ, TNF-α, G-CSF, and GMCSF, after treatment with 50µg/ml of the TNPs. It is noteworthy that the levels of
IL-6 (p<0.01), TNF-α (p<0.05) and G-CSF (p<0.01) were significantly increased
after incubation of RAW 264.7 macrophages with the TNPs for 24 h as indicated
by ELISArray (Figure 5A). TNF-α is a multifunctional cytokine that plays a key
role in apoptosis, cell survival, inflammation and immunity. The importance of
TNF-α in the immune system mainly stems from its ability to interact with different
receptors, and then activate several signal transduction pathways, leading to the
diverse functions, especially its immunostimulatory effect [69]. It has also been
reported that TNF-α could act synergistically with other drugs at the molecular
level to trigger the apoptosis and dissociation of tumor vascular endothelial cells
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in cancer treatment.[70, 71] IL-6 has been recognized as an important host
defense molecule that can affect tumor cells.[72] It also plays key roles in T-cellmediated immune responses, acting as a cofactor for T-cell proliferation.[73] GCSF has a variety of functions including the induction of proliferation, survival
and differentiation of hematopoietic cells, as well as mobilization of bone marrow
cells.[74] Because G-CSF can stimulate the differentiation of bone marrow stem
cells, and promote the mobilization of hematopoietic precursor cells from the
bone marrow into the bloodstream,[75] it has been reported to be used in many
cancer patients to prevent and counterbalance chemotherapy-associated
neutropenia.[76] In addition to the ability of the TNPs to stimulate IL-6, TNF-α,
and G-CSF secretion, secretion profiles of the 12 chemokines, including
RANTES, MCP-1, MIP-1a, MIP-1b, SDF-1, IP-10, MIG, Eotaxin, TARC, MDC,
KC, and 6Ckine, were also analyzed. As shown in Figure 5B, significantly
enhanced productions of RANTES (p<0.01), IP-10 (p<0.05) and MDC (p<0.01)
were observed after incubation with the TNPs. The primary function of
chemokines is chemoattraction and activation of specific leucocytes in various
immune-inflammatory responses. Besides their actions on haematopoietic cells,
chemokines were also demonstrated to induce distinct effects in stromal and
solid tumour cells.[77] RANTES was the first chemokine reported to mediate antitumor immunity in part through direct T cell effector recruitment.[78, 79] IP-10
has been suggested to exhibit anti-tumor and anti-metastatic properties, and its
immunological properties appear to be dependent on the attraction of monocytes

29

Figure 5 Effects of the TNPs (50µg/ml) on in vitro secretion of cytokines
Effects of TNPs (50ug/ml) on in vitro secretion of cytokines (IL-1A,IL-1B, IL-2, IL-4, IL-6, IL-10, IL12, IL-17A, IFN-γ, TNF-α, G-CSF, and GM-CSF), and chemokines (RANTES, MCP-1, MIP-1a,
MIP-1b, SDF-1, IP-10, MIG, Eotaxin, TARC, MDC, KC, and 6Ckine) by RAW264.7 macrophage
cells. (A) Inductions of cytokines (IL-6, TNF-α and G-CSF) were determined by ELISArray in
supernatants of the cells cultured for 24 h. (B) Secretion of chemokines (RANTES, IP-10 and
MDC) were determined by ELISArray in supernatants of the cells cultured for 24 h. The values
stand for means ± SD obtained from three independent experiments. *P<0.05 and †P< 0.01, as
compared with the controls.
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and T lymphocytes.[80] Moreover, IP-10 can induce tumor regression and
immunity to subsequent tumor challenge.[77, 81] There is also in vivo evidence
indicating that MDC is identified in diversion of effective antitumor responses.[82]
These evidences indicate that the TNPs may exert various beneficial
pharmacological effects, especially antitumor effect, via their ability to modulate
macrophage immune function.
DOX loading in TNPs via electrostatic and hydrophobic interactions

As mentioned above, the TNPs have a surface potential of ~-26mV at pH7.0,
which is a desirable property for binding cationic chemo-drugs. To test the
potential of the TNPs as a nanocarrier, complexation of the isolated TNPs with
the cationic cancer theraputic DOX was conducted. Typically, there are two ways
to load DOX onto nanoparticles: electrostatic binding of cationic DOX to
nanoparticles, and entrapment of the neutral DOX with hydrophobic groups.[83]
Considering the negative surface potential of the TNPs at the physiological pH,
the complexation of DOX with the TNPs through electrostatic interactions was
performed. For this purpose, 0.3mM of DOX was mixed with 1mg/ml of the TNPs
in 20mM HEPES buffer (pH 7.0) and incubated for 3 hours at room temperature.
After loading the mixture onto a Sephadex G75 column, the DOX-loaded TNPs
were collected from the first peak of the elution profile.[56] As shown in Figure
6A. the first peak (5-10 ml) stands for the DOX-loaded TNPs, while the second
peak (11-20 ml) represents the free DOX.[56] The association efficiency of DOX
loaded onto the TNPs was 46% at pH 7.0. The average diameter of the DOX31

loaded TNPs was similar to the blank TNPs; however the DOX-loaded TNPs
showed a lower zeta potential (-6.34 mV) as compared with that of blank TNPs (26.52 mV) (Table 1). This decrease in zeta potential suggests that the positively
charged DOX molecules may be adsorbed onto the negatively charged TNPs
through electrostatic interactions. To verify this hypothesis, 1mg/ml of TNP
solution was mixed with 0.3mM of DOX at various pH (7.0, 5.5 and 3.5). The
loading profiles of DOX to the TNPs under different pH values were recorded by
separating the DOX-loaded TNPs from free DOX using G75 column. As shown in
Figure 6A, compared with pH 7.0, there was a slight decrease for the amount of
DOX loaded onto the TNPs at pH 5.5, while when the pH was adjusted to 3.5,
the area of the first peak decreased dramatically and the second peak increased,
indicating that DOX was not efficiently loaded. While a clear difference in loading
was observed at pH 3.5, the average diameters and size distributions of the
DOX-loaded TNPs under different pH did not show a clear difference (Figure 3).
Apart from the electrostatic interaction between DOX and the TNPs, hydrophobic
interactions may also contribute to the formation of the DOX-loaded TNPs. As
shown in Figure 6B-C, compared to free DOX, a significant DOX fluorescence
quenching effect in the DOX-loaded TNP sample was observed, while there was
no significant decrease in UV absorption for the DOX-loaded TNPs at the same
DOX concentration. This data suggests that hydrophobic interactions may lead to
complexation of DOX to the TNPs, and the resulting quenching effect may be
due to the dense packing of the DOX molecules on the nanoparticle surface.[84]
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Figure 6 Characterization of the DOX-loaded TNPs.
(A) Loading profiles of DOX to TNPs under various pH conditions: acidic (pH= 3.5 and 5.5), and
neutral (pH= 7.0). With the decrease of the pH value, the binding between the TNPs and DOX
decreased. (B) UV-Vis absorbance spectra of DOX (blue), the TNPs (black), and the DOX-loaded
TNPs (red) solution. Characteristic DOX absorption peak is at 480nm. (C) Fluorescence spectra
of free DOX and the DOX-loaded TNPs solutions with the same DOX concentration (5 µM) under
480 nm excitation. A quenching effect of DOX fluorescence was observed for the DOX-loaded
TNPs. (D) Release profiles of DOX from the TNPs under different pH conditions (pH=5.0, pH=6.0
and pH=7.5). Free DOX was used as a control.
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To further evaluate whether covalent bonds were available between the TNPs
and DOX, the DOX-loaded TNPs were characterized by FTIR, using free DOX
and the TNPs as controls. Comparing the FTIR spectrum of the DOX-loaded
TNPs with those of the blank TNPs and free DOX, there were additional
absorption bands at ~1734 and 1289 cm-1 corresponding to the C-O-CH3
stretching bands of DOX (Figure 7), indicating DOX was successfully loaded
onto the TNPs. No other new peaks appeared or shifted, suggesting that there
was no covalent bonding between DOX and the TNPs.
pH-responsive DOX release from TNPs
In order to evaluate the potential of the TNPs as a nanocarrier for cancer
treatment, DOX release behavior from the DOX-loaded TNPs was evaluated at
neutral and acidic pH by using buffers with varying pH values (pH=5.0, 6.0 and
7.5). As shown in Figure 6D, more than 90% of free DOX was released under
the neutral condition after 6 hours, while the release of DOX from the TNPs
under different pH values reached a plateau after 25 hours. The sustained DOX
release from the TNPs demonstrated that the release process is a pH-responsive
release at various pH conditions. During the first 10 hours of the first-order
release curve, there was no significant difference in the cumulative release of
DOX from the TNPs at both neutral and acidic pH, presumably because the
hydrophobic interaction dominated the stability of the DOX-loaded TNPs, when
more DOX was associated with the nanoparticles [85].
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Figure 7 FTIR spectra of DOX (black), the TNPs (red), and the DOX-loaded TNPs (blue).

The absorption bands at ~1734 and ~1289 cm-1 correspond to the C-O-CH3 stretching
bands of DOX. The band around 1652 cm-1 and 1223 cm-1 may be due to the C=O and
CN stretch vibrations of amide, which comes from proteins and polysaccharides of the
TNPs. For the spectrum of the DOX-loaded TNPs, the bands all come from DOX and the
TNPs, and no other new peaks appeared or shifted, suggesting that there is no covalent
bonding between DOX and the TNPs.
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While after 10 hours, the cumulative release of DOX from the TNPs was
significantly higher in the acidic condition compared with the neutral condition.
About 88% of DOX was released from the TNPs under the acidic condition at pH
5.0, while around 80% and 70% of DOX was released under pH 6.0 and 7.5 after
25 hours. It likely indicated that the dominant driving force maintaining the
stability of the DOX-loaded TNPs was gradually shifted to the electrostatic
interaction between DOX and the TNPs, due to the fact that a majority of DOX
(~70%) released and less DOX remained in the TNPs.[85] Since acidic
conditions could potentially cause a decrease in the negative charges on the
TNPs, the binding between the TNPs and DOX was weakening, and more DOX
was disassociated from the TNPs with the decrease of the pH value. The pHresponsive drug release behavior is regarded as a favorable property for in vivo
antitumor applications.[86] Since only small amounts of DOX release in the blood
circulation (pH=7.4), more active drug could be released after reaching the target,
as a result of the lower pH in the tumor tissue or in the endosomes (pH=~ 5) after
entering into cells via endocytosis.[86] Thus, the pH-responsive release property
of DOX from the TNPs would probably make them to be used as an effective
nanocarrier for drug delivery in cancer treatment.

TNPs facilitate intracellular DOX delivery in sensitive and resistant tumor
cells
The quantitative determination of DOX uptake in cancer cells was conducted by
flow cytometry. Two sensitive tumor cell lines, A549 human lung cancer cells and
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MCF-7 breast cancer cells, were incubated with the DOX-loaded TNPs at a DOX
concentration of 10 µM for1 h, 2 h and 3 h. The cell-associated fluorescence
intensity, which was directly proportional to the amount of DOX internalized in
cells, was then measured.[87] Figure 8A-F show the flow cytometry histograms
of DOX fluorescence from both cells incubated with the DOX-loaded TNPs, free
DOX and the blank TNPs. For all time points, the treatment of the DOX-loaded
TNPs showed a significant increase in the level of DOX uptake compared with
free DOX. To test if the TNPs could also increase the uptake and accumulation
of DOX in drug-resistant cancer cells, the uptake of the DOX-loaded TNPs and
free DOX by resistant MCF-7/ADR breast cancer cells was evaluated. As shown
in Figure 8G-J, compared with free DOX, the intracellular accumulation of DOX
increased from 1h to 3h in the resistant MCF-7/ADR cells treated with the DOXloaded TNPs. The above data suggested that the DOX-loaded TNPs could
provide an alternative treatment option for drug-resistant tumors.[88] To assess
the intracellular distribution of the DOX-loaded TNPs, we incubated both
sensitive cell lines with the DOX-loaded TNPs at a DOX concentration of 10 µM
for 1h and 3 h, and then conducted confocal laser scanning microscopy (CLSM).
The nucleus and endolysosomes were labeled with the nucleus-selective dye
(Hoechst 33342, blue), and acidic endolysosomes-selective dye (LysoTracker®,
green DND-26), respectively. As shown in Figure 9, the intracellular distribution
of the DOX-loaded TNPs was different from that of free DOX in both cells. After
1h incubation, treatment of both cells with free DOX resulted in weak DOX
fluorescence in the cytoplasm.
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Figure 8 Quantitative flow cytometry analysis for intracellular uptake of free DOX and the
DOX-loaded TNPs
Quantitative flow cytometry analysis for intracellular uptake of free DOX and the DOX-loaded
TNPs in A549 (A-C), MCF-7(D-F) and MCF-7/ADR (G-J) cells at different time points (1h, 2h and
3h). All cells were treated with the DOX-loaded TNPs and free DOX at the same DOX
concentration of 10 µM for different time intervals.
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Figure 9 CLSM images of the intracellular distributions of the DOX-loaded TNPs in A549
and MCF-7 cells.
CLSM images of the intracellular distributions of the DOX-loaded TNPs and free DOX with the
same DOX concentration (10µM) in sensitive human lung cancer A549 and human breast cancer
MCF-7 cells for different time incubation (1 h and 3 h). The cells were stained with Lysotracker®
green DND-26 (green) and Hoechst 33342 (blue). The pink color shows the localization of DOX
(red) in nucleus (blue), and the yellow color indicates the localization of DOX (red) in
endosomes/lysosomes (green). The scale bars represent 10 μm.
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However, for the DOX-loaded TNPs treatment, stronger DOX fluorescence could
be detected in the cytoplasm in both cells. Differences in intracellular distribution
of the DOX-loaded TNPs and free DOX in both cells were also obtained after 3h
treatment. The intense DOX fluorescence was visualized in both cytoplasm, and
the nucleus for the treatment of the DOX-loaded TNPs, while in the treatment of
free DOX, it appeared that there was less DOX fluorescence in the cytoplasm
and a smaller amount of DOX fluorescence in the nucleus. These results are
consistent with the cellular uptake investigated by flow cytometry in Figure 8A-F.
In terms of DOX localization in both cells, a large fraction of the DOX-loaded
TNPs was found to be entrapped in endolysosomes after 1 h incubation, while
more DOX fluorescence was observed to be out of endolysosomes and localized
in cytoplasm and nucleus after 3h incubation (Figure 9). Since the enhanced
uptake of the DOX-loaded TNPs was also observed in resistant cells by flow
cytometry, we visualized their intracellular distribution in MCF-7/ADR cells to
further assess the potential of the TNPs for cancer treatment. As shown in
Figure 10, after 1h treatment, small amount of DOX was localized in the
cytoplasm of MCF-7/ADR cells; however, more DOX fluorescence accumulated
in the discrete cytoplasm area was observed, when the MCF-7/ADR cells were
treated with the DOX-loaded TNPs. For 3h treatment, most free DOX
accumulated in discrete granules in the cytoplasm, and a little was observed in
nucleus.
In case of the DOX-loaded TNPs, significant increase of intracellular DOX
fluorescence

was

observed

in

both
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nucleus

and

cytoplasm.

Figure 10 CLSM images of the intracellular distributions of the DOX-loaded TNPs and free
DOX in MCF-7/ADR cells
CLSM images of the intracellular distributions of the DOX-loaded TNPs and free DOX with the
same DOX concentration (10µM) in MCF-7/ADR cells for different time incubation (1 h and 3 h).
The cells were stained with Lysotracker® green DND-26 (green) and Hoechst 33342 (blue). The
pink color shows the localization of DOX (red) in nucleus (blue), and the yellow color indicates the
localization of DOX (red) in endosomes/lysosomes (green). The scale bars represent 10 μm.
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The TNPs were not possible to enter the nucleus due to size limitations for entry
via the nuclear pore complex.[89] The results indicated that the TNPs could
enhance the cellular uptake of DOX, and then affected its nuclear localization in
both sensitive and resistant tumor cells. These observations demonstrated that
the TNPs might be an effective nanocarrier to efficiently transport DOX into both
sensitive and resistant tumor cells.
TNPs enhance in vitro cytotoxicity of DOX against sensitive and resistant
tumor cells
Due to the enhanced intracellular DOX uptake by the TNPs in sensitive and
resistant cell lines, we hypothesized that the TNPs could confer higher
cytotoxicity against sensitive or even resistant tumor cells by enhancing
intracellular delivery of drugs. To verify the hypothesis, we investigated the in
vitro cytotoxic activity of the DOX-loaded TNPs against the sensitive cell lines
and the resistant cell line for cancer therapy. First, it was determined that the
TNPs had no cytotoxicity from 1.28 ng/ml to 100 µg/ml in the three cell lines after
48h treatment (Figure 11A). Different tumor cells were then treated with the
DOX-loaded TNPs and free DOX at a series of DOX concentrations. Figure 11BD shows the dose-dependent cell viability with the DOX-loaded TNPs and free
DOX. The IC50 values for DOX-loaded TNPs and free DOX are listed in Table 2,
indicating the enhancement of cytotoxic effect on DOX-loaded TNPs.
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Figure 11 In vitro cytotoxicity of the TNPs and DOX-loaded TNPs
In vitro cytotoxicity of the TNPs (A) and the DOX-loaded TNPs in human lung cancer A549 (B),
human breast cancer MCF-7 (C), and its drug resistant cell line MCF-7/ADR (D). All tumor cells
were treated with the blank TNPs at the concentration of 1.28 ng/ml to100 µg/ml for cytotoxic test
of the TNPs themselves. For the DOX-loaded TNPs and free DOX, the DOX dosage was from
0.1 nM to 10 µM (for A549 cells), from 0.3 nM to 20 µM (for MCF-7 cells), and from 0.5 nM to 40
µM (for MCF-7/ADR cells). The cells were treated with different samples for 48 h. Data are
presented as the mean ± SD from three independent experiments.
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Table 2 IC50 values (µM) of free DOX and the DOX-loaded TNPs in lung
cancer A549 cells, human breast cancer MCF-7 and its drug-resistant cell
line MCF-7/ADR after 48 h incubation.
IC50(µM)

A549

MCF-7

MCF-7/ADR

DOX

0.30±0.05

0.46±0.09

69.69±21.67

DOX-loaded

0.026±0.005*

0.036±0.012*

15.16±7.05*

TNPs
Note: IC50 was determined by using ―Dose Resp‖ function of OriginPro 8.0; *P<0.05 as compared
with free DOX.
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Treatment of A549 cells with the DOX-loaded TNPs (from 0.64 nM to 10 µM) had
significant higher cytotoxicity than the treatment with free DOX (p<0.05), with a
half-maximal value of ~0.3µM (for free DOX) compared to ~0.026µM (for the
DOX-loaded TNPs). Similarly, the IC50 value of the DOX-loaded TNPs (~0.036
µM) against MCF-7 cells was significantly lower than that of free DOX (~0.46 µM)
(p<0.05), indicating much higher cytotoxicity of the DOX-loaded TNPs. In both
cell lines, the IC50 value was ~12 times lower when associating of DOX with the
TNPs (Table 2). More interestingly, in the case of resistant MCF-7/ADR cells, the
IC50 value of the DOX-loaded TNPs was about 15.16 µM, which was 4.6 times
lower than that of free DOX (69.69 µM) (p<0.05) (Table 2). The data indicated
that the enhanced DOX uptake exerted by the TNPs could effectively increase
the cytotoxicity against both sensitive and resistant tumor cells. The cytotoxicity
data combined with the increased cellular uptake substantiate the use of the
TNPs as a nanocarrier for the delivery of cancer therapeutics, especially for
multidrug resistant tumors.
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Further purification of the TNPs
It is well-known that the bioactivity of nature-based nanoparticles depends on
their chemical characteristics. Thus, the verification of the components and their
chemical structures in the TNPs is very important for the future biomedical
applications. In this thesis, the TNPs were simply purified by using weak anion
exchanger (WAX) and size exclusion chromatography (SEC). The TNPs were
subjected to ion exchange chromatography on a 10×70 mm column of DEAEcellulose. Different fractions were prepared in a stepwise elution with a series
concentration of NaCl (0.1-1 M) solution, and with collection of 1 ml for each tube.
The nanoparticles content in each fraction were determined by anthronesulphuric acid method [54]. The elution pattern plotted by the anthrone-sulfuric
acid method suggested these fractions contained abundant polysaccharides. The
fractions eluted with 0.2 M NaCl gradient, and then chromotographed on the
Sephadex G75 in DI water, were designated TNP-D1 (Figure 12 A). Similarly,
the fractions eluted with 0.3 M NaCl gradient, and then chromotographed on the
Sephadex G75 in DI water, were designated TNP-D2 (Figure 12 B). These
results suggested that TNP-D2 had the stronger negative charge owing to the
elute solvent was the higher concentration of NaCl (0.3 M), while TNP-D1 had
the weaker negative charge owing to the elute solvent at the lower concentration
of NaCl (0.2 M).
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Figure 12 Elution profile of the isolated TNP-D on a DEAE-cellulose column (10×70mm).
TNP-D1 was eluted with 0.2M NaCl and B) TNP-D2 was eluted with 0.3M NaCl.

.
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The purified fractions were further characterized by AFM, DLS and ELS. As
shown in Figure 13, all the purified fractions contained a large amount of
spherical nanoparticles had similar particle size of 50-100 nm in diameters. The
surface charge potential of the purified TNPs was analyzed using ELS, and the
zeta potential of TNP-D2 was found to be -44.9 at pH 7.0, which was lower than
those of TNP-D1 (-32 mV) (Table 3). These results further supported the elution
profiles through the WAX column that the lower surface charges of TNP-D1 were
easily eluted at lower concentration of NaCl solution (0.2M). In addition to the
morphology, sizes and zeta potentials, it was found that neutral polysaccharides
were considered to be the main components for TNP-D1, TNP-D2 fractions,
which is similar to the TNPs. The presence of neutral polysaccharides was
shown in TNPs, TNP-D1 and TNP-D2 by PAS staining after SDS-PAGE analysis
(Figure 13). The quantitative data of polysaccharides and proteins in all samples
were listed in Table 3. To further identify the functional groups in different TNP
fractions, FTIR analysis was employed. As shown in Figure 14, the IR spectra of
all samples exhibited the obvious characteristic absorption at 3600-3200 cm-1,
3000-2800 cm-1, 1400-1200 cm-1, 1200-1000 cm-1 corresponding to the
existence of polysaccharides [90]. The absorption peaks at around 1650 and
1250 cm-1 indicated the existence of ring sugar [91]. The strong peak at around
3400 cm-1 was assigned to –OH stretching. The peaks at 1740 cm-1 and 1632
cm-1 were attributed to C-O stretching vibration of carbonylic group and N-H
vibration or C=O asymmetric vibration of carboxyl group, which were also the
characteristics of polysaccharides [90].
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Figure 13 Characterization of purified TNPs
AFM images of purified TNPs: TNP-D1 (A), TNP-D2 (B). The size distribution of the purified TNPs:
TNP-D1 (C), TNP-D2 (D) at pH=7.0 in suspension measured by DLS. (E) Analysis by SDS-PAGE
of crude TNP samples: TNPs and purified TNP samples: TNP-D1 and TNP-D2. Samples were
prepared in DI water and separated on 10% SDS-PAGE. Gel stained with PAS showed the
neutral polysaccharides in all samples.
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Table 3 Characterization of the purified TNPs via AEX and SEC procedures
Samples

TNP

TNP-D1

TNP-D2

Size(nm)

306.1

330.0

263.7

PDI

0.301

0.206

0.293

Zeta Potential (mV)

-32.5±2.4

-32±1.2

-44.9±0.7

Polysaccharide (mg/ml)

1.20±0.015

0.53±0.11

0.45±0.006

Protein (mg/ml)

0.67±0.005

0.05±0.004

0.03±0.001

50

Figure 14 FTIR spectra of TNPs (Black), TNP-D1 (Red) and TNP-D2 (Blue) in the range of
4000-800 cm-1.
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Conclusions
In this work, an infusion-dialysis based procedure for isolating organic
nanoparticles from green tea was developed. Using this method, the TNPs
isolated were spherical with diameters of 100-300 nm and a zeta potential of -26
mV at pH 7.0. Chemical analyses revealed that there were two macromolecules
(polysaccharide and protein) and no small molecules (EGCG, caffeine and
theobromine) were identified in the TNPs. It was determined that the TNPs had
an immunostimulatory effect by inducing the secretion of various cytokines (IL-6,
TNF-α, G-CSF) and chemokines (RANTES, IP-10, MDC) from RAW264.7 mouse
macrophages. Further analysis showed that DOX could be effectively loaded
onto the TNPs via electrostatic and hydrophobic interactions. More importantly,
compared to free DOX, greater DOX uptake was observed for the DOX-loaded
TNPs in sensitive tumor cells (A549 cells and MCF-7) and drug resistant tumor
cells (MCF-7/ADR), all resulting in the enhanced cytotoxicity. Although the
underlying mechanism of how the TNPs facilitate the DOX uptake in tumor cells
and eventually lead to higher cytotoxic activity is still unknown; however,
considering the immunostimulatory activity of the TNPs, this work provides a
potential basis for utilizing the multifunctional nanoparticles from tea to improve
antitumor efficacy in the cancer immunochemotherapy.
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CHAPTER III
NATURALLY OCCURRING NANOPARTICLES FROM
ARTHROBOTRYS OLIGOSPORA AS A MULTIFUNCTIONAL
DRUG CARRIER FOR TUMOR IMMUNOCHEMOTHERAPY
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Introduction
Cancer is a leading cause of death worldwide, accounting for 7.6 million deaths
(around 13% of all deaths) in 2008, and the deaths are expected to continue
rising, with an estimated 13.1 million in 2030 [92]. Chemotherapy is generally
regarded as the first line approach for the treatment of malignant cancer in the
past decades [93, 94]. However, conventional chemotherapy remains a daunting
challenge to the successful treatment of metastatic tumors and becomes
ineffective in many patients after first few treatments [95]. This might be due to
the tumor heterogeneity, plasticity, and ineffective drug delivery to tumor tissues
and cells, which enable a subgroup of cancer cells to mutate and evade the
chemotherapy [96-98]. Simply increasing drug dose does not guarantee
elimination of this subset of tumor cells, but would eventually lead to systemic
toxicity in normal tissues and high frequency multi-drug resistance in tumor cells
[95, 99].
To evade the emergence of the systemic toxicity and therapy resistance, it is
critical to design a treatment modality with multiple mechanisms of cell killing in
tumors. One such therapy is the combined immuno-chemo-therapeutic regimen,
which has demonstrated great potential in maximizing the clinical outcomes of
cancer patient due to synergistic antitumor effects between chemotherapy and
immunotherapy [100]. Different clinical trials incorporating cancer vaccines,
immune checkpoint blockade, or adoptive cellular therapy have typically tested
the immunotherapies integrated with standard-dose chemotherapy [101]. Current
clinical data suggest that combined immunochemotherapy regimens are not only
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drug dependent but also dependent on drug dose, timing and schedule in related
to immune-based intervention [100, 101]. Because of the aforementioned
strategy conditionally dependent synergism between chemotherapy and
immunotherapy, it is expected that developing rational carriers that could
incorporate and simultaneously deliver both immune-stimulating and cytotoxic
chemotherapeutic agents [102] may be facilitate the precise temporal and spatial
delivery of different therapeutics. From this perspective, a few combination
therapies using engineered nanoparticle-based delivery systems, including
nanoparticles [102, 103], liposomes [104-106] and macromolecular conjugates
[98], etc, in conjunction with different chemical drugs and immune-stimulants,
have been reported for chemoimmunotherapy in various cancers, providing
promising preclinical outcomes[107]. However, among these nanoparticleenhanced combinatorial immunochemotherapies, few engineered biomaterials
themselves have been used as immunostimulants or adjuvants. They are
generally inert biomaterials, simply conjugated or encapsulated with an
immunostimulatory agent and a chemo-drug for the use of the combined
antitumor therapy. Due to the complex pathogenesis of malignancy, which
juxtaposes intrinsic aberrations in tumor cells with profound effects on the host
innate and acquired immune system, it demands a multi-functional therapeutic
strategy that targets tumor cells and improves or reestablishes antitumor immune
responses [108]. Thus, future rational immunochemotherapies call for novel
therapeutic biomaterials with multi-functional modes of action, in conjunction with
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conventional

chemo-drugs,

to

establish

the

utility

and

feasibility

of

immunochemotherapy [108].

Naturally occurring nanoparticle is an alternative source for production of
biopolymer-based nanoparticles with diverse properties and biofunctions through
different biological systems. The use of naturally occurring organic nanoparticles
and their biomimetic/bioinspired nanomaterials in biomedical and industry fields
have recently drawn significant interest from scientific communities. In previous
study, our group first discovered that the adventitious roots of English ivy
secreted organic nanoparticles and demonstrated that they were an attractive
candidate for sunscreen fillers [23]. Similar organic nanostructures have been
discovered in the secretions of a variety of marine species, including polychaetes,
mussels, barnacles, and sea stars [109-113] and their potential applications in
diverse industry fields were also explored and discussed [25]. It is anticipated
that the study on naturally occurring nanoparticles will not only help us to
understand the roles of nanoparticles in biological systems, but also provide
insight into the development of these nanomaterials for novel treatment of
diseases. As a natural counterpart of engineered nanoparticles, naturally
occurring organic nanoparticles, with multi-pronged modes of action in the
context of cancer therapy, may be approached in the same way as other
engineered inert nanoparticles that have been used for the aforementioned
combined immunochemotherapy, producing improved immune responses. In
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2012, our group has first revealed that the secreted nanoparticles from a
carnivorous fungus, Arthrobotrys oligospora, had promising properties as an
immunostimulatory and antitumor agent for cancer treatment [114]. A. oligospora
is a representative flesh eater in the fungal kingdom, and it can develop into the
specialized 3D adhesive traps for capturing, penetrating and digesting free-living
nematodes in diverse environments [115]. The natural-based nanoparticles from
A. oligospora, designated as fungal nanoparticles (FNPs) in this study, had mild
cytotoxic activity in tumor cells, induced the secretion of tumor necrotic factor
(TNF-α) from macrophage, and could be simultaneously used as a drug carries
for chemical drug delivery into the tumor cells [114]. Therefore, the novel
therapeutic bionanomaterial from this carnivorous fungus would be a new
multifunctional modality for optimal cancer treatment by simultaneously
modulating immune system, direct killing antitumor cells and delivery chemo-drug
into tumor cells and tissues.

The purpose of this study was to further evaluate the immunostimulatory activity,
dissect the mechanism of the cytotoxicity, and explore the potential in cancer
immunochemotherapy using the FNPs as a multifunctional nanocarrier in vitro.
We have established a cost-effective and robust platform to produce and collect
the FNPs from the sitting drop culture system established in our lab. The FNPs
collected by a washing-dialysis procedure in our previous study showed a size of
200-300 nm in diameters measured by SEM/AFM, and even 300-400 nm in
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aqueous solution measured by DLS analysis [114]. From the perspective of mere
passive targeting tumor in vivo, the upper bound size for nanoparticles
participating in the enhanced permeability and retention (EPR) effect is believed
to be approximately 400 nm[116], and an effective drug carrier for in vivo cancer
treatment should have a diameter less than 200nm considering the multiple
factors in vivo, such as limited fenestration size of the leaky vasculature in
tumors and rapid systemic clearance [99]. Thus, in this study, we first established
a new approach for purification of the crude FNPs collected from the sitting drop
culture system in order to obtain the purified FNPs with proper size ranges,
followed by characterization of critical physical-chemical properties of the purified
FNPs. The purified FNPs used as a novel multifunctional nanocarrier for cancer
immunochemotherapy in vitro was investigated, including immunostimulation, the
mechanism of the cytotoxicity, synergistic cytotoxicity, drug delivery into tumor
cells and combined immunochemotherapeutic effect. Here we report a novel
immunochemotherapy

approach

based

on

the

multifunctional

nanoparticles, which may open a new avenue for
immunochemotherapy in the future.
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fungal

combined cancer

Materials and Methods
Chemicals, fungus and cell lines
Arthrobotrys oligospora (ATCC 24927), A549 human non-small-cell lung cancer
cells (CCL-185) and RAW 264.7 murine macrophages (TIB-71) were obtained
from the American Type Culture Collection (Manassas, VA). B16BL6 murine
melanoma cells, MCF-7 human breast tumor cell line and its resistant cell line
MCF-7/ADR were obtained from the National Cancer Institute-Central Repository
(Frederick, MD). Splenocytes, derived from C57BL/6 mice, were purchased from
the Allcells Company (Emeryville, CA). HEPES, 1, 9-dimethyl-methylene blue
(DMMB), chondroitin sulfate (CS), Sephadex G75, DEAE-cellulose and
phosphate buffered saline (PBS) were purchased from Sigma-Aldrich (St. Louis,
MO). Doxorubicin hydrochloride (DOX) was purchased from Abcam (Combridge,
MA). LysoTracker Green DND-26 and Hoechst 33342 were purchased from
Invitrogen Life Technologies (Grand Island, NY). Fetal bovine serum, DMEM
medium and RPMI 1640 medium were purchased from Mediatech (Manassas,
VA). Penicillin (10000 units/ml)-streptomycin (10000 µg/ml) solution was obtained
from MP biomedicals (Solon, OH).
Arthrobotrys oligospora culture and purification of FNPs
A. oligospora was cultured in the sitting drop culture system as the previously
study [114] with minor modifications. Briefly, conidia suspension (about 10002000 conidia in 200 µl) was inoculated into the media droplet and incubated at
25˚C for 7 days. The isolation procedures were shown in Figure 15A.
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(A)

Figure 15 Schematic of a new isolation method, SEC-WAX-SEC procedure
For the FNP purification (A), and the elution profiles of the FNPs-containing media collected by
washing mycelia in the sitting drop culture system using a size exclusion chromatography (SEC,
Sephadex G75, 15 mm×70 mm) column (B) and a weak anion exchange (WAX, DEAE-cellulose,
10mm×70mm) column (C). The FNPs isolated from SEC column was designated as FNP0, which
is a crude nanoparticle sample. After loading FNP0 into the WAX column, two FNP fractions
eluted from 0.5M NaCl and 1.0M NaCl were designated as the FNP1 and FNP2, respectively.
The FNPs were qualitatively determined by colorimetrically measuring the absorbance (λ525) of
glycosaminoglycan (GAG) in the FNPs (M&M Section 2.2).
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First, the mycelia developed on the cover slip were washed more than 10 times
using distilled water. The wash water containing nanoparticles was collected, and
the samples were then filtered through a 0.2 µm syringe filter (cellulose acetate,
VWR, Radnor, PA). The FNPs were desalted by a Sephadex G75 column as
reported previously [56]. The desalted FNPs is designated FNP0, which is a
crude sample. To purify the FNP0, weak anion-exchange (WAX) chromatography
on DEAE-cellulose was performed as described previously [117]. The DEAEcellulose columns were then eluted in a stepwise fashion with 0.1 M, 0.2 M, 0.3
M, 0.5 M and 1.0 M NaCl. As our previous study, glycosaminoglycan (GAG) is
one of the main components in the FNPs [114]. Thus, the colorimetric assay
(λ525nm) for GAG with 1, 9-dimethyl-methylene blue was used to monitor the
FNPs in the eluent from the DEAE-cellulose column. The elution profiles of the
FNPs, reflected from GAG concentration, were plotted versus elution volumes.
The collected peaks containing FNPs from WAX column were subjected to the
Sephadex G-75 column for desalting, and the desalted FNPs were concentrated
to final volume of 150µl using a centrifugal filter tube (Amicon Ultra-15 100K,
Merck Millipore, Ireland).
Characterization of FNPs
To characterize morphology and particle size of the FNPs, the samples were
analyzed using AFM (MFP-3D, Asylum Research, Santa Barbara, CA). Briefly,
10µl of the particle solution was air-dried on a glass cover slip, and analyzed in
AC mode based on the software Igor Pro from Wavemetrics and an ACTA Probe
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from AppNano (Santa Clara, CA) at room temperature. The nanoparticle samples
were further analyzed by dynamic light scattering (DLS) and electrophoretic light
scattering

(ELS),

using

a

Zetasizer

Nano

(Malvern

Instruments

Ltd,

Worcestershine, UK), to determine the size distribution and zeta potential of the
samples in solution. To qualitatively determine the chemical components in the
nanoparticles, SDS-PAGE was used for staining the GAG and neutral
polysaccharides in the nanoparticles using Alsian blue and PAS reagents
(Thermo Scientific, MI), respectively. To quantitatively determine the chemical
components in the nanoparticle samples, the total amounts of polysaccharides
were measured using the anthrone-sulfuric acid assay [54]. The amount of GAG
in each sample was determined by a Proteoglycan Detection Kit (1, 9dimethylmethylene blue, Astarte Biologics, Redmond, WA) [114], and the uronic
acid in the nanoparticles were determine using carbozole assay [118]. Meanwhile,
the concentration of protein in the samples was quantitatively determined by the
BCA protein assay (Pierce, Rockford, IL) following the manufacturer’s
instructions. In addition, the endotoxin concentration in the nanoparticle samples
was measured by using the ToxinSensor Chromogenic LAL Endotoxin Assay Kit
(GenScript, Piscataway, NJ) following the manufacturer’s instructions.
Immunostimulatory activity
The mouse macrophage RAW 264.7 cells and splenocytes derived from
C57BL/6 mice were cultured in DMEM and RPMI 1640 culture media,
respectively. Both media were supplemented with 10% FBS and 1% penicillin62

streptomycin at 37°C in 5% CO2. The cells were plated in 12-well plates at a
density of 5×106 cells/ml, treated with the FNPs at the GAG concentration of
5µg/ml. After a 24-h incubation, the supernatants were collected for ELISArray
analysis. Mouse common cytokines and chemokines multi-analyte ELISArray kits
(SABiosciences Corporation, Frederick, MD) were used to determine 12
cytokines (IL-1A, IL-1B, IL-2, IL-4, IL-6, IL-10, IL-12, IL-17A, IFN-γ, TNF-α, GCSF, and GM-CSF) and 12 chemokines (RANTES, MCP-1, MIP-1a, MIP-1b,
SDF-1, IP-10, MIG, Eotaxin, TARC, MDC, KC, and 6Ckine) in the supernatants
following the manufacturer’s instructions. The concentration of nitric oxide (NO)
in the supernatants of both cells treated with the FNP samples were also
determined using Griess assay, as described elsewhere [119].
MTT assay
The cytotoxicity of the purified FNP samples and the DOX-FNP complexes
against four cancer cell lines (A549, B16BL6, MCF-7 and MCF-7/ADR cells) was
evaluated by MTT assay as early described [56], and the biocompatibility of the
purified FNP samples toward mouse fibroblast NIH3T3 cell was also measured
with MTT assay[120]. Briefly, 8000-10000 cells were plated in 96-well plates in
100 µl culture media per well and incubated at 37 °C in 5% CO2 for 24 h to allow
the cells to attach. Specifically, DMEM were used for A549 and B16BL6 cells,
RPMI 1640 for MCF-7 and MCF-7/ADR cells and DMEM-α for MIH3T3 cells. The
media were supplemented with 10% fetal bovine serum (for tumor cells) or calf
serum (only for NIH3T3), and 1.0 % penicillin-streptomycin. The cells were then
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treated with different concentrations of the FNPs or the DOX-FNP complexes.
After a 48-h treatment, 10 μl of MTT solution (5 mg/ml in PBS, pH 7.4) was then
added to each well and the plates were incubated for another 4 h. The cell
culture media were removed and replaced with 100 µl DMSO. The absorbance
was measured by a microplate reader (Bio-Tek µQuant) at 570 nm. For the DOXFNP complexes, the average IC50 value (the dose having 50% cell inhibition) was
determined by cell survival plots using the ―DoseResp‖ function in OriginPro 8.0.
Apoptotic assay
The apoptosis study was determined by evaluating DNA ladder formation [121].
Briefly, A549 cells and B16BL6 cells were treated with the FNP samples at the
GAG concentration of 10µg/ml, and then incubated at 37 °C in 5% CO2 for 48h.
Apoptotic cells were identified by TdT-mediated dUTP nick and labeling (TUNEL)
assay using APO-BrdUTM TUNEL Assay Kit (Invitrogen, Eugene, OR) according
to the manufacturer’s instructions. The cells were then analyzed using flow
cytometry (Epics XL Analyzer, Beckman Coulter Inc., Brea, CA) by collecting
20000 events for each sample and measuring the cell associated fluorescence.
Cell cycle analysis
To determine cell cycle distribution, A459 and B16BL6 cells were passed into 24well plates and treated with the FNP samples at the GAG concentration of
10µg/ml, and then incubated at 37°C in 5% CO2 for 24h. The cells were then
trypsinized, washed with PBS, and fixed in 75% ethanol at 4°C for 2 h. The fixed
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cells were stained with propidium iodide/RNase A staining buffer (Invitrogen,
Eugene, OR) at 37˚C for 30 min in the dark. The cell cycle analysis was
conducted using flow cytometry (Epics XL Analyzer, Beckman Coulter Inc., Brea,
CA) by collecting 20000 events for each sample and measuring the cell
associated fluorescence.
Formation of DOX-FNP complexes
To prepare the complexes between DOX and the FNPs, 60µl of DOX (3mM) was
added into 110µl of the FNP1 (~143 µg/ml GAG) or 160µl of the FNP2
(~95µg/ml) in 20mM HEPES buffer at pH 7.0, and then incubated at room
temperature overnight. The precipitates between DOX and the FNPs were then
centrifuged at 10,000 rpm for 10 min. The precipitates were dispersed in 500µl
PBS buffer, and then sonicated for 10min in a bath sonicator (Aquasonic 7500,
VWR). The amount of DOX in the dispersed precipitates was quantified by
measuring UV absorbance at 480nm and the entrapment ratios of DOX in the
complexes were calculated as previously reported [56]. To determine the stability
of DOX in the complexes in the PBS buffer, the dispersed complexes were
applied to Sephadex G75 column. The first peak, standing for the stable
complexes, and the second peak, standing for free DOX, was collected for
quantification. The morphology, particle size and zeta potential of the DOX-FNP
complexes were characterized using AFM, DLS and ELS analysis, as above
described.
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In vitro release study
DOX release from the DOX-FNP complexes was studied at different pH values.
150µl of the DOX-FNP1 complexes (168µM for DOX), 200µl of DOX-FNP2
complexes (~126µM for DOX), or 84µl of free DOX (300µM) were placed in a
dialysis tube (MWCO 300 K, Spectra/por membrane tubing, Spectrum Labs, CA),
and then immersed in tubes containing 6 ml of release buffers at different pH
values (1 × PBS, pH 7.4; 0.1 M acetic acid buffer, pH 5.5). All tubes were
incubated at 37˚C under mild agitation. The dialysate sample (0.5 ml) was
collected at different time points and replenished immediately with the same
volume of the fresh medium. The concentration of DOX in the dialysate was
analyzed fluorometrically at λex480 nm and λem590 nm, and the cumulative
release profiles were plotted verse release times.
Cellular uptake and confocal microscopic study
The quantification of intracellular DOX uptake in cancer cells was evaluated by
flow cytometry. A549 and B16BL6 cells were cultured in 6-well plates at densities
of 1×106 cells/ml, and incubated at 37°C in 5% CO2. The DOX-FNP complexes
at the DOX concentration of 10µM were added into each well, and free DOX was
used as a control. After a 4-h incubation, the media were aspirated. The cell
monolayer was rinsed with PBS for three times, and then trypsinized. Flow
cytometry analysis was carried out on an Epics XL Analyzer (Beckman Coulter
Inc., Brea, CA) by collecting 20000 events for each sample.
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Confocal laser scanning microscopy (FluoView FV1000 Confocal Microscope,
Olympus, Japan) was used to investigate intracellular DOX distribution in tumor
cells treated with the DOX-FNP complexes. Briefly, the cells were seeded on
cover slips with a density of 106 cells/ml in 6-well plates and cultured at 37°C in
5% CO2 for 24 h. The cells were then treated with the DOX-FNP complexes at
the DOX concentration of 10 µM for 4h. Free DOX was used as a control. To
observe the intracellular distribution, endolysosome- and nuclear-specific
markers, LysoTracker® green (100 nm) and Hoechst 33342 (4µM), were
incubated with the cells for 30 min prior to the confocal imaging. After that, the
cover slip was washed with PBS three times, set on a microscope slide, and then
examined by confocal microscopy.
To observe the internalization of the FNPs themselves, the FNPs were first
labeled with FITC. For such a purpose, 3.5mg/ml of FITC in DMSO was diluted to
0.7mg/ml with 100 mM carbonate buffer (pH 9.3), and then 150μl of the FNP1
(138.56μg/ml) and FNP2 (56.83μg/ml) were added into 400μl of the above
carbonate buffer. After a 24-h incubation at the room temperature, resulting
solution was dialysized (MWCO 300 K, Spectra/por membrane tubing, Spectrum
Labs, CA) against PBS buffer for three days. After that, the cells were treated
with the FITC-labeled FNPs at the FITC concentration of 2ng/ml, and the
internalization of the FNPs was then imaged with confocal microscopy as above
detailed.
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Co-culture system for testing immunochemotherapeutic activity

A co-culture system using B16BL6 tumor cells and the splenocytes derived from
C57BL/6 mice was used to evaluate the immunotherapeutic effect of the DOXFNP complexes in vitro [98, 103]. Briefly, 2×105 tumor cells, labeled with 5 μM
CFSE, were co-cultured with 5 x106 splenocytes, and then the co-cultures were
treated with free DOX and both DOX-FNP complexes at the DOX concentration
of 1µM. After a 24-h incubation, the death of tumor cells was determined by the
PI uptake method using flow cytometer after gating on the CFSE labeled cancer
cells.
Statistical analysis
All the values were presented as mean ± standard deviation (S.D.) of at least
three independent measurements. Statistical significance was tested by one-way
ANOVA followed by a Student's t test for multiple comparison tests. A p value of
<0.05 was considered statistically significant.
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Results and Discussion
Purification and characterization of FNPs
The sitting drop culture system for the fungus A. oligospora has been established
in our lab, from which the secreted FNPs was isolated and characterized [114].
Using a dialysis procedure, these crude isolates of the FNPs demonstrated a
spheroidal shape with diameter of 100-500 nm [114]. In this study, we
established a new purification procedure using a combination of size exclusion
chromatography (SEC) and weak anion exchanger (WAX) to purify the FNPs. As
shown in Figure 15A, after inoculation of at least 1000 conidia per cover slip on
which about 500µl of media drop was added, the fungal mycelia were grown for 7
days and the mycelia thrived on the cover slip were washed using distilled water.
The collected wash media were then filtered to remove any debris, and then
applied to Sephadex G75 column. Through the SEC column, the first peak,
designated as FNP0, was collected (Figure 15B), and characterized using AFM.
As shown in Figure 16A-B, spheroidal nanoparticles with 100-300nm in diameter
were observed. The nanoparticle FNP0 was further analyzed with DSL and ESL,
showing average size of ~300nm (Figure 16C) and negative zeta potential of
~30 mV (Table 4). These crude isolates of FNPs were further applied to DEAEcellulose column, leading to production of two FNP fractions that were eluted
respectively using 0.5M NaCl and 1.0M NaCl (Figure 15C). Both FNP fractions,
designated respectively as FNP1 and FNP2, were further characterized for their
morphology, hydrodynamic size and zeta potential using AFM, DLS and ELS.
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Figure 16 AFM images (A-B, D-E and G-H) and size distribution (C, F and I) of the FNPs
prepared with the SEC-WAX-SEC procedure.
(A-C) The nanoparticle FNP0, prepared with only SEC procedure (Sephadex G75 column); (D-F)
The nanoparticle FNP1, prepared with the SEC-WAX-SEC procedure and eluted with 0.5M NaCl;
(G-H) The nanoparticle FNP2, prepared with the SEC-WAX-SEC procedure and eluted with 1.0M
NaCl.
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Table 4 Physicochemical characterization of the FNPs prepared with the
SEC-WAX-SEC procedure
Size
(nm)

Zeta
potential
(mV)

Protein
(µg/ml*)

GAG
(µg/ml*)

Uronic acid
(µg/ml*)

Total Sugar
(µg/ml*)

FNP0

294.2 ± 152.3

-30.7 ± 9.1

661.1
±10.7

187.6
±10.7

162.6±23.1

410.1±6.4

FNP1

147.5 ± 78.4

-26.9 ± 6.9

86.8 ±6.3

296.5
±38.1

153.9±10.8

506.2±25.2

FNP2

148.5 ± 67.4

-32.1 ± 7.6

3.7 ±0.7

98.7 ±7.4

40.4±7.7

162.7±8.5

Note: * The concentrations of protein, glycosaminoglycan (GAG), uronic acid and total sugar in
the FNPs were determined after they were concentrated to 150 µl using a spin filter (M&M
Section 2.2&2.3). Therefore, the unit here is designated as µg/ml nanoparticle solution instead of
µg/mg freeze-dried nanoparticles. All concentrations were based on the following preparation
methods: the FNP0 was prepared using one batch of fungal culture (40 small disks), and the
purified FNP1 and FNP2 were prepared using three batches of fungal culture (120 small disks).
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As shown in Figure 16 D-F, the first peak (FNP1), eluted from 0.5M NaCl, were
spheroidal nanoparticles with ~150nm in hydrodynamic diameter. The second
peak, FNP2, had similar hydrodynamic size with spheroidal morphology (Figure
16 G-I). However, as shown in Table 1, the FNP1 had zeta potential of ~ -27 mV,
which is lower than that of FNP2 (~ -32mV). The difference in zeta potentials for
both FNP fractions is consistent with their elution profiles through the WAX
column. Due to relatively lower surface charge of the FNP1 fraction, it was eluted
more easily at low concentration of NaCl than FNP2 fraction [117] (Figure 15 C).
Therefore, at low salt concentration, i.e. 0.5M NaCl, the FNP1 was first eluted,
and then the FNP2 was selectively eluted at higher concentration, i.e. 1.0M NaCl.
Apart from the differences in morphology, sizes and zeta potentials, FNP1 and
FNP2 had chemical components as similar as the crude FNP0. As shown in
Figure 17 A-B, glycosaminoglycan (GAG) and neutral polysaccharides were
demonstrated to be the major components for both FNP1 and FNP2 fractions,
which is similar to the crude FNP0 sample. The quantitative data for GAG, uronic
acid and total sugars in the three FNPs are listed in Table 4. For the protein
component in the three FNP samples, the ratio of protein to total sugar in the
FNP0 was much higher than those in the TNP1 and TNP2 (Table 4), indicating
most proteins in the crude FNP0 were free and unbound proteins. These proteins
were not bound to FNPs, leading to complete washing away through the
purification procedure with lower salt concentration (< 0.5M NaCl). Therefore,
compared to the amount of total sugar, the purified FNP1 and FNP2 only had
lower

ratios

of

proteins

to

total
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sugars

in

the

nanoparticles.

(A)

(B)

Figure 17 SDS-PAGE analyses of polysaccharides in the FNPs by using Alcian blue
staining (A) and PAS staining (B).
Alcian blue were used for glycosaminoglycan (GAG) staining and PAS for neutral polysaccharide
staining.
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Due to most GAGs covalently attaching to core proteins to form proteoglycan
[122], we presume that some proteins probably were bound to the GAGs in the
nanoparticles. On the other hand, two protein bands were observed in the FNP
sample prepared using dialysis method in our previous report [114] and the
protein bands with similar MW were also observed in the FNP0 samples in this
study. For the purified FNP1 and FNP2, both similar protein bands with relatively
weaker intensities were also appeared in the SDS-PAGE analysis (Data not
shown). No matter how the proteins are chemically bound to or physically
associated with the FNPs, the polysaccharides, including acidic GAG and neutral
polysaccharides, are main chemical components in the purified FNPs.

FNPs stimulate secretion of multiple proinflammatory cytokines and
chemokines from macrophage and splenocytes
In our previous study, it has been demonstrated that the FNPs prepared using a
dialysis approach induced the secretion of TNF-α from a macrophage cell line
RAW264.7 in a dose-dependent manner [114], indicating the potential of
antitumor immunity using the FNPs. In this work, after obtaining the purified
FNPs, FNP1 and FNP2, macrophage stimulatory activity was first studied using
the cultured mouse macrophage RAW 264.7 as a cell model. As shown in Figure
18A, after a 24-h incubation of the FNP-treated macrophage RAW264.7 at the
GAG concentration of 5µg/ml, ELISArray demonstrated significantly elevated
levels of IL6, TNF-α, and G-CSF from the macrophage treated by the three FNP
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samples, FNP0, FNP1 and FNP2, as compared to the untreated cells. Of the
panel of 12 cytokines assayed, except for above three cytokines, low but
statistically significant increases in IL1α and IL17A were also detected for the
FNP1 and FNP2 in the supernatant of the treated macrophage, respectively. As
is well known, TNF-α is a Th1-biased cytokine as a potential anticancer agent for
many years [123], playing a key role in apoptosis, cell survival, inflammation and
immunity [69]. It has been demonstrated that TNF-α was critical for antitumor T
cell immunity in mice [124] and could act synergistically with other drugs at the
molecular level to trigger the apoptosis and dissociation of tumor vascular
endothelial cells in cancer treatment [70, 71]. As a Th2-biased cytokine, IL-6
plays key roles in T-cell-mediated immune responses, acting as a cofactor for Tcell proliferation [73], and as a growth inhibiting factor, the antitumor effects of IL6 on multiple murine tumor in vivo has been reported [125-127]. G-CSF can
enhance the differentiation of stem cells in bone marrow, facilitate the
mobilization of hematopoietic precursor cells into the bloodstream [75],and
accelerate recovery from chemotherapy-induced myelosuppression [128]. The
synergistic antitumor effect of TNF-α and G-CSF has been established and
antitumor effect of TNF was enhanced by combination with G-CSF in multiple
tumors in vivo [129]. As such, we presume that significant higher amount of TNFα, IL-6 and G-CSF secreted from the treated macrophages will be benefit for
adjuvant anticancer therapy using the FNPs. FNP0, FNP1 and FNP2, as
compared to the untreated cells. Of the panel of 12 cytokines assayed, except for
above three cytokines, low but statistically significant increases in IL1α and IL17A
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were also detected for the FNP1 and FNP2 in the supernatant of the treated
macrophage, respectively. As is well known, TNF-α is a Th1-biased cytokine as a
potential anticancer agent for many years [123], playing a key role in apoptosis,
cell survival, inflammation and immunity [69]. It has been demonstrated that TNFα was critical for antitumor T cell immunity in mice [124] and could act
synergistically with other drugs at the molecular level to trigger the apoptosis and
dissociation of tumor vascular endothelial cells in cancer treatment [70, 71]. As a
Th2-biased cytokine, IL-6 plays key roles in T-cell-mediated immune responses,
acting as a cofactor for T-cell proliferation [73], and as a growth inhibiting factor,
the antitumor effects of IL-6 on multiple murine tumor in vivo has been reported
[125-127]. G-CSF can enhance the differentiation of stem cells in bone marrow,
facilitate the mobilization of hematopoietic precursor cells into the bloodstream
[75], and accelerate recovery from chemotherapy-induced myelosuppression
[128]. The synergistic antitumor effect of TNF-α and G-CSF has been established
and antitumor effect of TNF was enhanced by combination with G-CSF in
multiple tumors in vivo [129]. As such, we presume that significant higher amount
of TNF-α, IL-6 and G-CSF secreted from the treated macrophages will be benefit
for

adjuvant

anticancer

therapy

using

the

FNPs.

To

confirm

this,

immunostimulation of the FNPs was further evaluated using the primary
splenocytes isolated from C57BL/6 mice, which have all types of immune cells
and the cross talk between immunocytes, including macrophage and T cells [98,
103].
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Figure 18 Effects of the FNPs on the secretion of cytokines (A and B), chemokines (C and
D) and nitric oxide (E and F) from RAW 264.7 macrophage cells (A, C and E) and
splenocytes (B, D and F).
The macrophage RAW264.7 cells and splenocytes were treated with the FNPs at the GAG
concentration of 5µg/ml for 24 h, and then the culture media were collected. A panel of 12
cytokines and 12 chemokines in the culture media were measured using ELISArry kits, and the
nitric oxide in the culture media was detected with Griess assay. The results are expressed as
mean ±SD. *P < 0.05, †P < 0.01, significantly different from the controls.
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As expected, significantly higher amount of IL6 and TNF-α were detected in the
culture supernatant of the splenocytes treated with the three FNP samples
(Figure 18B) in comparison with the untreated control. The other stimulatory
cytokines, including IL-1α, IL-1β and IL2, were also secreted in a low but
significantly higher amount from the treated groups with the three FNP samples.
It has been reported that IL-1 has multiple effects, involving immunomodulation,
inflammation, wound healing, hematopoiesis, metabolism and the endocrine
system [130]. IL-1, including IL1α and β, also has a number of properties
potentially useful in the treatment of cancer, including direct antiproliferative
activity against certain human tumor cell lines and several murine tumors, the
activation of effector cells in vitro, and the inhibition of tumor angiogenesis [130].
In addition, IL-1 has the capacity to protect and restore the bone marrow from
radiation or chemotherapy-induced injury [130]. The cytokine IL-2 is known to be
a T-cell growth factor, inducing clonal expansion of T cells following antigen
stimulation, and is also important for the differentiation of CD4+ T cells into Th1
and Th2 effector subsets [73]. IL-2 has been used for the treatment of melanoma
and renal cell carcinoma [131], and recombinant human IL-2 is a potent cytokine
and a FDA-approved anticancer drug [132]. As such, we believe that the three
cytokines, IL-1α, IL-1β and IL-2, with elevated levels in the supernatant of
splenocytes after the treatment with the FNPs also favor the antitumor immunity
in the cancer treatment. Additionally, in the treated splenocytes, only the crude
fungal nanoparticle, FNP0, induced significantly higher amount of IL-10, IL-17A,
IFN-γ, and G-CSF as compared to the untreated control, while the purified FNPs
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didn’t show this activity. As is well known, IFN-γ is a functionally pleiotropic
cytokine, is able to induce anti-viral activity, and has direct anti-proliferative
effects on some tumor cell lines [133]. Hence, like G-CSF, IFN-γ is also benefit
for antitumor immunity. Unfortunately, both purified fungal nanoparticles, FNP1
and FNP2, didn’t have the activity on both macrophage and splenocytes.
However, the bias in immunostimulatory activity between the purified FNPs and
the crude FNPs may also helpful to establish the antitumor immunity in vivo,
because the elevated level of IL-10, an anti-inflammatory, immunosuppressive
cytokine that favors tumor escape from immune surveillance [134], was observed
in the supernatant of splenocytes treated with the crude fungal nanoparticles,
FNP0. It is notable that a higher amount of another cytokine, IL-17A, was
observed from the treated splenocytes by the crude FNP0, and a low but
significant increase in this cytokine was also observed in the treated macrophage
by the FNP2. The role of IL-17A in anti-tumor immunity is controversial and
remains elusive, and both pro- and anti-tumor activities of IL-17A have been
reported [135, 136]. Overall, these results suggest that the FNPs, especially two
purified FNPs, can potentially modulate the immune cells to an activated state to
induce an efficient antitumor response in the cancer immunotherapy.
Subsequently, we investigated the production of chemokines by the FNPs in both
macrophages and splenocytes. Chemokines are small chemotactic cytokines
which can induce migration of leukocytes, activate inflammatory responses, and
are implicated in the regulation of tumor development and growth [137]. They can
modulate tumor growth via regulation of tumor-associated angiogenesis, by
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activation of host immunological responses, by direct inhibition of tumor cell
proliferation [137], or by modulation of the neutrophils influx into the tumor tissue
after treatment with chemo-drug during the immunochemotheray [138]. As shown
in Figure 18C, of the panel of 12 chemokines assayed, TRANTES, MCP-1 and
IP-10 were highly induced in the treated macrophages by the three FNPs, and
low but statistically significant increases in MDC was also observed in the FNP2treated macrophages. It has been reported that RANTES enhances antitumor immunity in a mouse model in part through direct T cell effector
recruitment [78, 79]. MCP-1 has been reported to augment the antitumor effects
by promoting lymphocyte infiltration into the tumor and subsequent cytokine
production [139]. IP-10 has been demonstrated to elicit strong anti-tumor and
anti-metastatic properties, and its immunological properties appear to be
dependent on the attraction of monocytes and T lymphocytes [80], while MDC is
chemotactic for a variety of leukocytes, and has been shown to be involved in
Th-2 mediated cellular immunity [140]. For the activation of the splenocytes,
except for RENTES, MCP-1, IP-10 and MDC, the elevated levels of the MIP-1a,
MIP-1b, TARC, and KC were also observed after treatment with the three FNPs
as compared to untreated control (Figure 18D). It has been demonstrated that
MIP-1a showed potent anti-tumor effect after intravenous administration along
with intra-tumor injection of certain adjuvants [141], while MIP-1b is a chemokine
which can chemoattract T cells and NK cells, inducing efficient antitumor
responses in a pre-established tumor model [137]. In conjunction with RANTES,
TARC, which mediate the chemoattraction of both antitumor-speciﬁc effector T
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cells, has been demonstrated to enhance the antitumor immune effects of GMCSF [142, 143]. The production of chemokine KC may amplify filtration of
inflammatory cells, creating a more sustained antivascular action [138]. Given the
elevated cytokines and chemokines from both macrophage and splenocytes,
they provide the evidences that the favorable antitumor immunity in vivo could be
established by stimulating different immunocytes, such as macrophages and
splenocytes, with the fungal nanoparticles, especially the purified FNPs, FNP1
and FNP2. Apart from multiple cytokines and chemokines, the bactericidal
mediator, nitric oxide (NO), stimulated by the FNPs was further evaluated on
both macrophages and splenocytes. As shown in Figure 18E-F, compared to the
untreated cells, significantly elevated levels of NO were produced in both
macrophages and splenocytes treated with the FNPs. NO is an important
regulator and mediator of macrophage-directed cytotoxicity against tumor cells
and microbes [119]. Significantly higher amount of NO production from the
treated macrophages and splenocytes substantiates the potential of anti-cancer
immunity in the cancer immunotherapy using the polysaccharide-based
nanoparticles secreted from fungi.

FNPs induce cytotoxicity in tumor cells via apoptosis and cell cycle arrest
The cytotoxicity of the crude FNPs, prepared with dialysis method, has been
demonstrated in A549 and B16BL6 cell lines in our previous study. In this work,
after obtaining two different FNP fractions, FNP1 and FNP2, we further
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investigated the in vitro cytotoxicity of both purified FNPs in four different tumor
cell lines. As shown in Figure 19 A-C, the three FNP samples showed a dosedependent cytotoxicity against four tumor cell lines, including A549, B16BL6,
MCF-7 and MCF-7/ADR. For the crude FNP0 sample, ~11-39% inhibition of cell
proliferation were seen in the three tumor cell lines, A549, B16BL6 and MCF-7,
at the concentration ranging from 1-10 µg/ml. For the purified FNP2, the inhibition
rates of 26-37% for B16BL6 cells, 9-33% for A549 cells, and 3-30% for MCF-7
cells were observed at the same concentration range. However, using a higher
concentration range (2-25µg/ml), the purified FNP1 showed similar inhibition
rates in the three tumor cells, i.e., 15-32% for B16BL6 cells, 11-28% for A549
cells, and 3-28% for MCF-7 cells. In comparison with the FNP1 and FNP2, we
found that the similar inhibition rates in the three tumor cells were resulted from
different concentration ranges. The concentrations of the FNP1 were at least 2fold higher than those of the FNP2, indicating that the purified FNP2 have
stronger cytotoxic activity than the purified FNP1. In addition, it is notable that all
the three FNP samples showed lower inhibition rates (8-18% for the FNP0, 5-15%
for the FNP1, and 9-17% for the FNP2) in the multidrug resistant cell line MCF7/ADR at the respective concentration ranges. The lower inhibition rates here
suggest that the FNPs only possess mild to moderate cytotoxic activity and the
maximal concentration tested in this study is still not enough to effectively inhibit
the proliferation of the resistant cells.
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Figure 19 Cytotoxicity of the FNPs and the DOX-FNPs complexes against multiple cell
lines.
(A-C) The cytotoxicity of the FNPs against four tumor cells, i.e. human non-small-cell lung cancer
A549 cells, mouse melanoma B16BL6 cells, human breast cancer MCF-7 cells and the multidrug
resistant cell line MCF-7/ADR; (D-F) The cytotoxicity of the FNPs against mouse embryo
fibroblast cell line NIH3T3; (G-J) The cytotoxicity of the DOX-FNP complexes against four tumor
cell lines (A549, B16BL6, MCF-7 and MCF-7/ADR). The sigmoidal dose-response curves were
fitted using OriginPro 8.0.
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Even for the sensitive tumor cells, the highest inhibition rates were still less than
40% at the maximal concentration of 10µg/ml for FNP2 or 25µg/ml for FNP1. The
mild to moderate cytotoxic activity of the FNPs were further evidenced by an in
vitro biocompatibility test using NIH3T3 cell line. NIH3T3 is a mouse embryo
fibroblast, which were commonly used in the biocompatibility evaluation of
nanomaterials [120, 144]. Less than 20% inhibition rate were seen in NIH3T3
cells treated with the three FNPs at the respective concentration ranges (Figure
19D-F), suggesting that the FNPs didn’t have strong cytotoxic effect against
normal cells, but had slightly higher cytotoxicity against tumor cells, especially
towards the sensitive tumor cells.
Even though the FNPs only possess mild to moderate cytotoxic activity, given
that the FNPs induced the secretion of multiple proinflamatory cytokines and
chemokines from immunocytes (Figure 18), we believe that they are a potential
immunomodulator of biological responses in the adjuvant antitumor therapy in
which the synergistic effect could be reached between the mild cytotoxic activity
and the immunostimulatory activity. For the purified FNPs, we have
demonstrated a similar immunostimulatory activity between the FNP1 and FNP2,
inducing almost same levels of cytokines and chemokines from immunocytes
(Figure 18). However, as far as the cytotoxic activity concerns, the FNP2
showed around 2-fold stronger activity in the tumor cells tested in this study
(Figure 19A-C). To better understand the difference in the cytotoxicity between
both purified FNPs, we further investigated the apoptotic effect and cell cycle
arrest in the tumor cells treated by both purified FNPs. As expected, the purified
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FNP2 induced strong apoptosis in the A549 cells and B16BL6 cells after an 48-h
incubation, and the crude FNP0 had similar but weaker apoptosis induction in
both tumor cells; however, the purified FNP1 couldn’t induce significantly
apoptotic effect in A549 tumor cells and induced only slight apoptotic effect in
B16BL6 cells (Figure 20A-B), which may explain the weaker cytotoxicity of the
FNP1 as compared to the FNP2. The cell cycle arrest analysis using A549 and
B16Bl6 cells treated with both purified FNPs substantially agrees with the
apoptosis assay. As shown in Figure 20C-D, the FNP2 arrested the cell cycle at
sub G0/G1 phase in both tumor cells after an 24-h incubation, and the crude
FNP0 showed the similar activity in both tumor cells. A significant increase in the
sub G0/G1 peak, which corresponds to apoptotic cells, represents that the tumor
underwent apoptosis [145, 146]. However, the purified FNP1 couldn’t significantly
induce the cell cycle arrested at the sub G0/G1 phage, indicating that there
should be different mechanisms for the cytotoxicity of the purified FNP1 and
FNP2, although they showed similar immunostimulatory activity.

Formation of pH-responsive complexes by efficiently binding DOX to FNPs
Utilizing the purified FNPs as a nanocarrier for chemo-drug delivery is the
purpose of this study to implement the synergistic effect between the
immunostimulation from FNPs themselves and cytotoxicity from both FNPs and
chemo-drugs. For such a purpose, DOX was used as a model chemo-drug in this
study to form a DOX-FNP nanocomplex.
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Figure 20 Apoptosis (A-B) and cell cycle arrest (C-D) in human non-small-cell lung cancer
A549 cells (A and C) and mouse melanoma B16BL6 cells (B and D) induced by the FNPs.
The cells were treated with the FNPs at the GAG concentration of 10µg/ml for 48 h (apoptosis
assay) or 24h (cell cycle analysis). For apoptosis assay, the fragmented DNA was stained with
TUNEL method (M&M Section 2.6) and then measured by flow cytometry. For cell cycle analysis,
the cells were stained with PI, and then measured with flow cytometry.
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The physical characteristics, in vitro cytotoxicity and immunochemotherapeutic
effect of the complexes were further evaluated. As shown in Figure 21A, DOX
could be efficiently bound to both fungal nanoparticle fractions, FNP1 and FNP2,
when mixing DOX and the FNPs in 20mM HEPES buffer at pH 7.0. Due to
negative surface charges for both FNP1 and FNP2 (Table 4), DOX, carrying
positive charges from deprotonation of the amino group at pH7.0 in HEPES
buffer [147], could be bound to FNPs via electrostatic interactions. The binding
between DOX and FNPs was so highly efficient that leads to formation of
precipitates overnight after centrifugation at 10,000 rpm for 10min (Figure 21A).
The collected precipitates were then dispersed in PBS buffer (pH 7.0) and nanosized DOX-FNP complexes were formed. As shown in Table 2, for both
complexes, DOX-FNP1 and DOX-FNP2, the hydrodynamic diameters, measured
by DLS analysis, were less than 200nm, which was slightly increased compared
to the blank FNPs (Table 4). The morphology of the dispersed DOX-FNP
complexes in the PBS buffer was also imaged with AFM, and both DOX-FNP
complexes were spheroidal nanoparticles with diameters of less than 200 nm
(Figure 21 C-D), similar to the blank FNPs (Figure 16). In addition, from Table 5,
there were significant decreases in zeta potentials for the DOX-FNP complexes
as compared to both blank FNPs, indicating a direct association of DOX with the
FNPs via electrostatic interactions [148]. More importantly, the entrapment ratio
of DOX in the FNPs was as high as ~72%-77%, and the precipitated DOX-FNP
complexes with such a high drug loading were demonstrated to be stable after
the nano-sized DOX-FNP complexes were formed in the PBS buffer.
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Figure 21 Characterization of the DOX-FNP complexes and pH-responsive release of DOX
from the complexes.
(A) The DOX-FNP complexes were precipitated in 20mM HEPES buffer (pH7.0) after
centrifugation at 10,000 rpm for 10min; (B) Purification of the precipitated DOX-FNPs complexes
from free DOX using SEC column after being well dispersed in PBS buffer (pH7.4); (C) AFM
images of the DOX-FNP1 complexes; (D) AFM images of the DOX-FNP2 complexes; (E) pHresponsive release of DOX from the complexes.
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Table 5 Physical characteristics and cytotoxicity of the DOX-FNP
complexes
Size
DOXFNP1
DOXFNP2
Free
DOX

Zeta
potential

Entrapment
ratio

A549

IC50 (nM)
B16BL6
MCF-7

MCF-7/ADR

194.5±79.5

-22.2±7.5

77.4%±2.4%

1170.60±92.33

494.87±38.00

1830.53±270.47

5464.57±16.87

186.9±89.7

-24.24±6.0

72.2%±0.7%

599.34±15.85

209.63±23.72

355.71±23.06

3522.55±110.03

-

1052.54±67.58

308.82±26.55

648.39±75.77

4177.36±116.12

-

-
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As shown in Figure 21B, the amount of DOX dissociated from the complexes in
the PBS buffer was as low as ~20%. As such, the DOX-FNPs complexes
dispersed in PBS buffer were directly used as a nano-sized antitumor agent
without further purification to remove free DOX for the following studies, including
uptake, cytotoxicity and immunochemotherapeutic effect.
In principle, pH-responsive release of DOX was expected from the nanocomplexes formed via an electrostatic driving force between DOX and
nanoparticles, which could provide a stimulus-responsive release mechanism
after internalization by tumor cells or penetration into the tumor tissue in vivo
[149]. The release profiles of DOX from both complexes at different pHs were
further evaluated by immersing the dialysis tubes in large volume centrifuge
tubes containing 6 ml of release buffers with different pH values. As shown in
Figure 21E, a free DOX control confirmed that the dialysis membrane tubing with
300K MWCO in this study couldn’t restrict diffusion of the released drugs into the
bulk release media in which the sink condition was established, and they were
able to reach 100% release after 5 h. However, the release of DOX from both
complexes at different pH couldn’t reach a plateau until at least 9-10 h. The total
released drug from both DOX-FNP complexes was significantly different under
different pH conditions (Figure 21E). Up to ~55% and ~65% of total drug were
released at the physiological pH 7.4 for the DOX-FNP1 and DOX-FNP2
complexes, respectively; however, around 80% of total drug released at pH 5.5
were observed for both complexes. More importantly, the release rate of drug
from both complexes increased with decreasing in the pH of release medium,
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indicating a pH-sensitive release behavior with accelerated release of DOX in an
acidic environment from both complexes. This favorable property is believed to
facilitate passive tumor targeting and endosome escaping since the interstitial
space of solid tumors and intracellular endosome compartments have a lower pH
value [56].

Cytotoxicity, uptake and intracellular distribution of DOX-FNP complexes in
tumor cells
Fungal nanoparticles have been demonstrated to be cytotoxic in our previous
study [114]. In current work, we also confirmed that both purified fractions, FNP1
and FNP2, had mild to moderate cytotoxic activity against multiple tumor cell
lines. However, compared to the FNP1, the FNP2 itself at the same GAG
concentration had around 2-fold increase in cytotoxicity against 4 tumor cell lines
tested in this study (Figure 19 A-C). In our early study, we demonstrated that
there was synergistic cytotoxicity exerted by covalently conjugating DOX with
FNPs via amide bond [114]. As such, a synergistic cytotoxic effect between DOX
and the FNPs when forming the physical complexes via the electrostatic
interactions is anticipated in this study. As expected, the DOX-FNP2 complexes
showed significantly higher cytotoxicity against 4 tumor cells than free DOX after
a 48-h incubation (Figure 19 G-J). The IC50 of the DOX-FNP2 complexes and
free DOX are listed in Table 5. For A549, B16BL6 and MCF-7 cell lines, the IC50
for the DOX-FNP2 complexes was ~1.5-1.8 fold lower than free DOX; even for
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the multidrug resistant cell line MCF-7/ADR, the IC50 for the DOX-FNP2 was still
~1.2 fold lower than free DOX. These data demonstrate a synergistic cytotoxic
effect when DOX was bound to one fraction of the FNPs, i.e., FNP2, even
against the resistant tumor cell line. As shown in Figure 5G-J, at the respective
IC50 values of free DOX (Table 5), free DOX inhibited cell proliferation by 50%,
whereas the DOX-FNP2 complexes showed ~62%-75% inhibition against the
four tumor cells. According to a ~72% entrapment ratio for the DOX-FNP2
complexes (Table 5), the concentration of the FNP2 in the complexes at the
respective IC50 values of free DOX for the A549, B16Bl6 and MCF-7 cells was
calculated to be less than 0.25 µg/ml of GAG concentration, and for the resistant
MCF-7/ADR cells less than 1.0µg/ml of GAG concentration. From Figure 19A-C,
almost no significant inhibition effect on four tumor cells was observed at that
concentration for FNP2 itself, indicating that DOX and FNP2 in their physical
complexes via the electrostatic interactions exerted synergistic cytotoxic effects
and led to the IC50 values 1.2-1.8 fold lower against four different tumor cells
(Table 5).
Unexpectedly, the cytotoxicity of the DOX-FNP1 complexes was similar or even
lower than free DOX in the four different cell lines, which is completely different
from the DOX-FNP2 complexes. As shown in Table 5, the IC50 values for the
DOX-FNP1 complexes were ~1.1-2.8 fold higher than free DOX against 4 tumor
cell lines, indicating that there is no obvious synergistic effect between DOX and
the FNP1 upon forming the physical complexes. We postulate that the difference
in the cytotoxicity of both complexes was due to their different cytotoxicity of the
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FNPs themselves, because the FNP1 showed at least 2-fold higher cytotoxicity
against different tumor cells than the FNP2 at the same GAG concentration
(Figure 19A-C). Presumably, the differences in the cytotoxicity of the FNPs
portend the different chemical structures for both FNP1 and FNP2 fractions,
including polysaccharide chain, monosaccharide composites and linkages, uronic
acid content, sulfation degree, and possible core proteins. Although the similar
chemical components were characterized for both FNPs in the Table 1 and
Figure 17, showing that the polysaccharide including acidic GAG and neutral
polysaccharides were main components in both FNPs, the specific chemical
structures for both FNPs still remained elusive. We presume that different
chemical structures in both purified FNPs eventually lead to different cytotoxicity
of FNPs themselves and the DOX-FNP complexes, as well as the different
physical properties including zeta potential and morphology (Table 4, Figure 16
and 21).
In order to elucidate whether the different cytotoxicity between the DOX-FNP1
and DOX-FNP2 complexes is related to DOX uptake and intracellular distribution
after forming the complexes, we quantitatively analyzed the cell-associated DOX
fluorescence intensity using flow cytometry after treatment of both tumor cell
lines, A549 and B16BL6, with both complexes. As shown in Figure 22, for both
tumor cells, there was no significant difference in the DOX fluorescence for both
complexes and free DOX at the DOX concentration of 10 μM after a 4-h
incubation, indicating that DOX uptake wasn’t impeded upon the formation of the
DOX-FNP complexes via the electrostatic interactions.
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(B)

(C)
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Figure 22 Quantitative analyses of DOX uptake by human non-small-cell lung cancer A549
cells (A-B) and mouse melanoma B16BL6 cells (C-D).
Both cells were treated with the DOX-FNP complexes or free DOX at DOX concentration of 10
μM for 4 h, and then the mean DOX fluorescence associated with the cells were measured by
collecting 20 000 events for each sample.
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On the other hand, these data substantiate that the different cytotoxicity of both
complexes was from their different cytotoxicity of the FNPs themselves rather
than the increase in the DOX uptake enhanced by the FNPs in the tumor cells.
To further observe intracellular distribution of both DOX-FNP complexes, the
nuclei and endolysosome were labeled with a nucleus-specific dye, Hoechst
33342 (blue), and an acidic endolysosome-specific dye, LysoTracker green
DND-26, respectively. Before investigating both DOX-FNP complexes, we first
tested if the FNPs themselves could be efficiently internalized in the tumor cells.
For such a purpose, the FNPs were conjugated with FITC (Table 6), and then
incubated with A549 tumor cells for 4 hours. As shown in Figure 23, both purified
FNPs, FNP1 and FNP2, were confirmed to be efficiently taken up by the tumor
cells after a 4-h incubation. The internalization of FNPs themselves by tumor
cells substantially indicates that the FNPs themselves could mediate the uptake
and distribution of DOX in tumor cells via the DOX-FNP complexes, instead of
free DOX released from the complexes. Upon confirming the uptake of the FNPs
themselves by tumor cells, we imaged sub-cellular distribution of the DOX-FNP
complexes in both tumor cells, A549 and B16BL6. As shown in Figure 24, the
confocal analysis showed that different intracellular distribution of both DOX-FNP
complexes and free DOX was observed in both tumor cells after a 4-h treatment.
The majority of DOX in both cells incubated with both complexes were
predominantly distributed in the endolysosomal compartment, while most of the
free DOX was located outside the organelle.
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Table 6 Characteristics of the FITC-labeled FNPs*
Size (nm)

Zeta potential
(mV)

Conjugation ratio (%)

FITC-labeled FNP1

246.9±42.6

-19.9±3.8

0.031%±0.007%

FITC-labeled FNP2

252.5±60.6

-27.1±0.9

0.025%±0.009%

*Note: The preparation of FITC-labeled FNPs was detailed in the M&M Section 2.10.
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Figure 23 Internalization of the purified FNP1 (A) and FNP2 (B) themselves in human nonsmall-cell lung cancer A549 cells.
Both FNPs were labeled with FITC and then incubated with A549 cells at the FITC concentration
of 2ng/ml for 4h. For confocal imaging, the nuclear-specific dye Hoechst 33342 was used to label
the tumor cell nuclear. The cells were also recorded in the bright-field for the morphology. Scale
bars represent 10 μm.
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Figure 24 Confocal analysis of intracellular distribution of the DOX-FNP complexes at the
DOX concentration of 10 μM in human non-small-cell lung cancer A549 cells (A) and
mouse melanoma B16BL6 cells (B).
The cells were incubated with the samples at 37 °C in 5% CO2 for 4 h, and then 100 nM
Lysotracer Green DND-26 and 4 μM Hoechst 33342 were added for 30 min incubation prior to
imaging by confocal microscopy. Scale bars represent 10 μm.
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As is well known, major nanoparticles internalized via endocytosis were mainly
found within endosomes or lysosomes [150]. Thus, we presume that the DOXFNP complexes might be internalized by endocytic pathway in both tumor cell
lines. In this study, the DOX-FNP complexes were demonstrated to have a pHsensitive release behavior with accelerated release of DOX in an acidic
environment (Figure 21B), which facilitate DOX escaping from endosome or
lysosomes after internalization of both complexes in tumor cells. Hence, we
believe that the different distribution couldn’t be another cause that led to the
different cytotoxicity for both DOX-FNP complexes. Overall, the results here
demonstrate that even though there was a different sub-cellular distribution, the
formation of the DOX-FNP complexes did not decrease DOX uptake by both
tumor cell lines, which further supports that the different cytotoxicity of both
complexes was from their different cytotoxicity of the FNPs themselves against
tumor cells.

Immunochemotherapeutic activity of DOX-FNP complexes in an in vitro coculture system
After demonstrating the different cytotoxicity of both DOX-FNP complexes
against tumor cells, the hypothesis of combined immunochemotherapy using the
complexes was further confirmed by the co-culture analysis. The co-culture study
is an in vitro model system for mimicking in vivo situation [98, 103]. For such a
purpose, B16BL6 tumor cells were first labeled with CFSE, and co-incubated with
splenocytes isolated from C57BL/6 mice; the co-cultures were then incubated
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with either DOX-FNP complexes, or free DOX at the DOX concentration of 1µM
for 24h. As expected, significantly higher death of the cancer cells was observed
with the treatment of the DOX-FNP2 complexes as compared to free DOX or the
DOX-FNP1 complexes (Figure 25), which is consistent with the data in the direct
cytotoxicity experiment using MTT assay (Figure 19G-J and Table 5). As the
DOX-FNP2 complexes had both cytotoxic and immunostimulating activity, these
two might be cooperating with each other to produce a synergistic effect,
resulting in higher death in the co-culture cells treated with the complexes.
Interestingly, compared to the direct cytotoxicity experiment where the DOXFNP1 complexes had lower cytotoxicity than free DOX (Figure 19G-J and Table
5), in the co-culture experiment where a mixed culture of cancer cells and
splenocytes were treated, the DOX-FNP1 complexes unexpectedly enhanced
tumor cell death as compared to free DOX alone. In this co-culture experiment,
higher death of the cancer cells exerted by both complexes, especially the DOXFNP1 complexes could be attributed to the immune stimulatory activity of the
FNPs as both FNPs have been shown to induce the secretion of multiple proantitumor cytokines and chemokines from splenocytes, such as TNF-α and MIP1a, which has direct cytotoxic activity. Overall, the enhanced tumor cell death by
both complexes in this experiment confirmed the potential in combined caner
immunochemotherapy using the DOX-FNP complexes in vivo in the future.
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Figure 25 Chemo-immunotherapeutic activities of both DOX-FNP complexes in an in vitro
experimental system where B16BL6 tumor cells were first labeled with CFSE and then cocultured with the splenocytes derived from C57BL/6 mice.
The co-cultures were treated with free DOX (B) and both DOX-FNP complexes(C-D) at the DOX
concentration of 1µM, incubated for a 24-h, and then the death of tumor cells was determined by
the PI uptake method using flow cytometry after gating on the CFSE labeled cancer cells. The
untreated co-cultured cells were used as a negative control (A). Statistical analysis of the mean
DOX fluorescence associated with the cells was performed, and significant differences (P<0.05)
between different treatments were observed (E).

102

Conclusions
The purpose of this study was to evaluate the immunostimulatory activity, dissect
the mechanism of the cytotoxicity, and explore the potential in cancer
immunochemotherapy using the FNPs as a multifunctional nanocarrier. For such
a purpose, we first established a new isolation procedure, SEC-WAX-SEC, to
purify the FNPs, by which two purified FNP fractions, FNP1 and FNP2, were
prepared. AFM imaging and DLS analysis showed that both purified FNPs had a
reduced diameter of 100-200 nm compared to the crude FNPs. SDS-PAGE and
chemical assays showed that polysaccharide including glycosaminoglycan were
main constituents in the purified FNPs. They were demonstrated to enhance the
secretion of multiple proinflammatory cytokines and chemockines from
macrophages and splenocytes, measured by ELISArray, suggesting the efficacy
of the FNPs as an immunomodulator of biological responses in the adjuvant
antitumor therapy. MTT assay showed that both purified FNPs had mild to
moderate cytotoxicity against multiple tumor cells but the FNP2 had stronger
cytotoxic activity than the FNP1. The apoptotic assay and cell cycle analysis
further demonstrated that the FNP2, not the FNP1, could inhibit cell proliferation
via inducing apoptosis and arresting tumor cells at sub G0/G1 phase, which may
explain the difference in the cytotoxicity between both FNPs. For testing the
combined cancer therapy, both FNPs formed the pH-responsive nanocomplexes
with chemo-drug, DOX, via the electrostatic interactions. Upon binding of DOX to
the FNPs, it was demonstrated that the DOX-FNP2 complexes had higher
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cytotoxic activity than free DOX against multiple tumor cells, while the cytotoxic
activity of the DOX-FNP1 complexes was weaker than free DOX. Interestingly, in
a co-culture experiment where splenocytes were co-cultured with tumor cells,
both nanocomplexes demonstrated higher antitumor activity than free DOX,
suggesting the synergistic effect between the immunostimulation of the FNPs
and cytotoxicity of the nanocomplexes in vitro. In conclusion, this work developed
a one-step therapy containing agents for both immuno- and chemotherapy using
the natural-based nanoparticles as a multifunctional nanocarrier, which may open
a new avenue for combined cancer therapy in the future.
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CHAPTER IV
BIO-SYNTHESIS OF GOLD NANOPARTICLES USING ENGLISH
IVY (HEDERA HELIX)
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Introduction
Gold nanostructures have been used in many applications, including waveguides
for electromagnetic radiation [151], optical coatings [11], Surface Enhanced
Raman Spectroscopy (SERS) [152-154], and cancer diagnostics [155-159].
Consequently, various physical, chemical and biological methods have been
reported to produce gold nanostructures [160-163]. Gold nanoparticles (AuNPs)
can be produced using a multitude of chemical and physical processes; however,
these approaches are often costly and have environmental risks associated with
their production. To reduce the use of toxic chemicals used in typical AuNP
synthesis, researchers are actively investigating alternative synthesis methods
using biological materials (proteins, polysaccharides, polyphenol, etc.) for greensynthesis of gold nanoparticles [164-167].
Recently, several plants have been reported to efficiently synthesize gold and
silver nanoparticles [168-170]. For example, the leaf extract from tea [171],
lemongrasss [11], Aloe vera [172], Fagopyrum esculentum [165], and the fruit
extract of Embica officinalis [173], and Tanacetum vulgare [174] have
demonstrated the potential for reducing gold ions into AuNPs. According to these
biosynthetic procedures, AuNPs could be obtained after simply mixing HAuCl4
solution with the plant extract [166]. Multiple reductases and chemical reducing
agents from the extracts have been found to be responsible for the formation of
these nanoparticles [9]. For instance, NADPH, a common biological coenzyme
[175], proteins, polyphenols, and carbohydrates from plant extracts have been
suggested to be involved in the synthesis of AuNPs [9]. However, the exact
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mechanism of this synthesis is still not completely understood, due to the large
number of components in the plant extracts, any of which could be involved in
the synthesis. The multitude of chemical compounds found in plant extracts also
leads to the formation of various species of AuNPs from a single reaction.
Synthesized AuNPs often vary in size, shape, and morphology, and further
processing must be conducted to isolate a single species [13, 164, 166, 176-178].
Despite the ease of AuNP synthesis using plant extracts, a major hurdle exists in
developing a sustainable procedure for the production of AuNPs. Previous
studies have attempted to resolve this challenge by using live plants to
synthesize AuNPs; however, most of these procedures involve harvesting AuNPs
from the plant tissue, which introduces increased complexity due to the limited
amount of AuNPs relative to the large plant biomass [48, 49]. Of greater concern
for sustainability, is that the plant must be sacrificed to harvest the AuNPs, which
means that plant will be removed from the production system. This will lead to
the increased costs, and delay the production of the nanoparticles.
In this work, both a sustainable biological synthesis method and a rapid synthesis
procedure have been developed for continuous and scalable manufacturing of
gold nanoparticles. The proposed approaches allow for the production of AuNPs
out of aqueous HAuCl4 with either actively growing English ivy (Hedera helix)
shoots or the extract formed from the adventitious roots. The synthesized AuNPs
were easily collected from both methods requiring minimal time and effort. By
replacing the HAuCl4 solution every 24 hours, in the sustainable production
system, AuNP synthesis was carried out over a period of 30 days using the same
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raw material. The development of a robust and sustainable procedure for
synthesizing AuNPs with a reduced environmental impact represents an
important step forward in scalable green production of metal nanoparticles.
Furthermore, the use of various molecular weight fractions of the adventitious
root extract demonstrated the ability to rapidly form smaller nanoparticles than
the sustainable method. Using these two methods, we have demonstrated how
plant materials represent an efficient ―green‖ solution to address the growing
need for AuNP synthesis.
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Materials and methods
Chemicals and Reagents
Chemical analysis grade hydrogen tetrachloroaurate (III) (HAuCl4), 1,9-DimethylMethylene Blue (DMMB) ), chondroitin sulfate (CS), and phosphate buffered
saline (PBS) were purchased from Sigma-Aldrich. For protein quantification, the
BCA Protein Assay Kit (Pierce) was purchased from Thermo Scientific. Dialysis
membranes were purchased from Spectrum Laboratories, Inc (Rancho
Dominguez, CA). Ivy shoots and adventitious roots were donated from Swan
Valley Farms (Bow, WA).
Method One: Sustainable synthesis of AuNPs using live shoots
Upon receipt, live ivy shoots were cut to lengths of 15 cm, leaving one attached
leaf on the apical end of the stem. After sterilization and treatment with auxins,
four shoots were placed into Magenta GA7 (MAG) boxes and held upright by
placing them through holes cut into the lids. After 24 hours, the boxes were
transported to a windowsill, where the nanoparticle synthesis was conducted. To
initiate nanoparticles synthesis, aqueous HAuCl4 was added to the 50 ml of
water present in the MAG boxes to achieve concentrations of 0, 0.025, 0.05, 0.1,
0.2, 0.5, 1 and 5 mM. The shoots were exposed to these concentrations for 24
hours, before the solution was removed to test for nanoparticle production. After
collecting the solution after 24 hours, fresh HAuCl4 solution at the same
concentration was added back to the MAG boxes. This method was repeated for
the duration of the study. To concentrate any nanoparticles present in the
solution, the solution was centrifuged at 14,000 rpm for 10 min. The supernatant
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was then removed, and DI water was added to the precipitate. This procedure
was repeated three times to remove soluble factors present in the solution,
including secreted proteins, polysaccharides, and excess HAuCl4. A schematic
for this method is shown in Figure 26A.
Method Two: Synthesis of AuNPs using adventitious root extract
Upon receipt, adventitious roots were homogenized in a minimal volume of water,
creating a dense solution. This solution was centrifuged at 4,400 rpm for 5 min to
remove large tissue debris from the homogenization. The resulting light brown
supernatant was then transferred to dialysis tubing with a molecular weight cutoff
value (MWCO) of 3.5 kDa, and dialyzed overnight against DI water. After dialysis,
the solution outside of the dialysis tubing was collected and labeled as Solution I.
The solution remaining in the tubing was then transferred to new tubing and
dialyzed at 12 kDa. As indicated above, the solution outside of the tubing was
collected and labeled Solution II, followed by a final dialysis through dialysis
tubing with a cutoff value of 300 kDa. The final solution outside of the membrane
was labeled as Solution III, and the solution remaining in the tubing was labeled
Solution IV. Prior to analysis, the extracts were freeze dried and re-suspended in
DI water. To synthesize gold nanoparticles from the ivy rootlet extract solutions,
500 µl of each solution (I-V) was transferred into a clean microfuge tube and
aqueous HAuCl4 was added to a final concentration of 0.5 mM. The mixture was
then vortexed, and reacted at room temperature. To concentrate the synthesized
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Figure 26 Schematic diagrams of two different methods used in this study.
A, Schematic of the sustainable biosynthesis and stability of AuNPs in ivy shoots culture
system.HAuCl4 solution was added to the culture media and the gold nanoparticles could be
collected after 24 hours. And then fresh HAuCl4 solution was added back for sustainable
synthesis of AuNPs; B, Procedure for the ivy rootlet extracts preparation, separation and gold
nanocrystal synthesis. Dialysis tubings with different molecular weight cutoff value (M.W.CO) of
3500 Da, 12,000 Da and 300,000 Da were used to separate different fractions from ivy rootlet
extract. And then the four factions were used to synthesize gold nanoparticles.
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gold nanoparticles, the solutions were centrifuged and washed as described
above. A schematic for this method is shown in Figure 26B.
Characterization of the gold nanoparticles
A variety of techniques were used to determine if AuNPs were formed using the
two methods described above. First, the Surface Plasmon Band (SPB),
generated by the formation of AuNPs was examined using a Thermo Scientific
Evolution 600 UV-Vis Spectrophotometer (Waltham, WA). After confirming the
presence of SPB, the samples were analyzed by DLS and Zeta Potential
analysis, using a Zetasizer Nano (Malvern Instruments Ltd, Worcestershine, UK),
to determine the size distribution of the nanoparticles, and also the stability of the
nanoparticles in solution. In order to characterize the morphology of the
synthesized AuNPs, 10 µl of solution was air-dried onto a piece of silicon wafer
and scanned at high resolution with a LEO 1525 FE-SEM equipped with a
Gemini Emission Column. Simultaneously, energy dispersive x-ray spectroscopy
(EDS) was conducted on the nanoparticle images to ensure that the
nanoparticles were Au. The amount of protein present in the culture water was
also characterized using a bicinchoninic acid (BCA) protein assay kit (Pierce)
following the manufacturer’s instructions. Similarly DMMB was used to measure
the concentration of proteoglycan in solution using standard methodology [179].

To evaluate the intracellular uptake of the synthesized AuNPs, pelleted AuNPs
were resuspended in PBS and added to cell culture medium. The AuNPs
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containing media were then incubated with mouse MC3T3 cells for 4 hours. After
incubation, cells were washed three times with PBS buffer and incubated in fresh
α-MEM medium supplemented with 10% fetal bovine serum (FBS), 1.0 × 105 U/l
penicillin (Sigma) and 100 mg/ml streptomycin (Sigma) overnight. The
intracellular uptake of the AuNPs was observed using the Cytoviva™ system
attached to a Nikon Eclipse E600.
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Results
UV-Vis analysis of AuNP Formation (Method One)
After a few hours, the culture solution changed in color from clear to red, violet,
dark purple, and light purple, depending on the concentration of HAuCl4 (insert in
Figure 27A). At this point the solution was removed for analysis of the AuNPs
formed during, and fresh HAuCl4 solution was added back to the GA7 boxes.
Analysis of the UV-Vis spectra of the solution collected after incubation with
HAuCl4 concentrations of 0.025, 0.05, 0.1, 0.2, 0.5 and 1 mM showed a SPB
around 550 nm, specific for AuNPs [180]. No SPB was present at HAuCl4
concentrations of 0 and 5 mM (Figure 27A). While the SPB appeared at the
same absorbance for AuNP forming concentrations, there was a significant
difference in the width of the SPB at different concentrations of HAuCl4 solution.
To test the sustainability of the AuNP synthesis procedure described above, the
HAuCl4 solution was removed and replaced with fresh solution every 24 hours
and UV-Vis spectroscopy was conducted on the freshly removed solution to
determine if AuNPs were still being produced. Figure 27B shows that at 0.1 mM
HAuCl4, AuNPs were formed every 24 hours continuously over a 10 day period.
Based on the Beer-Lambert law, the UV- Vis absorbance of a solution is directly
proportional to the concentration of the absorbing species in the solution and the
path length [181]. In our experiments, the path length was kept constant, thus the
concentration of AuNPs in the solution, can be linearly correlated to the
absorbance of the AuNP solution. We used this relationship to determine the
relative concentration of AuNPs at each time interval, and to calculate the
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Figure 27 UV absorption spectra of gold nanoparticles synthesized.
A. UV-vis absorption spectra of gold nanoparticles synthesized in 0.025, 0.05, 0.1, 0.2, 0.5, 1 and
5mM aqueous AuCl4- in ivy culture system in the 1st day. The inset photo showed gold
nanoparticles formed with different concentration of aqueous AuCl4- (a. 1 mM, b. 0.5 mM, c. 0.2
mM, d. 0.1 mM, e. 0.05 mM, f. 0.025 mM) in ivy culture system. B. UV-vis absorption spectra
recorded the gold nanoparticles formation in live ivy culture system, rich with 0.1 mM aqueous
-

AuCl4 environment from the 1st day to the 10th day respectively (Each curve experienced 24
hours reaction time).
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efficiency of the synthesis procedure over time. From the spectral data, the
efficiency of AuNP production remained high for the first 5 days, and decreased
from day 6 -30. Despite the decrease in efficiency, AuNPs could still be obtained
from the production system for greater than 30 days, demonstrating the
sustainability of this method. The same sustainable property was also observed
at lower HAuCl4 concentrations (0.025 mM, 0.05 mM) (Figure 28A-B). In the
presence of higher concentrations of HAuCl4 solution (0.5 mM, 1 mM) the
decrease in production efficiency was more obvious compared to the lower
concentrations (Figure 28C-D), especially at 1 mM HAuCl4. At this high
concentration of HAuCl4 some toxicity may occur in the ivy shoots, which
decreases the rate of the overall production.
UV-Vis analysis of AuNP Formation (Method Two)
Solutions I-IV were reacted with 0.5 mM HAuCl4 solution at room temperature,
as described in the Material and Methods section. A characteristic surface
plasmon resonance band (SPR) for gold nanoparticles at 500-600 nm was
detected in all four samples (I-IV) (Figure 29), confirming the synthesis of gold
nanoparticles in these solutions.
Morphological analysis of AuNPs in Solution
DLS and Zeta potential analysis was used to analyze the size of the AuNPs in
solution, and to determine the stability of nanoparticles. DLS of the AuNPs
formed using Method One, indicated that the average size of the AuNPs
increased from 10 to 300 nm with an increasing concentration of HAuCl4 from
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Figure 28 UV-Vis absorption spectra recorded the gold nanoparticles formation in live ivy
culture system.
UV-Vis absorption spectra recorded the gold nanoparticles formation in live ivy culture system,
rich with different concentration of aqueous AuCl4- environment (A, 1 mM; B, 0.5 mM; C, 0.05
mM; D, 0.025 mM) from the 1st day to the 10th day respectively.

117

Figure 29 UV/Vis spectra of gold nanoparticles synthesized by different ivy rootlet extract
solutions.
UV/Vis spectra of gold nanoparticles synthesized by different ivy rootlet extract solutions. Gold
nanoparticles from solution I has a larger absorbance value at λmax, indicating more gold
nanoparticles synthesized from solution I. Gold nanoparticles from solution III and IV have more
absorbance over 720 nm, suggesting more nanoplates or clusteres in the solution III and IV.
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0.025 to 2 mM. This agreed well with the red-shift of the UV-Vis spectra with
higher concentrations, as shown in Figure 27. The size distribution of gold
nanoparticles, formed from 0.1, 0.5 and 1 mM HAuCl4, were measured by DLS
and displayed in Figure 30A-C. Based on the Zeta potential analysis, none of the
solutions containing the AuNPs, formed using Method One, was stable in water,
with zeta potentials ranging from -18.1 to -33.5 mV. This analysis was not
surprising, since the AuNPs were observed to sediment from solution, and could
easily be centrifuged at a low speeds.
The size distributions of AuNPs synthesized using Method Two, were also
analyzed by DLS and Zeta potential analysis. AuNPs formed using Solution I
and II showed smaller average sizes compared with solution III and IV (Figure
30D-G). A significant difference was observed in the Zeta potential of the AuNPs
synthesized from the different solutions. Solution I, with a Zeta potential < -30 mV
was moderately stable in solution. In solution II, the Zeta potential increased to >
-30 mV, suggesting an instability of the AuNPs in solution. The Zeta potential
further increased in solution III and IV to larger than -15 mV. Precipitates in these
two solutions could be clearly observed, indicating the instability of the AuNPs
and the aggregation of these AuNPs.
Morphological analysis of dry AuNPs
To examine the effect of the HAuCl4 concentration on the morphology of the
nanoparticles produced, SEM was conducted. SEM images of the AuNPs
synthesized using Method One revealed different sizes and shapes of gold
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Figure 30 Size/ intensity histograms of gold nanostructures
Size/ intensity histograms of gold nanostructures synthesized from 0.1mM (A), 0.5Mm (B), 1mM
(C) aqueous AuCl4- by live ivy shoots at room temperature. Size/ intensity histograms of gold
nanoparticles synthesized by different ivy rootlet extract solutions I (D), II (E), III (F) and IV (G).
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nanostructures produced by the varying HAuCl4 concentration (Figure 31A-C).
Fig. 6A showed relatively uniform, spherical gold nanoparticles with sizes ranging
from 10 to 100 nm, formed from 0.1 mM HAuCl4. The SEM images of gold
nanoparticles synthesized using 0.5 mM HAuCl4 showed that most of the AuNPs
had a spherical morphology, with a narrow size range of around 100 nm. At 1
mM HAuCl4, the AuNPs formed were heterogeneous with triangular, hexagonal,
and spherical morphologies (Figure 31C). EDS was run simultaneously and
determined that the nanoparticles were Au (Figure 31D).
Similar to the results obtained from the AuNPs synthesized using Method One,
SEM images of AuNPs formed using Method Two revealed micro- or nanocrystals in all samples (Figure 31E-H). In solution I, spherical nanoparticles with
a size range of 20-50 nm size were observed, with no other shapes of
nanocrystals (Figure 31E). In solution II, nanoplates, nanorods, and spherical
nanoparticles were observed (Figure 31F). In solution III, nanocrystals with sizes
larger than 50 nm dominated, with triangular nanoplates also appearing (Figure
31G). Analysis of solution IV revealed the presence of predominately triangular
nanoplates, with only a small number of spherical nanoparticles and nanocrystals
with small diameters (Figure 31H).
Protein and polysaccharide concentration of the reaction solutions
Using a BCA kit, the concentration of protein present in the reaction solution for
Method One was determined to be 1.45 µg/ml. However, the protein
concentration of the adventitious root extract without dialysis in Method Two,
121

Figure 31 SEM images of gold nanostructure synthesized in 0.1mM, 0.5mM, 1mM aqueous
AuCl4- by live ivy shoots at room temperature.
SEM images of gold nanostructure synthesized in 0.1mM (A), 0.5mM (B), 1mM (C) aqueous
AuCl4- by live ivy shoots at room temperature, (D) EDX of the treated sample. SEM micrographs
of gold nanoparticles synthesized by different ivy rootlet extract solutions I (E), II (F), III (G) and IV
(H). (All scale bar= 100nm)
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prior to reaction with HAuCl4, was found to be 1815.3 µg/ml. After reaction with
HAuCl4, using Method Two, only 340.1 µg/ml remained in the supernatant, an 80%
decrease compared to the starting concentration. Unlike the trend in protein
concentration between the two methods, the DMMB assay determined that the
concentration of proteoglycan in the reaction solution using Method One was
4.675 µg/ml, while the concentration for Method Two was 2.33 µg/ml.
Intracellular uptake of synthesized AuNPs
To test whether the AuNPs produced by both methods could be transported into
cells for potential biomedical applications, a Cytoviva™ condenser mounted to a
Nikon Eclipse microscope was used. Briefly, various AuNPs obtained from both
methods were incubated with DMEM containing 10% serum for 24 hours,
followed by centrifugation at 14,000 rpm and three washes of PBS. Microscopic
analysis showed the internalization of the AuNPs into MC3T3 cells. Using the
Cytoviva™ condenser, AuNPs were distinct from organelles due to their
scattering properties, which make them appear scarlet or yellow in color (Figure
32). The control group without nanoparticles had no internal particulates,
whereas the experimental samples displayed scarlet or yellow nanoparticles.
This confirmed that the AuNPs synthesized in this study can be transported
across the cell membrane, similar to AuNPs produced by other methods used for
cancer therapy [182]. Previously, AuNPs have been proven to have great
potential in drug delivery, cancer therapy and bio-imaging applications [183]. It is
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Figure 32 Dark-field microscopy images of Au NPs synthesized from HAuCl4
Dark-field microscopy images of Au NPs synthesized from 0.1 mM HAuCl4 (B), 0.5 mM HAuCl4
(C), 1 mM HAuCl4 (D) in MC3T3 cells respectively. (A) is the control group, without AuNPs.
MC3T3 cell incubated with gold nanoparticles from solution II (E), and gold nanocrystals from
solution III, IV (F).
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conceivable that proteins, polysaccharides and other small molecules would
provide a robust coating around gold nanoparticles to prevent aggregation. The dark
field images demonstrated that our synthesized AuNPs using both methods could be
easily taken up by the cells.
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Discussion
Two methods for the synthesis gold nanoparticles using English ivy were
developed. In Method One, a system was developed for the sustainable
synthesis of AuNPs from the addition of aqueous HAuCl4 to actively growing
English ivy shoots. The resulting AuNPs were collected from the culture medium
every 24 hours, and fresh HAuCl4 solution was added to replenish the media. In
Method Two, AuNPs were synthesized using four fractions of adventitious root
extract separated by molecular weight using dialysis. When comparing the two
methods at the same concentration of HAuCl4, 0.5 mM, both methods
demonstrated the ability to form predominately spherical nanoparticles. However,
the nanoparticles formed using Method Two, Solution I, showed a much smaller
nanoparticle size compared to Method One at the same concentration. When
Solutions II-IV were used, more diverse nanoparticle morphology was observed,
with nanotriangles representing the dominant morphology. A similar trend was
observed using Method One, where increasing concentrations of HAuCl4 led to
the formation of nanotriangles, and fewer spherical nanoparticles. Considering
that spherical nanoparticles are the most sought after morphology for biomedical
applications, it would seem that the nanoparticles formed using Method One at a
concentration of 0.5 mM HAuCl4, or Method Two using Solution I would be the
best choices for green synthesis of spherical nanoparticles. In addition to the
shape of synthesized AuNPs, the size of nanoparticles is also important in
biomedical applications, and in general, the AuNPs formed from Method Two
(Figure 30 D-G) were smaller than those formed from Method One (Figure 30 A126

C). While the size and shape of AuNPs necessary for a given application may
dictate the choice of methods used for synthesis, other factors should be
considered when comparing the two synthesis methods developed in this study.
Using Method One, a significant amount of nanoparticles was synthesized over
an extended period of time by simply replenishing HAuCl4 in the growth media of
the ivy shoots. In this study, we were able to generate sustained nanoparticle
production over a period of 30 days using the same shoots. Thus, Method One
does not require a large input of raw plant materials, since a single batch of
shoots can be sustained for over a month. This represents an economically
favorable strategy, compared to strategies that require the destruction of the
plant tissue for the formation of an extract, such as that described in Method Two.
However, since the only control parameter that can be varied in Method One is
the concentration of HAuCl4, it is expected that there would be less control over
modifying this method for the generation of a particular AuNP size or morphology.
In essence, the metabolic nature of the shoots will dictate the size and shape of
the nanoparticles. Using Method Two, it is possible to more finely tune the
synthesis of the AuNPs. For example, in Method Two, temperature, pH, extract
concentration, and HAuCl4 concentration can be varied to more finely control the
formation of specific AuNP sizes and morphology. In addition, while Method One
represents a sustainable method, the AuNPs are collected every 24 hours,
whereas in Method Two, the AuNPs can be collected in a matter of hours. The
more rapid synthesis of AuNPs using Method Two may lead to the formation of a
greater number of nanoparticles per unit time than Method One. As mentioned
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earlier, since the extract formed using Method Two destroys the plant tissue in
the formation of the extract, there would be an associated cost with this method
over Method One. As such, the choice of green synthesis method depends on a
variety of factors, with the ultimate choice being left to the user.
Another difference between the two methods is the potential biomolecules
involved in the formation of the nanoparticles. The synthesis of gold
nanoparticles in Method One could be achieved through two different routes.
They can be synthesized directly in water, or can be formed in live shoots then
released back to the water through the vascular system present in the stem. To
investigate how these gold nanoparticles formed, 50 ml deionized water without
HAuCl4 was placed into the GA7 box with live ivy shoots for 24 hours. The water
was then removed from the box and mixed with different concentrations of
HAuCl4 outside the culture system. It was observed that the AuNPs were slowly
formed in solution, as evidenced by the gradual color change. The UV-Vis
spectra were used to confirm the formation of gold nanoparticles (Figure 33 A).
The broad SPB in the spectra resulted from the formation of large anisotropic
particles. It was also observed from the SEM image of polydispersed AuNPs
synthesized at 1 mM aqueous HAuCl4 solution (Figure 33 B). From these results,
we hypothesized that biomolecules or small chemicals were continuously
released into the culture water through ivy stems, which are responsible for
reducing, stabilizing and shape-controlling agents for AuNPs synthesis.
In Method Two, the ivy rootlet extract was separated into four fractions using
different MWCO dialysis bags. Most polyphenols are in the size range of 0.5128

Figure 33 UV-Vis spectra of gold nanoparticles synthesized using different concentration
of HAuCl4 solution
UV-Vis spectra of gold nanoparticles synthesized using different concentration of HAuCl4 solution
(1mM, 0.5mM, 0.2mM, 0.1mM) with DI water derived from ivy culture system. B, SEM image of
gold nanoparticles synthesized at 1mM HAuCl4 solution with DI water derived from ivy culture
system. (the scale bar= 100nm)
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4kD, and thus would be contained in solution I or II. Based on the size range,
solution III was expected to contain the majority of biopolymers, such as
polysaccharides and proteins, while solution IV may contain protein complexes
and large macromolecules, such as glycoproteins or proteoglycans. The
synthesis of gold nanoparticles by these four different solutions implied that
molecules in different size ranges could individually and independently contribute
to the synthesis of gold nanoparticles. To confirm the chemical components
possibly involved in the synthesis process, the BCA protein assay, and
proteoglycan assay were used to determine protein and proteoglycan
concentrations. The results showed that both proteins and GAGs were available
in the reaction solution of two methods. The concentration of proteins was much
lower in Method One (1.45 µg/ml) than the extract solution without treatment in
Method Two (1815.3 µg/ml), while the polysaccharide concentration in Method
One (4.675 µg/ml) was twice that of Method Two (2.33 µg/ml). Considering that
proteins secreted from the shoots of English ivy will be minimal, and that Solution
I from Method Two, where most proteins will have been removed, generated the
most uniform spherical nanoparticles, it is expected that other molecules are
driving the formation of the AuNPs. Due to the comparably larger size of proteins,
it is not surprising that the nanoparticles formed using Solutions II-IV of Method
Two have increasingly larger size distributions, most likely due to the adsorption
of proteins to the nanoparticle surfaces.
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Conclusion
Two methods for the green synthesis of AuNPs using English ivy have been
developed. Method One is a simple, sustainable synthesis system for AuNP
production using actively growing English ivy shoots. This system allows
continuous synthesis of gold nanoparticles in water with the addition of HAuCl4
solution.

Compared to other plant-based synthesis methods for metal

nanoparticles, the newly established system described in Method One does not
require the preparation of plant extracts, or complicated isolation from live plants,
thus representing a significant advancement in plant-based green manufacturing
of metal nanoparticles. In Method Two, the facile synthesis of AuNPs from
different molecular weight fractions of adventitious root extract was examined.
Using different molecular weight ranges of the extract, AuNPs could be tuned to
generate different shapes and sizes of AuNPs. The synthesized biocompatible
AuNPs obtained from both methods could easily enter into MC3T3 cells, making
them attractive candidates for bio-imaging, cancer therapy, and drug delivery.
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CHAPTER V
ONE-STEP SYNTHESIS OF DENDRITIC GOLD NANOFLOWERS
WITH HIGH SURFACE-ENHANCED RAMAN SCATTERING (SERS)
PROPERTIES

132

Introduction
Gold nanostructures have drawn increasing interest due to their tunable
morphology and promising optical as well as electronic properties for biomedical
applications [45, 51, 184]. Especially in recent years, gold nanoparticles have
demonstrated great potential in molecular imaging and sensing for disease
diagnosis and therapy [185]. The majority of gold nanostructure research has
focused on how the changes in size and shape of the nanostructures may
influence their properties for applications in cancer therapy [186-188]. To
enhance surface properties of gold nanostructures, efforts have been made into
the development of nanostructures with unique morphology. Of particular interest
is that gold nanopaticles have shown promise in bioimaging and biosensing [185].
Colloidal gold nanoparticles have been proposed as therapeutic nanocarriers for
cancer treatment [186]. The most significant advance in increasing surface
morphology of gold nanoparticles is the discovery of gold nanoflowers [189].
Gold nanoflowers are specialized gold nanoparticles with large amounts of highly
branched tips that give the overall appearance of a flower. Nanomorphology of
the highly branched surfaces with tips often leads to the formation of sharp peaks
and valleys, which are potential ―hot spots‖ for localized near-field enhancements
[45, 50, 51]. The highly branching nanostructures can drastically increase the
ratio of total surface to volume. These factors could potentially lead to the
enhancement of

the

Raman

scattering on

the highly branched

gold

nanostructures [52, 53]. Therefore, compared with smooth surfaces, highly
branched surfaces (such as dendrites, multi-pods, and nanoflowers) have a
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greater potential for SERS based bioimaging and biosensing. For these reasons,
studies have been conducted on the use of gold nanoflowers in bioimaging[45],
biosensing[190], drug delivery and tissue engineering [191]. Despite the promise
of gold nanoflowers, it remains a major challenge to repeatedly synthesize the
unique nanostructures with low cost.
Currently, several

synthetic methods have been proposed to synthesize

branched metal nanostructures and gold nanoflowers [188, 192-194], including
seed-mediated growth approaches, such as using CTAB, ascorbic acid [195],
and one-pot methods using

polyvinylpyrrolidone (PVP) [196], and tris base

(TB)[197] . Some one-step synthesis approaches have been effective at
producing thin gold nanoplates or multipods with a limited number of sharp tips,
but have not been proven effective at the formation of highly branched gold
nanoflowers [51, 189, 198, 199]. Seed-growth approach has been used to
synthesize gold nanoflowers; however, concerns remain over repeatability of the
method. For instance, size and shape of the gold nanoflowers synthesized by the
two-step seed-mediated growth often depend on the facets of seed molecules,
whose mechanism currently is not well understood [188, 193]. As such, it is
difficult to control the formation of highly branched gold nanoflowers using most
current methods. In addition, the multiple steps and the use of hazardous
chemical reactants remains a major concern for biomedical applications [200].
Thus, the development of highly branched (more sharp tips) gold nanoparticles
with biocompatible, low-cost, eco-friendly, and well-defined hierarchical structure
is still a daunting challenge.
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It is well-known that the oxidation of dopamine by AuCl4- could contribute to the
formation of gold nanoparticles [201]. In this communication, a one-step
approach for synthesizing gold nanoflowers (Au NFs) with multiple tips and
dendritic structures is proposed by using dopamine. Briefly, Au NFs synthesized
by combining HAuCl4 with dopamine hydrochloride in a rapid one-step reaction.
The method uses dopamine, a natural neurotransmitter, as both the reducing and
shape-directing agents, which is environmental friendly. Additionally, the Au NFs
synthesized using this method have increased biocompatibility, due to the
coating of the Au surface with an organic molecule that is normally present in
mammalian cells. In order to further control the synthesis and morphology of the
Au NFs, the effects of variations in reactant concentration, pH and temperature
are discussed. Upon completion and tuning of the Au NF formation process,
SERS activities and intracellular uptake of the Au NFs by human lung A549
cancer cells and mouse melanoma B16BL6 cells are present.
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Results and Discussion
In the proposed experiment, Au NFs were synthesized by mixing 1mM HAuCl4
with 5mM dopamine hydrochloride with the original pH of 2.5 and vortexing for 1
min at room temperature. The color of the solution immediately changed from a
light yellow to a dark orange, indicating the reduction of Au (III) to Au (0) [202].
The Au NFs were collected by centrifugation at 16,873 × g for 5 min followed by
three washes using DI water. As shown in Figure 1, the synthesized flower-like
particles exhibited multiple tips with dendritic structures. The Au NFs were
dispersed with the average size in the range of 310-820 nm (Figure 34 A), and
were comprised of numerous dendritic tips of 60-240 nm in length (Figure 34 B).
The average hydrodynamic size of the nanoflowers in solution was approximately
630nm characterized by dynamic light scattering (DLS). The average zeta
potential of the Au NFs was about -27.1 mV, indicating moderate stability of the
Au NFs in solution. Furthermore, the crystal structure of the Au nanostructure
was confirmed using X-ray diffraction (XRD). As shown in Figure 35, the XRD
pattern of the Au NFs showed five peaks assigned to diffraction from the (111),
(200), (220), (311), and (222) planes of face-centered-cubic (fcc) gold, which
indicated the pure and well-crystallized gold [203].
The formation of the Au NFs over time was followed to determine how quickly
they were formed, and the effect of increased reaction time on their formation.
The reaction and evolution of the Au NFs were followed by time-dependent UVvis spectroscopy and SEM. A decrease in intensity of the band at 390 nm, which
is a characteristic band for dopamine-o-quinone,[204] indicated that the
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Figure 34 SEM images of the Au NFs obtained from an aqueous solution of HAuCl4 and
dopamine
SEM images of the Au NFs obtained from an aqueous solution of HAuCl4 (1mM) and dopamine
(5mM). (A) The Au NFs had the average size ranging from 310-820 nm. Insert picture (B) is the
enlarged image of the Au NFs, showing multiple tips with dendritic structures with the length of
approximately 60-240 nm.
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Figure 35 XRD pattern obtained from a thin film of Au NFs on a glass substrate.
The Au NF solution was on a glass substrate to obtain a smooth plane surface, and the diffraction
pattern was recorded over a 2θ range of 35˚ - 85˚. The sharp reflections at 38.2˚, 44.3˚, 64.7˚,
77.6˚ and 81.8˚ correspondingly index as (111), (200), (220), (331) and (222), indicating
characteristics of face-centered cubic (fcc) gold.
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dopamine was reacting with the gold substrate (Figure 36). With the decrease of
the dopamine-o-quinone peak, a shoulder began to form at ~510 nm, indicating
the time dependent formation of the dendritic gold nanoparticles (Figure 36).
Previous studies analyzing the UV-vis formation of dendritic gold nanostructures
reported a similar trend, with the emergence of a broad peak from 500-600 nm,
which was correlated with the gold nanostructures[205]. As shown in Figure 37
A-D, the possible development of reaction and the evolution of Au NFs were
proposed as follows. First, the nanocrystals formed through the nucleation of
gold, followed by equilibrium of gold nanocrystal growth, which is most likely via a
Volmer-Weber mechanism [206]. Briefly, the stacked aggregations of small gold
nanoparticles (roughly 10-50 nm) build up the tip of gold dendrites, and then
AuCl4- ions and dopamine in solution are continuously captured by the tips via
migration and diffusion [207]. The oriented attachment process could contribute
to the formation of gold dendrites by the addition of new gold nanoparticles on
the surface[207]. Then, several dendritic nanocrystals with different sizes were
generated and their centers were randomly positioned in a spherical core. Finally,
successive agglomerations of large amounts of dendritic tips around the core
form flower-like nanostructures. Considering the possible growth processes of
the Au NFs, we hypothesized that the concentration of the reactants (HAuCl4 and
dopamine) might affect the size and morphology of Au NFs. To validate this
hypothesis, the concentration of dopamine was decreased from 5 mM to 1 or 0.5
mM, while keeping the concentration of gold precursor (HAuCl4) constant as
1mM. As shown in Figure 37 A-B, irregular gold nanoparticles were formed with
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Figure 36 Time-dependent UV-vis spectra of reaction between HAuCl4 and dopamine.
Time-dependent UV-vis spectra of reaction between HAuCl4 (1mM) and dopamine (5mM). The
decreasing band at 390 nm is the characteristic band for dopamine-o-quinone. An increasing
shoulder at ~510 nm indicates the formation of dendritic gold nanoflowers, similar to previous
studies of dendritic gold nanostructures.
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Figure 37 SEM images of the proposed mechanism for the formation of Au nanoflowers
SEM images of the proposed mechanism for the formation of Au nanoflowers (from A to D). First,
several dendritic nanoparticles with different diameter were generated (A-B) and their centers
were randomly positioned in a spherical space (C). After the generation of the primary structure,
the inner core of the nanoflowers was formed by adding new dendritic nanoparticles around their
center (D).
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Figure 38 SEM images show the size and morphology of Au NFs affected by the
concentration of the reactants (HAuCl4 and dopamine).
SEM images show the size and morphology of Au NFs affected by the concentration of the
reactants (HAuCl4 and dopamine). Au nanoparticles obtained from an aqueous solution of (A)
HAuCl4 (1mM) and dopamine (0.5mM), (B) HAuCl4 (1mM) and dopamine (1mM). The images
show irregular Au nanoparticles were formed with the size ranging from 50 to 300 nm. Au
nanoparticles obtained from an aqueous solution of (C) HAuCl4 (0.25mM) and dopamine (5mM),
(D) HAuCl4 (0.5mM) and dopamine (5mM). Random gold nanoparticles were observed, and few
irregular flower-like nanostructures appeared with the aggregation of several small nanoparticles.
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the size ranging from 50 to 300 nm. These gold nanoparticles were devoid of the
sharp tips observed in the Au NFs. According to a previous study [201], gold
nanoparticles also formed with the HAuCl4 concentration at 0.2 mM in the
presence of lower concentrations of dopamine ranging from 2.5 µM to 0.02 mM.
These findings indicate that low concentration of dopamine leads to the rough
gold nanoparticles formation rather than flower-like gold nanostructures with
sharp tips. However, when the dopamine concentration was increased to 5 mM,
flower-like nanostructures were formed. Similar to the effect of changes in
dopamine concentration, changes in the starting HAuCl4 concentration led to
observable changes in size and morphology. When the HAuCl4 concentration
was decreased from 1 mM to 0.5 mM and 0.25 mM, gold nanoparticles were
formed along with irregular Au NFs (Figure 38 C-D). These Au NFs appeared
with the aggregation of multiple smaller nanorods or spherical nanoparticles,
while they were devoid of sharp tips and dendritic structures. In this study,
dopamine likely acted as both the reducing and capping agents, attributing to the
formation of Au NFs. To study the surface capping effect of dopamine, the
Fourier transform infrared spectroscopy (FTIR) was used to characterize the pure
dopamine and the synthesized Au NFs. As shown in Figure 39, some strong
absorption features such as 1342 cm-1 (due to CH2 bending vibration), 1320 cm1 (due to C-O-H asymmetry bending vibration), 1190 cm-1 (C-O symmetry
vibration) in dopamine hydrochloride spectrum all disappeared in the Au NF
spectrum [208]. The appearance of peaks at around 1455 and 1410 cm-1 in Au
NF spectrum was due to the formation of the dopaminechrome [209]. The FTIR
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Figure 39 FTIR spectra of dopamine and synthesized Au NFs.
Some strong absorption features such as 1342 cm-1 (due to CH2 bending vibration), 1320 cm-1
(due to C-O-H asymmetry bending vibration), 1190 cm-1 (C-O symmetry vibration) in dopamine
hydrochloride spectrum all disappeared in the Au NF spectrum. Instead, the appearance of peaks
at around 1455 and 1410 cm-1 in Au NF spectrum was due to the formation of the
dopaminechrome.
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spectra provided evidence that the oxidation of dopamine might reduce Au ions
to Au (0), and oxidative dopamine was absorbed on the Au NF surface.
Considering the effect of reactant concentration on Au NF synthesis, other
reaction conditions, including pH, and temperature were also investigated. It was
found that the tip length of the nanoflowers decreased with increasing pH values.
2N NaOH solution was used to regulate the pH value to be 3.5, 7.0, 8.5, and 9.0.
When the pH increased to 3.5, smaller nanoflower-like gold nanoparticles with
shorter tips in the length of around 20-80 nm were observed under SEM (Figure
40 A). As the pH value increased beyond 7.0, globular nano- and microparticles
were formed as opposed to the flower like structures observed at pH 3.5 (Figure
40 B). We hypothesize that the reason for the above phenomenon is due to the
increase of the oxidation rate of dopamine through increasing the pH values [201,
210], the chance for dopamine to cap and reduce the Au ions will be significantly
reduced. Another parameter expected to alter the size and morphology of the Au
NFs is the reaction temperature, since it affects nucleation, diffusion, and growth
rates [211]. To determine the effect of reaction temperature, reactions of 1 mM
HAuCl4 and 5 mM dopamine were maintained at different temperatures (20 °C;
40°C; 60 °C; 80 °C; 100 °C) with the pH value of 2.5. Interestingly, the reaction
temperature did not affect the size and morphology of the Au NFs (Figure 40 CF); however, with the increase of the reaction temperature, the color of the
reacting solution was changed quickly, indicating the faster growth rate of the Au
NFs.
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Figure 40 SEM images of Au NFs obtained from an aqueous solution of HAuCl4 and
dopamine
SEM images of Au NFs obtained from an aqueous solution of HAuCl4 (1mM) and dopamine
(5mM) at pH= 3.5 (A) and pH= 8.5 (B). And Au NFs obtained from an aqueous solution of HAuCl4
(1mM) and dopamine (5mM) with the original pH value of 2.5 at different temperature: 40˚C (C),
60˚C (D), 80˚C (E) and 100˚C (F). They showed at different reaction temperatures, the size and
morphology of Au NFs did not have significant change.
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Based on the above results, we may modify the Au NF structures through
regulating concentration of the reactants, and the pH values.
SERS of gold nanoparticles and nanostructures has been regarded as a new
optical spectroscopic analysis technique for sensitive detection of biomolecules
in medicine [212, 213]. Since the weak spontaneous Raman scattering, colloidal
gold nanoparticles has been well documented, where the increase in surface to
volume ratio often leads to an enhanced SERS by 10 14-1015 folds [45]. To
demonstrate the importance of the Au NFs synthesized in this study, we have
analyzed the surface enhanced Raman scattering (SERS) of the Au NFs, and
their potential for intracellular delivery. In previous work, the optimum size range
of spherical gold nanoparticles for SERS was determined to be 20-70 nm [214].
Considering the small size of these gold nanoparticles, to further increase the
SERS signals, it is necessary to alter the surface morphology to increase the
surface to volume ratio. As such, studies have demonstrated that highly
branched flower-like nanostructures can further enhance SERS by 10 times [45].
Furthermore, gold multipods with a limited number of tips (less than 10) or
multiple tips without complex structures have been shown to create large
electromagnetic field enhancements at the particle tips, with the efficiency of
SERS effects related to the number of tips [45, 51, 188]. Based on this data, and
the highly branching dendritic tips present on the Au NFs synthesized in this
study, we hypothesize that this complex nanostructure may be used for SERS
applications. To confirm this hypothesis, rhodamine 6G (Rh6G), a standard
SERS probe molecule, was used to investigate the SERS capability of the Au
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NFs. As a control, spherical gold nanoparticles (Au NPs) with a diameter from 10
to 100 nm were synthesized using a previously defined method [160]. Note that
the control Au NPs are within the optimum size range for SERS applications. The
typical SERS spectra of Au NFs and Au NPs with adsorbed Rh6G are presented
in Figure 41. For the typical peaks (1315 cm-1, 1345 cm-1, 1450 cm-1, 1515 cm1) in the Raman spectra, Au NFs showed much stronger enhancement of the
SERS effect than gold nanoparticles. The significant enhancement might be due
to the large amount of sharp tips on the surface of Au NFs that potentially act as
―hot spots‖ [45]. Additionally, numerous tiny sharp tips or cavities on the dendritic
structures may also act as ―hot spots‖ [215], which attribute to achieve an doubleenhanced SERS effect.
Due to the enhanced SERS of Au NFs, the combination of bio-imaging and
delivery using the Au NFs were evaluated. Considering that biocompatibility is a
major concern for biomedical applications, the cytotoxicity of the Au NFs was
tested in A549 human lung tumor cells, and B16BL6 mouse melanoma cells.
Both cells were treated with Au NFs in different concentrations (0.128-400 µg/ml)
for 48 h and then the cell viability was analyzed using the MTT assay. As shown
in Figure 42 A-B, the cell viability in both cell lines was > 85% with the Au NF
concentrations as high as 400 µg/ml. The low cytotoxicity of the Au NFs
demonstrates a similar biocompatibility with gold nanoparticles often used in
biomedical applications, thus validating the good biocompatibility of the Au
NFs[216, 217]. Furthermore, the intracellular uptake of the nanoflowers in tumor
cells was tested using dark field microscopy. As shown in Figure 42 C-F,
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Figure 41 SERS spectra of Rh6G adsorbed on Au NFs and Au NPs, pure Rh6G as a control.
SERS spectra of Rh6G adsorbed on Au NFs (Black) and Au NPs (Red), pure Rh6G as a control
(Blue). The concentrations of Rh6G in all samples were 5×10-5 M. The increased intensities of
bands at 1315 cm-1, 1345 cm-1, 1450 cm-1, 1515 cm-1 on Au NFs compared with Au NPs
indicated the Au NFs exhibited strong surface-enhanced Raman scattering effects.
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Figure 42 Survival histograms for A549 and B16BL6 cells exposed to AuNFs.
Survival histograms for A549 (A) and B16BL6 (B) cells exposed to Au NFs with various
concentrations for 48 hours. Cell viability was measured by the MTT assay. Dark field images of
A549 cells treated without nanoflower (C) and with Au NFs (D); B16BL6 cells treated without
nanoflower (E) and with Au NFs (F). The Au NFs were incubated with cells for 4 hours at room
temperature. The bright spots in B and D suggested the Au NFs were internalized in cancer cells.
The scale bar indicates 10µm.

150

compared with the control group (without Au NF treatment) (Figure 42 C, E),
more Au NFs entered into the cells (Figure 42 D, F). It is likely that the Au NFs is
internalized by cancer cells through endocytosis, which is similar with other
synthesized gold nanoparticles[218, 219]. These results suggest that the Au NFs
could be proposed as active tags combined with specific biomolecules for in vitro
detection.
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Conclusion
In summary, a one-step approach for the synthesis of well-defined hierarchical
Au NFs with low cost and eco-friendly has been developed. The highly branched
Au NFs exhibited a strong SERS effect, due to the unique surface morphology
with a large amount of sharp tips and dendritic structures. Furthermore, the Au
NFs can be readily internalized by cancer cells along with promising
biocompatibility. The above features make the Au NFs a unique candidate for
bio-imaging, biosensors, and other biomedical applications.
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CHAPTER VI
FUTURE PERSPECTIVES
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Although nature based nanoparticles are generally biocompatible and less
environmental toxicity associated with their production, there are still many
aspects of their development that need to be improved. To be effective
nanoparticles must maintain in vivo biostablity, circulate freely through the
vascular systems of patients, and target specified cell types and organelles.
Once they are produced, nature based nanoparticles must be modified and
linked to small peptides, antibodies, or proteins to achieve particle stealthing,
cellular targeting and organelle targeting.

Nanoparticle shields
When nanoparticles are administered systemically and circulate in the blood
stream, sinusoids in the spleen filter the nanoparticles, and target them for
removal via the reticuloendothelial system (RES) [220]. Nanoparticles bind to
specific proteins of the RES cells [221]. Immunoglobulin and complement
proteins are the major contributors to the recognition of the nanoparticles by the
RES cells. The cells, which are macrophages will activate complement and
induce

hypersensitivity

reactions

[222].

The

selective

removal

of

the

nanoparticles by the RES cells can be reduced by changing the characteristics of
the nanoparticles’ surface to render them more hydrophilic and neutralize the
nanoparticle surface charge. The strategy covertly being investigated involve
linkage of PEG to the surface of the nanoparticle to slow down the process of the
RES cells binding to the nanoparticles [223]. Recently, Furumoto found that
particles covalently bound with the albumin to their surface circulate longer
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compared to the naked or PEGylated particles [224]. In another study by binding
the nanoparticles to albumin, Furumoto was able to improve pharmacokinetic
and pharmacodynamics properties of the doxorubicin-containing particles
compared to PEGylated particles. Chemical modification of nature based
nanoparticles with albumin to gain an extended circulation time and better
stability.

Cellular targeting
Drug-carrying nanoparticles circulating in the blood stream need to be directed to
specific target cells with minimal off-target effects. Many targeting mechanisms
have been examined, utilizing both positive and negative targeting methods.
Negative targeting, takes advantage of the fact that nature based nanoparticles
accumulate in tumors due to enhanced permeability and retention effects, which
is the result of the leaky, underdeveloped tumor vasculature that allows
macromolecules to accumulate in the tumor [225]. Positive targeting of specific
cells, involves the use of antibodies, aptamers, peptides and small molecules
which bind to specific receptors. Most rapidly dividing cancer cells overexpress
transferrin and folate receptors [226]. Unfortunately, these receptors are
expressed to some degree on other non-target cells, resulting in off-target effects.
The use of multi-specific antibodies to target the unique molecular marks on the
cancer stem cells (CSCs), the source of the cancer, will alleviate the problems.
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Cancer stem cells are a self-renewing population that express high ATPbinding cassette transporters (ABC transporters), which tend to export the
chemotherapy agents, making the cells highly drug-resistant [227]. If CSCs leave
their tissue barriers and circulate in the blood stream, they are able to
metastasize and the cancer spreads. CSCs are characterized by their selfrenewing ability and tumor regenerative ability. CSCs have distinct cell surface
markers, which are different from the bulk of the tumor. In the breast cancer for
example, breast cancer cells that express high levels of CD44 and low or
undetectable levels of CD24 (CD44+/CD24-/low) are resistant to chemotherapy
and have a significantly higher tumor generating ability compared to cells without
these characteristics [228]. Therefore, by linking muti-specific antibodies, which
are unique to certain CSCs, to nature based nanoparticles, an effective and
highly selective method, can be developed for cancer treatment.

Organelle-specific targeting
Once the carrier nanoparticles enter a cell, the treatment efficiency is still heavily
dependent on the ability of the carrier to deliver the drug to the site of action. If
nanoparticle drug complex cannot successfully escape from the harsh
endolysosome, it will be degraded. To enhance the endosomal escape, positively
charged nanoparticles will be developed, which will mediate the rupture of the
endosome following entry [229]. Subsequent to endosomal escape, the
nanoparticles will be free to deliver DOX to nucleus generate DNA
topoisomerase II mediated lesions in nuclear DNA, leading to apoptosis [230].
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DOX has been used to treat many tumor types, but often its delivery has been
problematic due to the drug-resistant cancer cells actively effluxing the drug out
of their nuclear membranes [231]. Recently, a mitochondrially targeted version of
mtDOX has been developed which has a peptide that targets mitochondria. It has
been proven to be highly effective even in cell lines with an overexpressed efflux
pump [232]. Nature based nanoparticle drug carriers; with a substitution of
mtDOX in place of the original DOX therefore have the potential to provide a
highly efficient drug delivery system targeting the drug-resist cancer cells.

In the development of nanoparticles that are site specific, efficient and of low
toxicity, nanoparticle stealthing, cellular targeting, and organelle targeting must
be considered. Nature based nanoparticles will be modified with albumin to
reduce the RES effects, providing greater stability in the blood stream. Linkage of
the nanoparticles to multi-specific antibodies will provide a means of targeting the
CSCs to eliminate the source of the cancer. The DOX currently being used will
be replaced by the mitochondrial targeting DOX to achieve better efficiency,
especially in the drug-resist cancer cells. There is no single combination of
nanoparticle modifications that will result in a perfect biomedical nanoparticle, but
this is one more step in the right direction. It takes a lot of small steps to reach
the final destination – the control and eradication of human disease.

157

LIST OF REFERENCES

158

[1] Kelkar SS, Reineke TM. Theranostics: Combining Imaging and Therapy.
Bioconjug Chem. 2011;22:1879-903.
[2] Heath T, Fraley R, Papahdjopoulos D. Antibody targeting of liposomes: cell
specificity obtained by conjugation of F(ab')2 to vesicle surface. Science.
1980;210:539-41.
[3] Farokhzad OC, Langer R. Impact of Nanotechnology on Drug Delivery. ACS
Nano. 2009;3:16-20.
[4] Oh Y-K, Park TG. siRNA delivery systems for cancer treatment. Adv Drug
Delivery Rev. 2009;61:850-62.
[5] Lee H, Park S, Kim JB, Kim J, Kim H. Entrapped doxorubicin nanoparticles for
the treatment of metastatic anoikis-resistant cancer cells. Cancer Lett.
2013;332:110-9.
[6] Soppimath KS, Liu LH, Seow WY, Liu SQ, Powell R, Chan P, et al.
Multifunctional Core/Shell Nanoparticles Self-Assembled from pH-Induced
Thermosensitive Polymers for Targeted Intracellular Anticancer Drug Delivery.
Adv Funct Mater. 2007;17:355-62.
[7] Giljohann DA, Seferos DS, Daniel WL, Massich MD, Patel PC, Mirkin CA.
Gold Nanoparticles for Biology and Medicine. Angewandte Chemie International
Edition. 2010;49:3280-94.
[8] Lytton-Jean AKR, Han MS, Mirkin CA. Microarray Detection of Duplex and
Triplex DNA Binders with DNA-Modified Gold Nanoparticles. Anal Chem.
2007;79:6037-41.
[9] Kumar V, Yadav SK. Plant-mediated synthesis of silver and gold
nanoparticles and their applications. Journal of Chemical Technology &
Biotechnology. 2009;84:151-7.
[10] Mohanpuria P, Rana N, Yadav S. Biosynthesis of nanoparticles:
technological concepts and future applications. J Nanopart Res. 2008;10:507-17.
[11] Shankar SS, Rai A, Ahmad A, Sastry M. Controlling the optical properties of
lemongrass extract synthesized gold nanotriangles and potential application in
infrared-absorbing optical coatings. Chem Mat. 2005;17:566-72.
[12] Chandran SP, Chaudhary M, Pasricha R, Ahmad A, Sastry M. Synthesis of
gold nanotriangles and silver nanoparticles using Aloe vera plant extract.
Biotechnology Progress. 2006;22:577-83.
[13] Shankar SS, Ahmad A, Pasricha R, Sastry M. Bioreduction of chloroaurate
ions by geranium leaves and its endophytic fungus yields gold nanoparticles of
different shapes. Journal of Materials Chemistry. 2003;13:1822-6.
[14] Ankamwar B, Chaudhary M, Sastry M. Gold nanotriangles biologically
synthesized using tamarind leaf extract and potential application in vapor sensing.
Synthesis and Reactivity in Inorganic Metal-Organic and Nano-Metal Chemistry.
2005;35:19-26.
[15] Yi S, Xia L, Lenaghan SC, Sun L, Huang Y, Burris JN, et al. Bio-Synthesis of
Gold Nanoparticles Using English ivy (Hedera helix). Journal of Nanoscience and
Nanotechnology. 2013;13:1649-59.

159

[16] Mukherjee P, Senapati S, Mandal D, Ahmad A, Khan MI, Kumar R, et al.
Extracellular Synthesis of Gold Nanoparticles by the Fungus Fusarium
oxysporum. ChemBioChem. 2002;3:461-3.
[17] He S, Guo Z, Zhang Y, Zhang S, Wang J, Gu N. Biosynthesis of gold
nanoparticles using the bacteria Rhodopseudomonas capsulata. Materials
Letters. 2007;61:3984-7.
[18] Ahmad A, Senapati S, Khan MI, Kumar R, Sastry M. Extra-/Intracellular
Biosynthesis of Gold Nanoparticles by an Alkalotolerant Fungus, Trichothecium
sp. J Biomed Nanotechnol. 2005;1:47-53.
[19] Strable E, Johnson JE, Finn MG. Natural Nanochemical Building Blocks:
Icosahedral Virus Particles Organized by Attached Oligonucleotides. Nano Lett.
2004;4:1385-9.
[20] Zheng G, Chen J, Li H, Glickson JD. Rerouting lipoprotein nanoparticles to
selected alternate receptors for the targeted delivery of cancer diagnostic and
therapeutic agents. Proc Natl Acad Sci U S A. 2005;102:17757-62.
[21] Mulder WJM, Strijkers GJ, van Tilborg GAF, Cormode DP, Fayad ZA,
Nicolay K. Nanoparticulate Assemblies of Amphiphiles and Diagnostically Active
Materials for Multimodality Imaging. Accounts Chem Res. 2009;42:904-14.
[22] Zhang M, Liu M, Prest H, Fischer S. Nanoparticles Secreted from Ivy
Rootlets for Surface Climbing. Nano Lett. 2008;8:1277-80.
[23] Xia L, Lenaghan S, Zhang M, Zhang Z, Li Q. Naturally occurring
nanoparticles from English ivy: an alternative to metal-based nanoparticles for
UV protection. Journal of Nanobiotechnology. 2010;8:12.
[24] Wang Y, Sun L, Yi S, Huang Y, Lenaghan SC, Zhang M. Naturally Occurring
Nanoparticles from Arthrobotrys oligospora as a Potential Immunostimulatory
and Antitumor Agent. Adv Funct Mater. 2012:DOI: 10.1002/adfm.201202619.
[25] Favi PM, Yi S, Lenaghan SC, Xia L, Zhang M. Inspiration from the natural
world: from bio-adhesives to bio-inspired adhesives. J Adhes Sci Technol.
2012:1-30.
[26] Cormode DP, Jarzyna PA, Mulder WJM, Fayad ZA. Modified natural
nanoparticles as contrast agents for medical imaging. Adv Drug Delivery Rev.
2010;62:329-38.
[27] Negishi H, Xu J-W, Ikeda K, Njelekela M, Nara Y, Yamori Y. Black and
Green Tea Polyphenols Attenuate Blood Pressure Increases in Stroke-Prone
Spontaneously Hypertensive Rats. J Nutr. 2004;134:38-42.
[28] Chen H, Zhang M, Qu Z, Xie B. Antioxidant activities of different fractions of
polysaccharide conjugates from green tea (Camellia Sinensis). Food Chemistry.
2008;106:559-63.
[29] Fassina G, Buffa A, Benelli R, Varnier OE, Noonan DM, Albini A.
Polyphenolic antioxidant (-)-epigallocatechin-3-gallate from green tea as a
candidate anti-HIV agent. AIDS. 2002;16:939-41.
[30] Khan SG, Katiyar SK, Agarwal R, Mukhtar H. Enhancement of Antioxidant
and Phase II Enzymes by Oral Feeding of Green Tea Polyphenols in Drinking
Water to SKH-1 Hairless Mice: Possible Role in Cancer Chemoprevention.
Cancer Res. 1992;52:4050-2.
160

[31] Chen C, Yu R, Owuor E, Tony Kong A. Activation of antioxidant-response
element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by
major green tea polyphenol components during cell survival and death. Arch
Pharm Res. 2000;23:605-12.
[32] Jankun J, Selman SH, Swiercz R, Skrzypczak-Jankun E. Why drinking green
tea could prevent cancer. Nature. 1997;387:561-.
[33] Paschka AG, Butler R, Young CYF. Induction of apoptosis in prostate cancer
cell lines by the green tea component, (−)-epigallocatechin-3-gallate. Cancer Lett.
1998;130:1-7.
[34] Wynder EL, Rose DP, Cohen LA. Nutrition and prostate cancer: A proposal
for dietary intervention. Nutr Cancer. 1994;22:1-10.
[35] Pianetti S, Guo S, Kavanagh KT, Sonenshein GE. Green Tea Polyphenol
Epigallocatechin-3 Gallate Inhibits Her-2/Neu Signaling, Proliferation, and
Transformed Phenotype of Breast Cancer Cells. Cancer Res. 2002;62:652-5.
[36] Valcic S, Timmermann BN, Alberts DS, Wächter GA, Krutzsch M, Wymer J,
et al. Inhibitory effect of six green tea catechins and caffeine on the growth of
four selected human tumor cell lines. Anti-Cancer Drugs. 1996;7:461-8.
[37] Katiyar SK, Mukhtar H. Tea antioxidants in cancer chemoprevention. J Cell
Biochem Suppl. 1997;27:59-67.
[38] Chung LY, Cheung TC, Kong SK, Fung KP, Choy YM, Chan ZY, et al.
Induction of apoptosis by green tea catechins in human prostate cancer DU145
cells. Life Sci. 2001;68:1207-14.
[39] Thakur VS, Gupta K, Gupta S. Green tea polyphenols causes cell cycle
arrest and apoptosis in prostate cancer cells by suppressing class I histone
deacetylases. Carcinogenesis. 2012;33:377-84.
[40] Khan N, Mukhtar H. Multitargeted therapy of cancer by green tea
polyphenols. Cancer Lett. 2008;269:269-80.
[41] Yang X, Zhao Y, Yang Y, Ruan Y. Isolation and Characterization of
Immunostimulatory Polysaccharide from an Herb Tea, Gynostemma
pentaphyllum Makino. J Agric Food Chem. 2008;56:6905-9.
[42] Chen H, Zhang M, Xie B. Quantification of Uronic Acids in Tea
Polysaccharide Conjugates and Their Antioxidant Properties. J Agric Food Chem.
2004;52:3333-6.
[43] Gröning R, Breitkreutz J, Baroth V, Stephanie Müller R. Nanoparticles in
plant extracts: influence of drugs on the formation of nanoparticles and
precipitates in black tea infusions. Eur J Pharm Sci. 2002;15:149-55.
[44] Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and
diagnosis. Adv Drug Delivery Rev. 2002;54:631-51.
[45] Xie J, Zhang Q, Lee JY, Wang DIC. The Synthesis of SERS-Active Gold
Nanoflower Tags for In Vivo Applications. ACS Nano. 2008;2:2473-80.
[46] Liu X, Dai Q, Austin L, Coutts J, Knowles G, Zou J, et al. A One-Step
Homogeneous Immunoassay for Cancer Biomarker Detection Using Gold
Nanoparticle Probes Coupled with Dynamic Light Scattering. J Am Chem Soc.
2008;130:2780-2.
161

[47] Visaria RK, Griffin RJ, Williams BW, Ebbini ES, Paciotti GF, Song CW, et al.
Enhancement of tumor thermal therapy using gold nanoparticle–assisted tumor
necrosis factor-α delivery. Mol Cancer Ther. 2006;5:1014-20.
[48] Beattie IR, Haverkamp RG. Silver and gold nanoparticles in plants: sites for
the reduction to metal. Metallomics. 2011;3:628-32.
[49] Sabo-Attwood T, Unrine JM, Stone JW, Murphy CJ, Ghoshroy S, Blom D, et
al. Uptake, distribution and toxicity of gold nanoparticles in tobacco (Nicotiana
xanthi) seedlings. Nanotoxicology.0:1-8.
[50] Wang H, Halas NJ. Mesoscopic Au ―Meatball‖ Particles. Advanced Materials.
2008;20:820-5.
[51] Hao E, Bailey RC, Schatz GC, Hupp JT, Li S. Synthesis and Optical
Properties of ―Branched‖ Gold Nanocrystals. Nano Letters. 2004;4:327-30.
[52] Yuan H, Khoury CG, Hwang H, Wilson CM, Grant GA, Vo-Dinh T. Gold
nanostars: surfactant-free synthesis, 3D modelling, and two-photon
photoluminescence imaging. Nanotechnology. 2012;23:075102.
[53] Erathodiyil N, Ying JY. Functionalization of Inorganic Nanoparticles for
Bioimaging Applications. Accounts Chem Res. 2011;44:925-35.
[54] Nie S, Xie M, Fu Z, Wan Y, Yan A. Study on the purification and chemical
compositions of tea glycoprotein. Carbohydr Polym. 2008;71:626-33.
[55] Zuo Y, Chen H, Deng Y. Simultaneous determination of catechins, caffeine
and gallic acids in green, Oolong, black and pu-erh teas using HPLC with a
photodiode array detector. Talanta. 2002;57:307-16.
[56] Wang Y, Chen L, Ding Y, Yan W. Oxidized phospholipid based pH sensitive
micelles for delivery of anthracyclines to resistant leukemia cells in vitro.
International Journal of Pharmaceutics. 2012;422:409-17.
[57] Wang Y, Hao J, Li Y, Zhang Z, Sha X, Han L, et al. Poly(caprolactone)modified Pluronic P105 micelles for reversal of paclitaxcel-resistance in SKOV-3
tumors. Biomaterials. 2012;33:4741-51.
[58] Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJA, Middaugh CR,
Winter G. Potential inaccurate quantitation and sizing of protein aggregates by
size exclusion chromatography: Essential need to use orthogonal methods to
assure the quality of therapeutic protein products. J Pharm Sci. 2010;99:2200-8.
[59] Roberts EAH. The phenolic substances of manufactured tea. X.—the
creaming down of tea liquors. J Sci Food Agric. 1963;14:700-5.
[60] Horie H, Kohata K. Analysis of tea components by high-performance liquid
chromatography and high-performance capillary electrophoresis. J Chromatogr A.
2000;881:425-38.
[61] Lv Y, Yang X, Zhao Y, Ruan Y, Yang Y, Wang Z. Separation and
quantification of component monosaccharides of the tea polysaccharides from
Gynostemma pentaphyllum by HPLC with indirect UV detection. Food Chem.
2009;112:742-6.
[62] Chen H, Wang Z, Qu Z, Fu L, Dong P, Zhang X. Physicochemical
characterization and antioxidant activity of a polysaccharide isolated from oolong
tea. Eur Food Res Technol. 2009;229:629-35.
162

[63] Schepetkin IA, Quinn MT. Botanical polysaccharides: Macrophage
immunomodulation and therapeutic potential. Int Immunopharmacol. 2006;6:31733.
[64] Paulsen BS. Plant Polysaccharides with Immunostimulatory Activities. Curr
Org Chem. 2001;5:939-50.
[65] WangWang, Li, Zhao. Components and Activity of Polysaccharides from
Coarse Tea. J Agric Food Chem. 2000;49:507-10.
[66] Lee J-H, Shim JS, Lee JS, Kim JK, Yang IS, Chung M-S, et al. Inhibition of
Pathogenic Bacterial Adhesion by Acidic Polysaccharide from Green Tea
(Camellia sinensis). J Agric Food Chem. 2006;54:8717-23.
[67] Eccles SA, Alexander P. Macrophage content of tumours in relation to
metastatic spread and host immune reaction. Nature. 1974;250:667-9.
[68] Gordon S. Alternative activation of macrophages. Nat Rev Immunol.
2003;3:23-35.
[69] Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S,
et al. B regulatory cells and the tumor-promoting actions of TNF-α during
squamous carcinogenesis. Proc Natl Acad Sci U S A. 2011;108:10662-7.
[70] van Horssen R, ten Hagen TLM, Eggermont AMM. TNF-α in Cancer
Treatment: Molecular Insights, Antitumor Effects, and Clinical Utility. Oncologist.
2006;11:397-408.
[71] Lokshin A, Raskovalova T, Huang X, Zacharia LC, Jackson EK, Gorelik E.
Adenosine-Mediated Inhibition of the Cytotoxic Activity and Cytokine Production
by Activated Natural Killer Cells. Cancer Res. 2006;66:7758-65.
[72] Han EH, Choi JH, Hwang YP, Park HJ, Choi CY, Chung YC, et al.
Immunostimulatory activity of aqueous extract isolated from Prunella vulgaris.
Food Chem Toxicol. 2009;47:62-9.
[73] Oliveira Silva F, Neves Santos P, Melo C, Teixeira E, Sousa Cavada B,
Pereira V, et al. Immunostimulatory activity of ConBr: a focus on splenocyte
proliferation and proliferative cytokine secretion. Cell Tissue Res. 2011;346:23744.
[74] Harada M, Qin Y, Takano H, Minamino T, Zou Y, Toko H, et al. G-CSF
prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat
pathway in cardiomyocytes. Nat Med. 2005;11:305-11.
[75] Thomas J, Liu F, Link DC. Mechanisms of mobilization of hematopoietic
progenitors with granulocyte colony-stimulating factor. Curr Opin Hematol.
2002;9:183-9.
[76] Metcalf D. The colony-stimulating factors and cancer. Nat Rev Cancer.
2010;10:425-34.
[77] Homey B, Müller A, Zlotnik A. Chemokines: agents for the immunotherapy of
cancer? Nat Rev Immunol. 2002;2:175-84.
[78] Mulé JJ, Custer M, Averbook B, Yang JC, Weber JS, Goeddel DV, et al.
RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity
in vivo: role of immune cell subpopulations. Hum Gene Ther. 1996;7:1545-53.

163

[79] BACON, B. K, PREMACK, A. B, GARDNER, P., et al. Activation of dual T
cell signaling pathways by the chemokine RANTES. Washington, DC, ETATSUNIS: American Association for the Advancement of Science; 1995.
[80] Keyser J, Schultz J, Ladell K, Elzaouk L, Heinzerling L, Pavlovic J, et al. IP10-encoding plasmid DNA therapy exhibits anti-tumor and anti-metastatic
efficiency. Exp Dermatol. 2004;13:380-90.
[81] Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, et al.
Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo.
J Exp Med. 1995;182:155-62.
[82] Mantovani A, Gray PA, Van Damme J, Sozzani S. Macrophage-derived
chemokine (MDC). J Leukoc Biol. 2000;68:400-4.
[83] Yang X, Kootala S, Hilborn J, Ossipov DA. Preparation of hyaluronic acid
nanoparticles via hydrophobic association assisted chemical cross-linking-an
orthogonal modular approach. Soft Matter. 2011;7:7517-25.
[84] Wang C, Cheng L, Liu Z. Drug delivery with upconversion nanoparticles for
multi-functional targeted cancer cell imaging and therapy. Biomaterials.
2011;32:1110-20.
[85] Kim JO, Kabanov AV, Bronich TK. Polymer micelles with cross-linked
polyanion core for delivery of a cationic drug doxorubicin. J Control Release.
2009;138:197-204.
[86] Ganta S, Devalapally H, Shahiwala A, Amiji M. A review of stimuliresponsive nanocarriers for drug and gene delivery. J Control Release.
2008;126:187-204.
[87] Singh R, Lillard Jr JW. Nanoparticle-based targeted drug delivery. Exp Mol
Pathol. 2009;86:215-23.
[88] Meng H, Liong M, Xia T, Li Z, Ji Z, Zink JI, et al. Engineered Design of
Mesoporous Silica Nanoparticles to Deliver Doxorubicin and P-Glycoprotein
siRNA to Overcome Drug Resistance in a Cancer Cell Line. ACS Nano.
2010;4:4539-50.
[89] Tang Y, Lei T, Manchanda R, Nagesetti A, Fernandez-Fernandez A,
Srinivasan S, et al. Simultaneous Delivery of Chemotherapeutic and ThermalOptical Agents to Cancer Cells by a Polymeric (PLGA) Nanocarrier: An In Vitro
Study. Pharm Res. 2010;27:2242-53.
[90] Wang Y, Mao F, Wei X. Characterization and antioxidant activities of
polysaccharides from leaves, flowers and seeds of green tea. Carbohydr Polym.
2012;88:146-53.
[91] Zhang L, Liu W, Han B, Sun J, Wang D. Isolation and characterization of
antitumor polysaccharides from the marine mollusk Ruditapes philippinarum. Eur
Food Res Technol. 2008;227:103-10.
[92] http://www.who.int/mediacentre/factsheets/fs297/en/.
[93] Morgan G, Ward R, Barton M. The contribution of cytotoxic chemotherapy to
5-year survival in adult malignancies. Clin Oncol (R Coll Radiol). 2004;16:549-60.
[94] Nowak AK, Lake RA, Robinson BWS. Combined chemoimmunotherapy of
solid tumours: Improving vaccines? Adv Drug Deliver Rev. 2006;58:975-90.
164

[95] Coley HM. Mechanisms and strategies to overcome chemotherapy
resistance in metastatic breast cancer. Cancer Treat Rev. 2008;34:378-90.
[96] Holzel M, Bovier A, Tuting T. Plasticity of tumour and immune cells: a source
of heterogeneity and a cause for therapy resistance? Nat Rev Cancer.
2013;13:365-U95.
[97] Nichols JW, Bae YH. Odyssey of a cancer nanoparticle: From injection site
to site of action. Nano Today. 2012;7:606-18.
[98] Roy A, Chandra S, Mamilapally S, Upadhyay P, Bhaskar S. Anticancer and
Immunostimulatory Activity by Conjugate of Paclitaxel and Non-toxic Derivative
of LPS for Combined Chemo-immunotherapy. Pharm Res. 2012;29:2294-309.
[99] Steichen SD, Caldorera-Moore M, Peppas NA. A review of current
nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J
Pharm Sci. 2013;48:416-27.
[100] Emens LA. Chemoimmunotherapy. Cancer J. 2010;16:295-303.
[101] Chen G, Emens LA. Chemoimmunotherapy: reengineering tumor immunity.
Cancer Immunol Immun. 2013;62:203-16.
[102] Lee IH, An S, Yu MK, Kwon HK, Im SH, Jon S. Targeted
chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates. J
Control Release. 2011;155:435-41.
[103] Roy A, Singh MS, Upadhyay P, Bhaskar S. Combined Chemoimmunotherapy as a Prospective Strategy To Combat Cancer: A Nanoparticle
Based Approach. Mol Pharm. 2010.
[104] Besch R, Poeck H, Hohenauer T, Senft D, Hacker G, Berking C, et al.
Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferonindependent apoptosis in human melanoma cells. J Clin Invest. 2009;119:2399411.
[105] Poeck H, Besch R, Maihoefer C, Renn M, Tormo D, Morskaya SS, et al. 5 'triphosphate-siRNA: turning gene silencing and Rig-I activation against
melanoma. Nat Med. 2008;14:1256-63.
[106] Karve S, Alaouie A, Zhou YP, Rotolo J, Sofou S. The use of pH-triggered
leaky heterogeneities on rigid lipid bilayers to improve intracellular trafficking and
therapeutic potential of targeted liposomal immunochemotherapy. Biomaterials.
2009;30:6055-64.
[107] Praetorius NP, Mandal TK. Engineered nanoparticles in cancer therapy.
Recent Pat Drug Deliv Formul. 2007;1:37-51.
[108] Zitvogel L, Kroemer G. Anticancer immunochemotherapy using adjuvants
with direct cytotoxic effects. J Clin Invest. 2009;119:2127-30.
[109] Xia LJ, Lenaghan SC, Zhang MJ, Wu Y, Zhao X, Burris JN, et al.
Characterization of English ivy (Hedera helix) adhesion force and imaging using
atomic force microscopy. J Nanopart Res. 2011;13:1029-37.
[110] Stevens MJ, Steren RE, Hlady V, Stewart RJ. Multiscale Structure of the
Underwater Adhesive of Phragmatopoma Californica: a Nanostructured Latex
with a Steep Microporosity Gradient. Langmuir. 2007;23:5045-9.

165

[111] Zhang M, Liu M, Bewick S, Suo Z. Nanoparticles to increase adhesive
properties of biologically secreted materials for surface affixing. J Biomed
Nanotechnol. 2009;5:294-9.
[112] Berglin M, Gatenholm P. The barnacle adhesive plaque: morphological and
chemical differences as a response to substrate properties. Colloids and
Surfaces B: Biointerfaces. 2003;28:107-17.
[113] Hennebert E, Viville P, Lazzaroni R, Flammang P. Micro- and
nanostructure of the adhesive material secreted by the tube feet of the sea star
Asterias rubens. Journal of Structural Biology. 2008;164:108-18.
[114] Wang YZ, Sun LM, Yi SJ, Huang YJ, Lenaghan SC, Zhang MJ. Naturally
Occurring Nanoparticles from Arthrobotrys oligospora as a Potential
Immunostimulatory and Antitumor Agent. Adv Funct Mater. 2013;23:2175-84.
[115] Yang Y, Yang E, An ZQ, Liu XZ. Evolution of nematode-trapping cells of
predatory fungi of the Orbiliaceae based on evidence from rRNA-encoding DNA
and multiprotein sequences. Proc Natl Acad Sci U S A. 2007;104:8379-84.
[116] Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors Affecting the
Clearance and Biodistribution of Polymeric Nanoparticles. Molecular
Pharmaceutics. 2008;5:505-15.
[117] Williams A, Frasca V. Ion-Exchange Chromatography. Current Protocols in
Molecular Biology: John Wiley & Sons, Inc.; 2001.
[118] Fedarko NS. Purification of proteoglycans from mineralized tissues.
Methods Mol Biol. 2001;171:19-25.
[119] Tincer G, Yerlikaya S, Yagci FC, Kahraman T, Atanur OM, Erbatur O, et al.
Immunostimulatory
activity
of
polysaccharide-poly(I:C)
nanoparticles.
Biomaterials. 2011;32:4275-82.
[120] Liu JY, Huang W, Pang Y, Zhu XY, Zhou YF, Yan DY. The in vitro
biocompatibility of self-assembled hyperbranched copolyphosphate nanocarriers.
Biomaterials. 2010;31:5643-51.
[121] Pumphrey CY, Theus AM, Li S, Parrish RS, Sanderson RD. Neoglycans,
Carbodiimide-modified Glycosaminoglycans: A New Class of Anticancer Agents
That Inhibit Cancer Cell Proliferation and Induce Apoptosis. Cancer Res.
2002;62:3722-8.
[122] Yip GW, Smollich M, Gotte M. Therapeutic value of glycosaminoglycans in
cancer. Mol Cancer Ther. 2006;5:2139-48.
[123] Roberts NJ, Zhou SB, Diaz LA, Holdhoff M. Systemic use of tumor necrosis
factor alpha as an anticancer agent. Oncotarget. 2011;2:739-51.
[124] Calzascia T, Pellegrini M, Hall H, xE, kan, Sabbagh L, et al. TNF-α is
critical for antitumor but not antiviral T cell immunity in mice. The Journal of
Clinical Investigation. 2007;117:3833-45.
[125] Kang HS, Cho DH, Kim SS, Pyun KH, Choi I. Antitumor effects of IL-6 on
murine liver tumor cells in vivo. J Biomed Sci. 1999;6:142-4.
[126] Mule JJ, Custer MC, Travis WD, Rosenberg SA. Cellular mechanisms of
the antitumor activity of recombinant IL-6 in mice. J Immunol. 1992;148:2622-9.

166

[127] Ishiguro H, Kishimoto T, Furuya M, Nagai Y, Watanabe T, Ishikura H.
Tumor-derived interleukin (IL)-6 induced anti-tumor effect in immunecompromised hosts. Cancer Immunol Immunother. 2005;54:1191-9.
[128] Voloshin T, Gingis-Velitski S, Bril R, Benayoun L, Munster M, Milsom C, et
al. G-CSF supplementation with chemotherapy can promote revascularization
and subsequent tumor regrowth: prevention by a CXCR4 antagonist. Blood.
2011;118:3426-35.
[129] Maeda M, Watanabe N, Tsuji N, Tsuji Y, Okamoto T, Sasaki H, et al.
Enhanced antitumor effect of recombinant human tumor necrosis factor in
combination with recombinant human granulocyte colony-stimulating factor in
BALB/c mice. Jpn J Cancer Res. 1993;84:921-7.
[130] Veltri S, Smith JW, 2nd. Interleukin 1 Trials in Cancer Patients: A Review of
the Toxicity, Antitumor and Hematopoietic Effects. Oncologist. 1996;1:190-200.
[131] Carmenate T, Pacios A, Enamorado M, Moreno E, Garcia-Martínez K,
Fuente D, et al. Human IL-2 Mutein with Higher Antitumor Efficacy Than Wild
Type IL-2. The Journal of Immunology. 2013;190:6230-8.
[132] Chou SH, Shetty AV, Geng YJ, Xu LP, Munirathinam G, Pipathsouk A, et al.
Palmitate-derivatized human IL-2: a potential anticancer immunotherapeutic of
low systemic toxicity. Cancer Immunol Immun. 2013;62:597-603.
[133] Tannenbaum CS, Hamilton TA. Immune-inflammatory mechanisms in
IFNgamma-mediated anti-tumor activity. Semin Cancer Biol. 2000;10:113-23.
[134] Jarnicki AG, Lysaght J, Todryk S, Mills KHG. Suppression of antitumor
immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor:
Influence of tumor environment on the induction of CD4(+) and CD8(+) regulatory
T cells. J Immunol. 2006;177:896-904.
[135] Wei C, Sirikanjanapong S, Lieberman S, Delacure M, Martiniuk F, Levis W,
et al. Primary mucosal melanoma arising from the eustachian tube with CTLA-4,
IL-17A, IL-17C, and IL-17E upregulation. Ent-Ear Nose Throat. 2013;92:36-40.
[136] Oshiro K, Kohama H, Umemura M, Uyttenhove C, Inagaki-Ohara K,
Arakawa T, et al. Interleukin-17A is involved in enhancement of tumor
progression in murine intestine. Immunobiology. 2012;217:54-60.
[137] Yu YZ, Luo XL, Liu SX, Xie Y, Cao XT. Intratumoral expression of MIP-1b
induces antitumor responses in a pre-established tumor model through
chemoattracting T cells and NK cells. Blood. 2004;104:402b-b.
[138] Wang LCS, Thomsen L, Sutherland R, Reddy CB, Tijono SM, Chen CJJ, et
al. Neutrophil Influx and Chemokine Production during the Early Phases of the
Antitumor Response to the Vascular Disrupting Agent DMXAA (ASA404).
Neoplasia. 2009;11:793-803.
[139] Nakasone Y, Fujimoto M, Matsushita T, Hamaguchi Y, Huu DL, Yanaba M,
et al. Host-derived MCP-1 and MIP-1alpha regulate protective anti-tumor
immunity to localized and metastatic B16 melanoma. Am J Pathol.
2012;180:365-74.
[140] Lee JM, Merritt RE, Mahtabifard A, Yamada R, Kikuchi T, Crystal TG, et al.
Intratumoral expression of macrophage-derived chemokine induces CD4(+) T
cell-independent antitumor immunity in mice. J Immunother. 2003;26:117-29.
167

[141] Nakano A, Yoneyama H, Ueha S, Kitabatake M, Ishikawa S, Kawase I, et
al. Intravenous administration of MIP-1α with intra-tumor injection of P. acnes
shows potent anti-tumor effect. International Immunopharmacology. 2007;7:84557.
[142] Inoue H, Iga M, Xin M, Asahi S, Nakamura T, Kurita R, et al. TARC and
RANTES enhance antitumor immunity induced by the GM-CSF-transduced
tumor vaccine in a mouse tumor model. Cancer Immunol Immun. 2008;57:1399411.
[143] Ghia P, Transidico P, Veiga JP, Schaniel C, Sallusto F, Matsushima K, et al.
Chemoattractants MDC and TARC are secreted by malignant B-cell precursors
following CD40 ligation and support the migration of leukemia-specific T cells.
Blood. 2001;98:533-40.
[144] Meenach SA, Anderson AA, Suthar M, Anderson KW, Hilt JZ.
Biocompatibility analysis of magnetic hydrogel nanocomposites based on poly(Nisopropylacrylamide) and iron oxide. Journal of Biomedical Materials Research
Part A. 2009;91A:903-9.
[145] Chuang JY, Tsai YY, Chen SC, Hsieh TJ, Chung JG. Induction of G0/G1
arrest and apoptosis by 3-hydroxycinnamic acid in human cervix epithelial
carcinoma (HeLa) cells. In Vivo. 2005;19:683-8.
[146] Williams O. Flow cytometry-based methods for apoptosis detection in
lymphoid cells. Methods Mol Biol. 2004;282:31-42.
[147] Wang Y, Ding Y, Liu Z, Liu X, Chen L, Yan W. Bioactive Lipids-Based pH
Sensitive Micelles for Co-Delivery of Doxorubicin and Ceramide to Overcome
Multidrug Resistance in Leukemia. Pharm Res. 2013;DOI 10.1007/s11095-0131121-5.
[148] Wang Y, Yi S, Sun L, Huang Y, Lenaghan SC, Zhang M. Doxorubicinloaded Cyclic Peptide Nanotube Bundles Overcome Multidrug Resistance in
Breast
Cancer
Cells.
Journal
of
Biomedical
Nanotechnology.
2013;doi:10.1166/jbn.2013.1724.
[149] Chen D, Song P, Jiang F, Meng X, Sui W, Shu C, et al. pH-responsive
mechanism of a deoxycholic acid and folate comodified chitosan micelle under
cancerous environment. J Phys Chem B. 2013;117:1261-8.
[150] Iversen T-G, Skotland T, Sandvig K. Endocytosis and intracellular transport
of nanoparticles: Present knowledge and need for future studies. Nano Today.
2011;6:176-85.
[151] Maier SA, Brongersma ML, Kik PG, Meltzer S, Requicha AAG, Koel BE, et
al. Plasmonics - A Route to Nanoscale Optical Devices. Adv Mater. 2003;15:562-.
[152] Dick LA, McFarland AD, Haynes CL, Van Duyne RP. Metal film over
nanosphere (MFON) electrodes for surface-enhanced Raman spectroscopy
(SERS): Improvements in surface nanostructure stability and suppression of
irreversible loss. J Phys Chem B. 2001;106:853-60.
[153] Qian X, Zhou X, Nie S. Surface-Enhanced Raman Nanoparticle Beacons
Based on Bioconjugated Gold Nanocrystals and Long Range Plasmonic
Coupling. J Am Chem Soc. 2008;130:14934-5.
168

[154] Mock J, Norton S, Chen SY, Lazarides A, Smith D. Electromagnetic
Enhancement Effect Caused by Aggregation on SERS-Active Gold Nanoparticles.
Plasmonics. 2011;6:113-24.
[155] El-Sayed IH, Huang X, El-Sayed MA. Surface Plasmon Resonance
Scattering and Absorption of anti-EGFR Antibody Conjugated Gold Nanoparticles
in Cancer Diagnostics: Applications in Oral Cancer. Nano Lett. 2005;5:829-34.
[156] Huang X, Jain PK, El-Sayed IH, El-Sayed MA. Gold nanoparticles:
interesting optical properties and recent applications in cancer diagnostics and
therapy. Nanomedicine. 2007;2:681-93.
[157] Lu W, Arumugam SR, Senapati D, Singh AK, Arbneshi T, Khan SA, et al.
Multifunctional Oval-Shaped Gold-Nanoparticle-Based Selective Detection of
Breast Cancer Cells Using Simple Colorimetric and Highly Sensitive Two-Photon
Scattering Assay. ACS Nano. 2010;4:1739-49.
[158] Agasti SS, Chompoosor A, You C-C, Ghosh P, Kim CK, Rotello VM.
Photoregulated release of caged anticancer dugs from gold nanoparticles. J Am
Chem Soc. 2009;131:5728-9.
[159] Chen C, Daniel M-C, Quinkert ZT, De M, Stein B, Bowman VD, et al.
Nanoparticle-Templated Assembly of Viral Protein Cages. Nano Lett.
2006;6:611-5.
[160] Xia L, Yi S, Lenaghan S, Zhang M. Facile synthesis of biocompatible gold
nanoparticles with organosilicone-coated surface properties. J Nanopart Res.
2012;14:1-11.
[161] Liu GQ, Cai WP, Wang JJ, Duan GT. Electric Field Induced Au
Nanoparticles with Controllable Morphology Under Surfactantless Condition.
Nanosci Nanotechnol Lett. 2010;2:248-52.
[162] Chaughule RS, Ramanujan RV. Nanoparticles: Synthesis, Characterization
and Applications. Los Angeles: American Scientific Publishers; 2011.
[163] Nalwa HS. Encyclopedia of Nanoscience and Nanotechnology. Los
Angeles: American Scientific Publishers; 2004/2011.
[164] Ankamwar B, Chaudhary M, Sastry M. Gold nanotriangles biologically
synthesized using Tamarind leaf extract and potential application in vapor
sensing. Synth React Inorg M. 2005;35:19-26.
[165] Babu P, Sharma P, Kalita M, Bora U. Green synthesis of biocompatible
gold nanoparticles using Fagopyrum esculentum leaf extract. Front Mater Sci.
2011;5:379-87.
[166] MubarakAli D, Thajuddin N, Jeganathan K, Gunasekaran M. Plant extract
mediated synthesis of silver and gold nanoparticles and its antibacterial activity
against clinically isolated pathogens. Colloids Surf B Biointerfaces. 2011;85:3605.
[167] Sreelakshmi Ch, Datta KKR, Yadav JS, Reddy BVS. Honey Derivatized Au
and Ag Nanoparticles and Evaluation of Its Antimicrobial Activity. Journal of
Nanoscience and Nanotechnology. 2011;11:6995-7000.
[168] Mishra A, Tripathy SK, Yun S-I. Bio-Synthesis of Gold and Silver
Nanoparticles from Candida guilliermondii and Their Antimicrobial Effect Against
169

Pathogenic Bacteria. Journal of Nanoscience and Nanotechnology. 2011;11:2438.
[169] Panda T, Deepa K. Biosynthesis of Gold Nanoparticles. Journal of
Nanoscience and Nanotechnology. 2011;11:10279-94.
[170] Sneha K, Sathishkumar M, Lee SY, Bae MA, Yun Y-S. Biosynthesis of Au
Nanoparticles Using Cumin Seed Powder Extract. Journal of Nanoscience and
Nanotechnology. 2011;11:1811-4.
[171] Nune SK, Chanda N, Shukla R, Katti K, Kulkarni RR, Thilakavathy S, et al.
Green nanotechnology from tea: phytochemicals in tea as building blocks for
production of biocompatible gold nanoparticles. J Mater Chem. 2009;19:2912-20.
[172] Chandran SP, Chaudhary M, Pasricha R, Ahmad A, Sastry M. Synthesis of
Gold Nanotriangles and Silver Nanoparticles Using Aloevera Plant Extract.
Biotechnol Prog. 2006;22:577-83.
[173] Ankamwar B, Damle C, Ahmad A, Sastry M. Biosynthesis of gold and silver
nanoparticles using Emblica Officinalis fruit extract, their phase transfer and
transmetallation in an organic solution. J Nanosci Nanotech. 2005;5:1665-71.
[174] Dubey SP, Lahtinen M, Sillanpää M. Tansy fruit mediated greener
synthesis of silver and gold nanoparticles. Process Biochem. 2010;45:1065-71.
[175] Duran N, Marcato P, Alves O, De Souza G, Esposito E. Mechanistic
aspects of biosynthesis of silver nanoparticles by several Fusarium oxysporum
strains. J Nanobiotechnol. 2005;3:8.
[176] Shankar SS, Rai A, Ankamwar B, Singh A, Ahmad A, Sastry M. Biological
synthesis of triangular gold nanoprisms. Nat Mater. 2004;3:482-8.
[177] Liu B, Xie J, Lee JY, Ting YP, Chen JP. Optimization of High-Yield
Biological Synthesis of Single-Crystalline Gold Nanoplates. J Phys Chem B.
2005;109:15256-63.
[178] Song JY, Jang H-K, Kim BS. Biological synthesis of gold nanoparticles
using Magnolia kobus and Diopyros kaki leaf extracts. Process Biochem.
2009;44:1133-8.
[179] French MM, Rose S, Canseco J, Athanasiou KA. Chondrogenic
Differentiation of Adult Dermal Fibroblasts. Ann Biomed Eng. 2004;32:50-6.
[180] El-Brolossy TA, Abdallah T, Mohamed MB, Abdallah S, Easawi K, Negm S,
et al. Shape and size dependence of the surface plasmon resonance of gold
nanoparticles studied by Photoacoustic technique. Eur Phys J - Spec Top.
2008;153:361-4.
[181] Mitschele J. Beer-Lambert Law. J Chem Educ. 1996;73:A260.
[182] Huang X, El-Sayed IH, Qian W, El-Sayed MA. Cancer Cells Assemble and
Align Gold Nanorods Conjugated to Antibodies to Produce Highly Enhanced,
Sharp, and Polarized Surface Raman Spectra: A Potential Cancer Diagnostic
Marker. Nano Lett. 2007;7:1591-7.
[183] Cheng Y, C. Samia A, Meyers JD, Panagopoulos I, Fei B, Burda C. Highly
Efficient Drug Delivery with Gold Nanoparticle Vectors for in Vivo Photodynamic
Therapy of Cancer. J Am Chem Soc. 2008;130:10643-7.
[184] Hao F, Nehl CL, Hafner JH, Nordlander P. Plasmon Resonances of a Gold
Nanostar. Nano Letters. 2007;7:729-32.
170

[185] Jain PK, El-Sayed IH, El-Sayed MA. Au nanoparticles target cancer. Nano
Today. 2007;2:18-29.
[186] Paciotti GF, Myer L, Weinreich D, Goia D, Pavel N, McLaughlin RE, et al.
Colloidal Gold: A Novel Nanoparticle Vector for Tumor Directed Drug Delivery.
Drug Delivery. 2004;11:169-83.
[187] Song Y, Steen WA, Peña D, Jiang Y-B, Medforth CJ, Huo Q, et al.
Foamlike Nanostructures Created from Dendritic Platinum Sheets on Liposomes.
Chemistry of Materials. 2006;18:2335-46.
[188] Nehl CL, Liao H, Hafner JH. Optical Properties of Star-Shaped Gold
Nanoparticles. Nano Letters. 2006;6:683-8.
[189] Jena BK, Raj CR. Seedless, Surfactantless Room Temperature Synthesis
of Single Crystalline Fluorescent Gold Nanoflowers with Pronounced SERS and
Electrocatalytic Activity. Chem Mat. 2008;20:3546-8.
[190] Liu B, Tang D, Tang J, Su B, Li Q, Chen G. A graphene-based Au(111)
platform for electrochemical biosensing based catalytic recycling of products on
gold nanoflowers. Analyst. 2011;136:2218-20.
[191] Kumari S, Singh RP. Glycolic acid-g-chitosan-gold nanoflower
nanocomposite scaffolds for drug delivery and tissue engineering. Int J Biol
Macromol. 2012;50:878-83.
[192] Guerrero-Martínez A, Barbosa S, Pastoriza-Santos I, Liz-Marzán LM.
Nanostars shine bright for you: Colloidal synthesis, properties and applications of
branched metallic nanoparticles. Current Opinion in Colloid & Interface Science.
2011;16:118-27.
[193] Kuo C-H, Huang MH. Synthesis of Branched Gold Nanocrystals by a
Seeding Growth Approach. Langmuir. 2005;21:2012-6.
[194] Xie J, Lee JY, Wang DIC. Seedless, Surfactantless, High-Yield Synthesis
of Branched Gold Nanocrystals in HEPES Buffer Solution. Chemistry of Materials.
2007;19:2823-30.
[195] Jena BK, Raj CR. Synthesis of Flower-like Gold Nanoparticles and Their
Electrocatalytic Activity Towards the Oxidation of Methanol and the Reduction of
Oxygen. Langmuir. 2007;23:4064-70.
[196] Ren Y, Xu C, Wu M, Niu M, Fang Y. Controlled synthesis of gold
nanoflowers assisted by poly(vinyl pyrrolidone)–sodium dodecyl sulfate
aggregations. Colloids and Surfaces A: Physicochemical and Engineering
Aspects. 2011;380:222-8.
[197] Luo Z, Fu T, Chen K, Han H, Zou M. Synthesis of multi-branched gold
nanoparticles by reduction of tetrachloroauric acid with Tris base, and their
application to SERS and cellular imaging. Microchim Acta. 2011;175:55-61.
[198] Chen S, Wang ZL, Ballato J, Foulger SH, Carroll DL. Monopod, Bipod,
Tripod, and Tetrapod Gold Nanocrystals. Journal of the American Chemical
Society. 2003;125:16186-7.
[199] Wang L, Liu C-H, Nemoto Y, Fukata N, Wu KCW, Yamauchi Y. Rapid
synthesis of biocompatible gold nanoflowers with tailored surface textures with
the assistance of amino acid molecules. RSC Advances. 2012;2:4608-11.
171

[200] Boca S, Rugina D, Pintea A, Barbu-Tudoran L, Astilean S. Flower-shaped
gold nanoparticles: synthesis, characterization and their application as SERSactive tags inside living cells. Nanotechnology. 2011;22:055702.
[201] Baron R, Zayats M, Willner I. Dopamine-, l-DOPA-, Adrenaline-, and
Noradrenaline-Induced Growth of Au Nanoparticles: Assays for the Detection of
Neurotransmitters and of Tyrosinase Activity. Analytical Chemistry.
2005;77:1566-71.
[202] Dai X, Tan Y, Xu J. Formation of Gold Nanoparticles in the Presence of oAnisidine and the Dependence of the Structure of Poly(o-anisidine) on Synthetic
Conditions. Langmuir. 2002;18:9010-6.
[203] Leff DV, Brandt L, Heath JR. Synthesis and Characterization of
Hydrophobic, Organically-Soluble Gold Nanocrystals Functionalized with Primary
Amines. Langmuir. 1996;12:4723-30.
[204] Barreto WJ, Ponzoni S, Sassi P. A Raman and UV-Vis study of
catecholamines oxidized with Mn(III). Spectrochimica Acta Part A: Molecular and
Biomolecular Spectroscopy. 1998;55:65-72.
[205] Han X, Wang D, Huang J, Liu D, You T. Ultrafast growth of dendritic gold
nanostructures and their applications in methanol electro-oxidation and surfaceenhanced Raman scattering. Journal of Colloid and Interface Science.
2011;354:577-84.
[206] Aizawa M, Cooper AM, Malac M, Buriak JM. Silver Nano-Inukshuks on
Germanium. Nano Lett. 2005;5:815-9.
[207] Fang J, Ma X, Cai H, Song X, Ding B. Nanoparticle-aggregated 3D
monocrystalline gold dendritic nanostructures. Nanotechnology. 2006;17:5841.
[208] Yu F, Chen S, Chen Y, Li H, Yang L, Chen Y, et al. Experimental and
theoretical analysis of polymerization reaction process on the polydopamine
membranes and its corrosion protection properties for 304 Stainless Steel.
Journal of Molecular Structure. 2010;982:152-61.
[209] Wang X, Jin B, Lin X. <i>In-situ</i> FTIR Spectroelectrochemical Study of
Dopamine at a Glassy Carbon Electrode in a Neutral Solution. Analytical
Sciences. 2002;18:931-3.
[210] Shen X-M, Dryhurst G. Oxidation Chemistry of (−)-Norepinephrine in the
Presence of l-Cysteine. Journal of Medicinal Chemistry. 1996;39:2018-29.
[211] Jiang Y, Wu XJ, Li Q, Li J, Xu D. Facile synthesis of gold nanoflowers with
high
surface-enhanced
Raman
scattering
activity.
Nanotechnology.
2011;22:385601.
[212] Xu D, Gu J, Wang W, Yu X, Xi K, Jia X. Development of chitosan-coated
gold nanoflowers as SERS-active probes. Nanotechnology. 2010;21:375101.
[213] Krpetić Ž, Guerrini L, Larmour IA, Reglinski J, Faulds K, Graham D.
Importance of Nanoparticle Size in Colorimetric and SERS-Based Multimodal
Trace Detection of Ni(II) Ions with Functional Gold Nanoparticles. Small.
2012;8:707-14.
[214] Jana NR, Pal T. Anisotropic Metal Nanoparticles for Use as SurfaceEnhanced Raman Substrates. Advanced Materials. 2007;19:1761-5.
172

[215] Jasuja K, Berry V. Implantation and Growth of Dendritic Gold
Nanostructures on Graphene Derivatives: Electrical Property Tailoring and
Raman Enhancement. ACS Nano. 2009;3:2358-66.
[216] Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD. Gold
Nanoparticles Are Taken Up by Human Cells but Do Not Cause Acute
Cytotoxicity. Small. 2005;1:325-7.
[217] Bhattacharya R, Mukherjee P, Xiong Z, Atala A, Soker S, Mukhopadhyay D.
Gold Nanoparticles Inhibit VEGF165-Induced Proliferation of HUVEC Cells. Nano
Lett. 2004;4:2479-81.
[218] Rodriguez-Lorenzo L, Krpetic Z, Barbosa S, Alvarez-Puebla RA, LizMarzan LM, Prior IA, et al. Intracellular mapping with SERS-encoded gold
nanostars. Integr Biol. 2011;3:922-6.
[219] Oh E, Delehanty JB, Sapsford KE, Susumu K, Goswami R, Blanco-Canosa
JB, et al. Cellular Uptake and Fate of PEGylated Gold Nanoparticles Is
Dependent on Both Cell-Penetration Peptides and Particle Size. ACS Nano.
2011;5:6434-48.
[220] Moghimi SM, Hunter AC, Murray JC. Long-Circulating and Target-Specific
Nanoparticles: Theory to Practice. Pharmacol Rev. 2001;53:283-318.
[221]
Porter
CJH,
Moghimi
SM,
Illum
L,
Davis
SS.
The
polyoxyethylene/polyoxypropylene block co-polymer Poloxamer-407 selectively
redirects intravenously injected microspheres to sinusoidal endothelial cells of
rabbit bone marrow. FEBS Lett. 1992;305:62-6.
[222] Moghimi SM, Hamad I, Andresen TL, Jørgensen K, Szebeni J. Methylation
of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol)
conjugate prevents PEGylated liposome-mediated complement activation and
anaphylatoxin production. The FASEB Journal. 2006;20:2591-3.
[223] Otsuka H, Nagasaki Y, Kataoka K. PEGylated nanoparticles for biological
and pharmaceutical applications. Adv Drug Delivery Rev. 2012;64,
Supplement:246-55.
[224] Furumoto K, Yokoe J-I, Ogawara K-i, Amano S, Takaguchi M, Higaki K, et
al. Effect of coupling of albumin onto surface of PEG liposome on its in vivo
disposition. Int J Pharm. 2007;329:110-6.
[225] Maeda H, Greish K, Fang J. The EPR Effect and Polymeric Drugs:
A Paradigm Shift for Cancer Chemotherapy in the 21st Century. In: SatchiFainaro R, Duncan R, editors. Polymer Therapeutics II: Springer Berlin
Heidelberg; 2006. p. 103-21.
[226] Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The
transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the
treatment of cancer. Clin Immunol. 2006;121:144-58.
[227] Jordan CT, Guzman ML, Noble M. Cancer Stem Cells. New England
Journal of Medicine. 2006;355:1253-61.
[228] Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al.
Residual breast cancers after conventional therapy display mesenchymal as well
as tumor-initiating features. Proceedings of the National Academy of Sciences.
2009;106:13820-5.
173

[229] Varkouhi AK, Scholte M, Storm G, Haisma HJ. Endosomal escape
pathways for delivery of biologicals. J Control Release. 2011;151:220-8.
[230] Pommier Y, Leo E, Zhang H, Marchand C. DNA Topoisomerases and Their
Poisoning by Anticancer and Antibacterial Drugs. Chem Biol. 2010;17:421-33.
[231] Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM.
Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219-34.
[232] Chamberlain GR, Tulumello DV, Kelley SO. Targeted Delivery of
Doxorubicin to Mitochondria. ACS Chem Biol. 2013.

174

VITA
Sijia Yi comes from China. She received her bachelor’s degree in Biomedical
Engineering from Huazhong University of Science and Technology. In August of 2010,
she entered University of Tennessee, Knoxville to pursue advanced degree in Biomedical
Engineering. She received her Ph.D. degree in August of 2013.

175

